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ABSTRACT

Machine Learning Applications for Drug Repurposing
by
Hansaim Lim

Advisor: Lei Xie, Ph. D.
The cost of bringing a drug to market is astounding and the failure rate is intimidating.
Drug discovery has been of limited success under the conventional reductionist model of onedrug-one-gene-one-disease paradigm, where a single disease-associated gene is identified and a
molecular binder to the specific target is subsequently designed. Under the simplistic paradigm of
drug discovery, a drug molecule is assumed to interact only with the intended on-target. However,
small molecular drugs often interact with multiple targets, and those off-target interactions are not
considered under the conventional paradigm. As a result, drug-induced side effects and adverse
reactions are often neglected until a very late stage of the drug discovery, where the discovery of
drug-induced side effects and potential drug resistance can decrease the value of the drug and even
completely invalidate the use of the drug. Thus, a new paradigm in drug discovery is needed.
Structural systems pharmacology is a new paradigm in drug discovery that the drug
activities are studied by data-driven large-scale models with considerations of the structures and
drugs. Structural systems pharmacology will model, on a genome scale, the energetic and dynamic
modifications of protein targets by drug molecules as well as the subsequent collective effects of
drug-target interactions on the phenotypic drug responses. To date, however, few experimental
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and computational methods can determine genome-wide protein-ligand interaction networks and
the clinical outcomes mediated by them. As a result, the majority of proteins have not been charted
for their small molecular ligands; we have a limited understanding of drug actions. To address the
challenge, this dissertation seeks to develop and experimentally validate innovative computational
methods to infer genome-wide protein-ligand interactions and multi-scale drug-phenotype
associations, including drug-induced side effects. The hypothesis is that the integration of datadriven bioinformatics tools with structure-and-mechanism-based molecular modeling methods
will lead to an optimal tool for accurately predicting drug actions and drug associated phenotypic
responses, such as side effects.
This dissertation starts by reviewing the current status of computational drug discovery for
complex diseases in Chapter 1. In Chapter 2, we present REMAP, a one-class collaborative
filtering method to predict off-target interactions from protein-ligand interaction network. In our
later work, REMAP was integrated with structural genomics and statistical machine learning
methods to design a dual-indication polypharmacological anticancer therapy. In Chapter 3, we
extend REMAP, the core method in Chapter 2, into a multi-ranked collaborative filtering
algorithm, WINTF, and present relevant mathematical justifications. Chapter 4 is an application
of WINTF to repurpose an FDA-approved drug diazoxide as a potential treatment for triple
negative breast cancer, a deadly subtype of breast cancer. In Chapter 5, we present a multilayer
extension of REMAP, applied to predict drug-induced side effects and the associated biological
pathways. In Chapter 6, we close this dissertation by presenting a deep learning application to
learn biochemical features from protein sequence representation using a natural language
processing method.
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CHAPTER ONE

Introduction to Artificial Intelligence and Machine Learning for Drug Discovery
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1.1 Introduction
The 2018 Nobel Prize in Physiology or Medicine was awarded to two researchers for their
revolutionary discovery of proteins that inhibit immune responses to cancers [1]. Although the
discovery of the checkpoint proteins initiated the development of targeted immunotherapies,
critical challenges remain to be addressed [2]. Limitations have been well known for
chemotherapies, where cytotoxic compounds are administered to directly kill tumor cells and slow
the progression of cancers [3]. Targeted therapies, where drug molecules interfere with tumorspecific molecular abnormalities also has been actively studied for over half a century and used in
parallel with other types of anticancer therapies. Although advancements in our understanding of
cancer biology and the treatment options have made some types of cancers manageable, challenges
remain in all types of anticancer therapies. First, the efficacy of treatment is often limited to a
minor group of patients, leaving an important, but difficult task to stratify patients prior to
treatment [4]. Moreover, many anticancer drugs, including both immunotherapeutic and other
targeted therapeutic agents cause serious side effects [5-7]. Biological complexity makes it even
more difficult to identify the targets that are critical for cancer development and progression due
to natural redundancy and diversity in biological network, such as feedback mechanisms, which
enhance robustness of phenotypical outcomes against perturbations. Multidrug resistance develops
over time, making the tumors immortal against the previously effective treatments [8-10]. Better
therapeutic options are needed to battle against and eventually conquer cancers.
Despite the urgent need, drug discovery is a time-consuming and costly process with low
success rate. A variety of risk factors delay new drugs entering the market and increase the chance
of withdrawal, increasing the overall cost of drug development [11]. Drug-induced side effects and
toxicity are one of the key issues relevant to the high rate of drug attrition [12]. The limited success
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of drug development suggests flaws in the long-standing paradigm: one-drug-one-target-onedisease, where the goal is to design a molecule that inhibits a biological target (e.g. protein) known
to be crucial for the disease. Under the paradigm, drug candidate molecules are optimized to
interact with the intended target (on-target), without proactively understanding off-target
interactions and leaving safety and toxicity tests to the later stage of pipeline. Off-target
interactions, most of time unexpected, may cause undesirable outcomes, even fatal ones in extreme
cases, leaving irreparable damages to the business and patients [13]. On the other hand, the
treatment of complex diseases may benefit from off-target interactions if both on- and off-target
synergistically reverse the pathological processes. Indeed, it is now known that many approved
drugs interact with more than one biological targets [14, 15], and the importance of understanding
the complex biological interactions for such multitargeting drug molecules is emphasized as a new
paradigm of drug discovery, polypharmacology [15, 16]. Instead of suffering from unexpected
outcomes caused by off-target interactions, polypharmacology is an attempt to understand drug
actions as results of multiple different interactions involving the drug molecule and maximize the
benefit from the interactions. Indeed, the superiority of multitargeting drugs over highly selective
single-target drugs is suggested [15]. Under the new paradigm, off-target interactions of existing
drugs can be used to repurpose them for new indications. Protein-ligand interaction profiles for
new ligands can be computationally predicted, and the chemical scaffolds active for multiple
targets of interest can be integrated into a single molecule to maximize therapeutic effects and
minimize adverse events [17]. New discoveries in biological studies reveal previously unattended
anticancer targets, and new drugs can be designed to play multiple roles in the biological network
[18, 19]. Therefore, early understanding of drug-target interaction profile across whole genome
space is essential for development of new, more effective and safer drugs. However, our
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knowledge of intermolecular interactions drug molecules cause is limited. It is prohibitive to
experimentally evaluate all possible drug interactions. Drugs and drug candidate molecules are
typically screened against a subset of potential biological targets, resulting in biased, noisy, sparse,
and incomplete interaction profiles. At present, no experimental techniques are affordable and
scalable enough to experimentally screen compounds for their complete bioactivity profile in
humans.

Figure 1.1 Illustration of a general workflow for computational protein-ligand interaction
prediction projects
*Appears in a book chapter, Drug repurposing in cancer therapy, Elsevier (in press)

Although not scalable yet to the whole human genome space, high-throughput
experimental methods have produced tremendous amount of compound bioactivity data, providing
rich resources for data-driven knowledge discovery. To rapidly and systematically explore the data
and discover hidden knowledge, various types of computational methods have been developed and
applied to predict potential interactions of drug molecules. Among many classes of computational
methods applicable for drug discovery, those specifically designed to predict unknown proteinligand interactions are particularly suitable to fill in the sparse knowledge in bioactivity. This
4

chapter aims to discuss the recent advancements in machine learning methods for the prediction
of protein ligand interactions as well as the efforts to collect and curate experimental data.
Although many different computational methods have been developed to fight against various
diseases, we focus in this chapter on the methods that are at least partially relevant to the
development of anticancer therapies. While some methods directly aim to discover new anticancer
therapies, other methods also provide opportunities to discover anticancer therapies when
appropriate data sets and validation steps are incorporated. Also, the strategies and methodologies
introduced in this chapter can be applied to important diseases other than cancers with appropriate
data preparation and evaluation strategies. We try to guide readers who are interested in computeraided drug discovery by providing information about collecting data, preprocessing the data, and
methods that can take the preprocessed data for inference. We discuss the major sources of
biopharmaceutical databases that are frequently used to train and evaluate computational methods.
Throughout this chapter, different types of computational approaches to predict intermolecular
interactions are discussed with examples, including the main methods that we present in later
chapters. Figure 1.1 illustrates a general workflow for computational protein-ligand interaction
prediction projects.
It should be emphasized that drug action is a complex process. The genome-wide proteinligand interaction alone may be insufficient to predict clinical end-points, such as therapeutic
efficacies and side effects. A systems biology approach is needed to model the collective behavior
of biomolecular interactions (e.g. DNA, RNAD, protein, metabolite, drug, etc.), which is beyond
the scope of this dissertation. Interested readers are referred to other publications [20-25].
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Table 1.1 Commonly used databases for artificial intelligence-based drug discovery projects
Name [Ref.]
ZINC [27]
ChEMBL [28]

Bioactivity-centric

PubChem [29]
BindingDB [30]
LINCS [31]
STITCH [32]
BioGRID [33]
SIDER [34]
KEGG [35]
DrugBank [36]
ExCAPE-DB [37]

Features

Bioactivity and biological pathway data
Drug-protein interactions for approved and
investigational drugs
Example of systematic data integration

MUV [43]
DUD-E [44]

Proteomic

Link

Large-scale compound library, compound 3D
https://zinc.docking.org
structures ready for docking
Continuous-valued bioactivities, large-scale bioassays
https://www.ebi.ac.uk/chembl
from publications
https://pubchem.ncbi.nlm.nih.gov
Large-scale compound library with activities
Continuous-valued bioactivities with focus on potential https://www.bindingdb.org/bind/inde
x.jsp
drug targets
https://lincs.hms.harvard.edu
Kinase-specific bioactivities
Protein-ligand and ligand-ligand interaction data,
http://stitch.embl.de
including predicted activities
Protein-ligand and protein-protein interaction data
https://thebiogrid.org
from publications
http://sideeffects.embl.de
Drug-induced side effect data

Example of systematic data split
Example of systematic data split
Primary amino acid sequences and functional domain
UniProt [38]
information
PDB [39]
Largest existing protein 3D structure database to date
Pfam [40]
Curated protein families with sequence homology
Protein-protein interaction with functional annotations,
STRING [41]
including predictions
The Human Protein Human protein classifications based on functions and
Atlas [42]
phenotypes
Multiple categories of data relevant to genes, proteins,
Harmonizome [43]
cell lines, and pathways

https://www.genome.jp/kegg/kegg1.h
tml
https://www.drugbank.ca
https://doi.org/10.5281/zenodo.25437
24
https://omictools.com/muv-tool
http://dude.docking.org
https://www.uniprot.org
https://www.rcsb.org
https://pfam.xfam.org/
https://string-db.org
https://www.proteinatlas.org
http://amp.pharm.mssm.edu/Harmoni
zome

*Appears in a book chapter, Drug repurposing in cancer therapy, Elsevier (in press)

1.2 Open-access databases for computational drug discovery projects
High-quality and large-scale compound activity data (e.g. protein-ligand binding affinity)
are indispensable in artificial intelligence and machine learning-based drug development projects.
To train a computational prediction method, often called a computational model, known proteinligand associations are preprocessed in the way the model can take. Many publicly available
databases curating experimentally measured protein-ligand interactions can be used for such
purposes. The protein-ligand pairs are numerically represented using techniques called molecular
fingerprints, which is discussed below. The model is trained and evaluated on the numerically
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preprocessed data sets. Therefore, it is critical to appropriately choose and utilize the databases.
Databases that provide compound bioactivity data or proteomic information are especially useful
for protein-ligand interaction prediction projects. While they are roughly divided into bioactivitycentric and proteomic databases, many current databases are actively maintained and updated to
integrate data from multiple sources, providing more rich and comprehensive data sets. Also,
biological network data can be integrated into computational models to help better prediction. The
following sections are to describe some of the commonly used bioactivity and proteomic databases
for artificial intelligence-based drug discovery projects (Table 1.1). Other types of large-scale
omics data include genomics, transcriptomics, metabolomics and biological pathway information,
and relevant databases are discussed elsewhere [26].
Bioactivity-centric databases
Bioactivity-centric databases provide rich resources for protein-ligand interaction data,
which can be used as the known protein-ligand association for computational models. While these
provide large-scale data sets, the interaction profiles are incomplete, and computational models
are used to partially complete the empty space in the profiles. The databases introduced here are
not comprehensive, but these are frequently updated to maintain the state-of-the-art quality and
quantity. The bioactivity data that these provide may overlap, so special care is necessary when
integrating them for a large-scale project. We introduce a few bioactivity centric databases in the
next paragraph.
ZINC is a free database of commercially available compounds, especially suitable for
virtual screening projects [27]. As of this writing, it contains over 700 million purchasable
compounds, among which over 200 million are available for 3D structures, which is essential for
structure-based projects, such as protein-ligand docking. ChEMBL, a part of the European
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Molecular Biology Laboratory – European Bioinformatics Institute (EMBL-EBI), is a publicly
available database of bioactivities from multiple sources [28]. ChEMBL database (version 27)
contains approximately 16 million bioactivity values from more than 1.2 million assays, covering
over 1.9 million unique compounds and 13000 proteins. While major sources of its bioactivity
samples are from over 76000 scientific publications, it also contains samples from both nonprofit
and commercial organizations deposited data sets. PubChem, a chemical information database at
the U.S. National Center for Biotechnology Information, contains about 250 million bioactivities
for over 200 million substances and 17000 protein targets from over 30 million publications and 3
million patents [29]. BindingDB contains over 1.7 million protein-ligand binding affinities, which
mainly focuses on small, drug-like molecules and potential druggable target proteins [30]. The
Library of Integrated Network-based Cellular Signatures (LINCS) is a database of cell-based
perturbation-response signatures, which contains data samples for small molecules, cells, genes,
and proteins categorized by the assay types [31]. STITCH is a protein-ligand interaction database
containing over 400000 chemicals and their interacting protein targets [32]. Its protein-ligand
interaction data contains computationally predicted samples as well as samples from other
databases. BioGRID contains protein and genetic interactions as well as chemical interactions with
post-translational modification information [33]. SIDER, which is also a part of EMBL, is a
database containing known drug-side effect associations [34]. Kyoto Encyclopedia of Genes and
Genomes (KEGG) contains a large-spectrum biochemical and biomedical data sets, including
protein-ligand interactions for approved drugs, gene-biological pathway associations, and
biomolecular functions named KEGG Orthology [35]. DrugBank provides rich resources for
approved and investigational drugs with their known associations with protein targets [36].
DrugBank is also a great resource for drug-drug interactions. ExCAPE-DB is a relatively new
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database providing open-access to the integrated bioactivies from ChEMBL and PubChem [37].
While its contents are from existing databases, ExCAPE-DB provides a unified set of samples
from the databases with appropriate, reproducible data integration steps.
Proteomic databases
UniProt is a large-scale database as a part of EMBL-EBI, containing over 120 million
proteins across all branches of life, with their primary sequences [38]. RCSB Protein Data Bank
(RCSB PDB, PDB) is a database containing 3D structures of biomolecules, including proteins and
protein-ligand complexes [39]. Pfam is a database of curated protein families, which contains over
18,000 families, each of which contains up to 676,776 protein sequences with homology search
information [40]. STRING database allows researchers to connect these proteins to build a largescale protein-protein interaction network [41]. The Human Protein Atlas project aims to map all
human proteins in cells, tissues, and organs using various experimental and computational
techniques, which provides category information for genes and proteins based on their functions,
compartments, and relevant diseases and drugs [42]. Harmonizome contains data sets for genes
and proteins with their associations with other biomolecules, expressions in cells and tissues, and
knockout phenotypes [43]. Harmonizome is a collection of data sets from multiple sources, so
users may also obtain other types of data sets according to the design of the project.
1.3 Data preparation for training and evaluating computational models
Data preparation
The databases described above are rich data sources regarding chemical compound
structures, properties and their biomolecular activities with relevant target information. The
differences and variety of data sets make it an important step to prepare samples appropriately for

9

the artificial intelligence and machine learning-based drug discovery projects. It often gives too
optimistic results when a computational model is trained on one database and evaluated another
without properly integrating multiple data sources, due to suboptimal coverage or overlapping
samples. The above-mentioned databases are updated on a regular basis to maintain the quality
and coverage as new samples become available. As a result, databases of similar kinds often
present samples from the same sources, making parts of database overlapping each other.
Therefore, a care is necessary when integrating multiple databases into a single data set. ExCAPEDB presents an example for integrating and quality-filtering steps for bioactivity databases [37].
Once databases are integrated, a proper data split strategy must be used to separate samples for
training and evaluating the model. It is essential to split a data set into training and evaluation sets
so that the samples in evaluation set has never been used to train the model. While a commonly
used procedure is to integrate multiple data sets with quality-filters and to randomly split into
training and evaluation sets, the random split is too simplistic, especially when there are many of
distinct, but highly similar compounds or targets in the integrated data set. Many samples in
evaluation set will have highly similar compounds or targets to those in training set, and they will
still be considered unique, non-overlapping samples.
A better approach is to consider properties of entities in the samples when splitting a data
set. For instance, when molecular structural similarity scores are available for chemical molecules,
it is possible to set a similarity threshold such that the maximum similarity between a molecule in
training set and a molecule in evaluation set is below the threshold. This strategy can enhance the
computational model in that the model better generalizes over larger spectrum of molecular
structures and prevent overfitting. Maximum Unbiased Validation (MUV) [44] and Directory of
Useful Decoys-Enhanced (DUD-E) [45] are two important data splitting schemes applied to
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provide well-prepared data sets for computational drug discovery projects. MUV was designed to
overcome artificial enrichment and analogue bias, two major biases in virtual screening data sets.
Artificial enrichment is the bias when some simple molecular properties, such as molecular weight,
separates the active and inactive compounds. Computational models suffer from analogue bias
when they are trained with data sets having some sub-structures overrepresented in the active sets.
A computational model well-trained on such data sets is likely to make biased predictions based
on the simple molecular features or overrepresented substructures. DUD-E adopts similar idea to
the two biases while it focuses on protein-ligand pairs with 3D structures available, making it
especially useful for virtual docking or structure-based models. The two data sets, however, are
not perfect for all kinds of projects. MUV excludes frequent hitters, the compounds that are active
in most tested assays, making it less suitable for projects where the aim is to predict all unknown
associations for drugs. DUD-E samples include activities for non-human homologs and exclude
targets with mutations, making it be subjective to species-specific or mutant-specific activities.
Furthermore, despite the efforts, DUD-E samples are still not free from the biases as shown in a
recent study regarding 3D structure-based protein-ligand binding prediction methods [46]. Both
data sets are relatively small as well, partly because of the developed date and the structural
coverage. As a result, the data sets and split strategies are often study-specific, and performances
may be provided on these data sets for comparison. A gold-standard data set for artificial
intelligence and machine learning-based protein-ligand association projects is needed.
Performance evaluation
Performance evaluation is an essential step during a computational modeling of drug
activities. Classification models output discrete values (e.g. binding/nonbinding, or stages of
cancer), whereas regression models output continuous values (e.g. strength of protein-ligand
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binding as pKd). As they have different predictive tasks, different metrics are used to evaluate the
models. A simple classification metric is accuracy, where the count of correct predictions is
divided by the count of total predictions. It is called zero-one-loss for binary classification tasks
(e.g. true/false). Especially when the classes are unbalanced, it is easy for a model to reach high
accuracy without capturing meaningful pattern in samples. For example, if there are 95 negative
samples out of 100 samples, a meaningless all-negative prediction model can reach 95% accuracy.
Other frequently used classification metrics are based on the confusion matrix, which is defined
as an 𝑛 × 𝑛 matrix C, where Ci,j is the number of observations known to be in the class i, but
predicted to be class j. For binary classification tasks, the diagonal elements of the confusion
matrix are true positives (TP) and true negatives (TN) while the off-diagonal elements are false
positives (FP) and false negatives (FN), where the names stand for the correctness and predicted
labels. For example, TN is the number of observations correctly predicted as negative. FP is for
observations wrongly predicted as positive (i.e. known to be negatives but predicted positive).
Precision and recall are the ratio of TP to all predicted positives and all known positives,
respectively, and the harmonic mean of the two is called F1 score. When the model output is a
probability value of an observation being positive and hence a predefined threshold 𝛼 is used (i.e.
prediction is positive only if probability ≥ 𝛼), the ratio values can be a function of probability
threshold. As 𝛼 increases, more predictions are treated as positives, gradually increasing FP. Area
Under Receiver Operating Characteristic curve (AUROC) measures how early a model reaches
high TP while maintaining low FP by plotting TP versus FP with gradually increasing 𝛼 [47]. An
ideal AUROC value is 1.0 while AUROC of 0.5 means random prediction in balanced cases.
Precision and recall can also be plotted with increasing 𝛼. It is called Area Under Precision-Recall
curve (AUPR).
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Regression metrics evaluate how close or consistent the predicted values are to the true
values. Two simple regression metrics are mean squared error (MSE) and mean absolute error
(MAE), where the differences between predictions and labels are averaged after squared or
unsigned. Prediction consistency is often evaluated by correlation coefficients, where higher
coefficients are obtained if higher (or lower) observation is consistently predicted to be higher (or
lower). Correlation coefficient values range from -1 to 1, from perfect anti-correlation to perfect
correlation. Although it is ideal to use a model that performs better in all metrics, it is common
that a model is better only in certain metrics. Thus, one or more performance metrics of interest
that are more important to the given problem should be defined for projects. For example,
correlation coefficients may provide better evaluation scores if the goal is to prioritize ligands with
high potential. Nevertheless, no one metric is a perfect measure for model performances in all
cases. Thus, it is common and highly recommended to present and compare multiple performance
metrics together.
1.4 Representation of molecules for a computational drug discovery project
Machine learning and artificial intelligence methods, including deep learning methods,
take numerical inputs. Thus, molecules, such as small molecular compounds and protein targets
must be represented as numeric vectors or tensors to be used as inputs. Since the inputs are the
information passed to the computational models, they should be meaningful, not just arbitrary or
sequential numbers. Many different approaches have been proposed to numerically represent the
molecules. The methods to numerically represent biochemical molecules are often called
molecular fingerprints or descriptors, and the numerical representations may be used to train
computational models or calculate similarity scores (or distances) between molecules.

13

Chemical molecular fingerprints
Chemical molecular fingerprints are a class of methods that capture some information –
commonly the atom types, bond types, topological distances and chemical substructures – about
the input molecules. Atom pair descriptor [48] and topological torsion descriptor [49] are both
molecular fingerprint methods developed early in 1980s. While both of them take atom types,
heavy atom neighbors, and 𝜋-electrons to numerically represent molecules, they differ in that atom
pair descriptor takes topological distances (e.g. how many bonds are in the shortest path between
two atoms) while topological torsion descriptor does not. 2D-pharmacophore fingerprint [50] is
another method that takes the topological distances in addition to the appearance of the 9
predefined classes of pharmacophores (e.g. hydrogen bond donor, halogen atoms, etc.). While
these fingerprint methods consider some atomic points in a molecule to form graphs connecting
them, Extended Connectivity Fingerprint (ECFP) [51] is another method that focuses on the
appearance of substructures. ECFP is often used in two different versions; count vectors which
counts the appearances of substructures, and hashed bits with ‘1’s for appeared substructures and
‘0’s for the rest. While 3D fingerprint methods exist, little to no benefit over ECFP is reported in
virtual screening experiments [52]. Thus, ECFP has often been used to numerically represent small
molecules. Many software tools exist for these conventional fingerprinting techniques, including
a few open-source tools, such as PaDEL descriptor [53], OpenBabel [54], and RDKit [55]. Users
can choose appropriate methods for their use cases.
Despite the extensive studies, there is no one consensus for the best molecular
representation technique for all computational drug discovery projects. Ligand-based virtual
screening studies suggest that the best-performing molecular fingerprint is dependent on the
method and data [56-59]. Moreover, the conventional fingerprints introduced above are very
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sparse, containing mostly zeros, wasting the computational resources. It is also known that
although with very low probability, bit collision may occur, where two different substructures are
represented as the same bit information. Importantly, they are “not learnable” from the given tasks.
In other words, the vector representation of a molecule will always be the same and are not adjusted
during model training. Thus, ongoing efforts are to develop innovative, novel, yet systematic and
efficient descriptors that are learnable and adjustable to the tasks. Several newer molecular
fingerprint techniques have been developed using more advanced artificial intelligence algorithms.
Mol2vec is a natural language processing (NLP)-based approach to represent small
molecular ligands into vectors of continuous values, overcoming the sparsity and bit collision
issues [60]. Ligands are first represented as an ordered list of small substructures, like a sentence
of words in NLP, which are fed into the word2vec model [61]. Word2vec is known to preserve the
semantic similarity of the input words, which is also the case in mol2vec. In other words, the
outputs of two similar ligands are closer than those of less similar ones. The output vectors can
then be used to train downstream tasks, such as molecular property prediction or protein-ligand
interaction prediction. Molecular dynamics fingerprint is a 3D-structure-based descriptor of small
molecules [62]. Molecular dynamics fingerprint, as the name suggests, describes the statistics of
biophysical molecular properties, such as free energy, from simulations of the molecules in various
solvent environment. This information-rich molecular descriptor can be combined with other
molecular descriptors to predict the behaviors of molecules. Neural molecular fingerprint (NeuMF)
method is one of the newest chemical molecular fingerprint techniques that uses convolutional
neural network (CNN) to represent small molecules [63]. NeuMF considers a molecule as a graph
of atoms and substructures that are connected by varying degree of topological distances. Then,
fully. Connected linear layers are applied to a set of atoms or substructures having certain degree
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of connectivity. NeuMF is technically similar to ECFP as they both split a molecule into a set of
substructures comprising it according to the topological distances. The weights for NeuMF are,
however, tuned particularly for the given tasks (e.g. solubility prediction, or binding affinity
prediction), and the output vectors contain continuous values, instead of binary digits. Coley et al.
demonstrated that incorporation of additional atomic and molecular features to the NeuMF can
improve the performance in molecular property prediction tasks [64]. It is noted that although these
newer fingerprinting techniques alleviate aforementioned issues, stereochemistry is mostly
ignored. To date, only a limited number of ligands have known 3D conformation linked to
activities and readily available in databases. While there are ways to obtain the lowest-energy
conformers, the lowest-energy conformation may be different from the conformation when the
ligands are in action (e.g. binding to a target protein). Also, a novel algorithm that learns accurate
representation from 3D graph is needed.
Representation of protein sequences and structures
Representing proteins as numeric vectors is often a critical step in data-driven drug activity
modeling. Proteins are in general, however, larger and more complex than drug molecules: they
are polymers of amino acids forming distinct folds and structures to perform biochemical activities.
As a result, there are many ways to represent proteins at different scales and depth from whole
primary sequence composition to more complex 3D interactions among atoms within binding
pockets. Simple protein descriptors can be built based on the composition of amino acids. For
example, how many times a particular amino acid appears in a protein can be counted and used as
a descriptor for the protein. In the same way, the appearance of doublets or triplets of amino acids
may be counted, which increases the complexity of the descriptor. These composition-based
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descriptors are however too simplistic to capture different properties of amino acids or positional
dependencies.
Physicochemical properties of amino acids have been studied, recorded, and continuously
refined as more data and techniques become available [65, 66]. Such physicochemical properties
are called amino acid index, which have been utilized to design various protein descriptors. For
instance, conjoint triad descriptor is a type of the composition-based descriptor for amino acid
triplets [67]. It categorizes amino acids into 7 distinct classes based on polarity and volume, which
reduces the dimension of the descriptor as well as takes some physicochemical properties into
account. Moreau-Broto autocorrelation descriptor is the average of the product of a selected amino
acid index between the 𝑖 !" and (𝑖 + 𝑑)!" amino acids along the sequence, where 𝑑 is called the
lag of the autocorrelation [68]. Other variants of the autocorrelation descriptor can be obtained by
using another type of descriptive statistics or amino acid index. Scale-based protein descriptors are
a class of statistical methods that attempt to capture the variability of amino acid features. A
pioneering effort in the scale-based descriptors was to use a large number of physicochemical
properties of the 20 natural amino acid and compress the features by principal component analysis
[69]. Further efforts to improve the quality of scale-based descriptors have been made by adjusting
the number of amino acid properties and/or including unnatural amino acids [70-72]. Various kinds
of these protein descriptors are available [73].
Two key properties are desired for an efficient protein descriptor for computational drug
discovery projects: position-dependency and long-range dependency. An amino acid may play
completely different roles in terms of biomolecular activities when its environment is changed,
and two sequentially distant amino acids may closely interact with each other to render important
functions (e.g. binding pocket). While the lag of autocorrelation partially accounts for the long-
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range dependency, it does not differentiate the amino acids that do interact from the rest. Moreover,
above mentioned methods consider little, if any, about the positional differences. Profile-based
descriptor is a position-dependent protein descriptor based on multiple sequence alignment [74].
Such a descriptor uses the observed and expected frequencies of amino acids at particular positions
of aligned sequences, which instead focuses less on the long-range dependency. A recent
advancement in natural language processing methods provide new opportunities to design protein
descriptors that account for both of the important dependencies. Based on the successful natural
language processing model, Bidirectional Encoder Representations from Transformers (BERT)
[75], Rives et al. showed that the model can learn biochemical properties of amino acids and
proteins, such as charge, size, secondary structures, and residue-residue contacts [76]. Briefly, a
large amount of protein sequence data from UniProt [38] is used to train the BERT model in a selfsupervised manner (i.e. some amino acids are hidden and the task is to predict the hidden ones)
without preprocessing the sequences. This step is called pre-training of BERT, which is followed
by fine-tuning steps with labeled data, such as protein family prediction, binding site prediction,
using the BERT-calculated protein vectors as descriptors. The BERT-based protein descriptor is
position-dependent and captures long-range dependency by design. BERT uses positional
embedding that differentiates the representation of a word by its position. The long-range
dependency is captured by one of the key components of BERT, the self-attention mechanism,
which aligns the input embedding vectors by their impacts on each output embedding [77]. One
drawback of BERT is the computational cost for training. A recent development of a light version
of BERT, called ALBERT, attempts to significantly reduce the computational costs by improving
the efficiency of parameters in BERT without compromising performance [78]. Computational
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costs can also be alleviated by using more powerful devices or down-sampling the input data by
preprocessing (e.g. multiple sequence alignment and sequence identity-based clustering).
1.5 Computational methods for protein-ligand interaction prediction
In this chapter, we divide computational protein-ligand interaction prediction methods into
four categories: ligand-based, structure-based, network-based, and deep learning-based methods
(Table 1.2). Please note that many deep learning-based methods can also be regarded as one of the
other three categories. Ligand-based methods rely on the assumption that the differences in
chemical molecular structures can explain their different bioactivities. Small molecular
compounds are numerically represented using molecular fingerprint techniques, and the
fingerprint vectors are mathematically compared to other compounds having known protein targets.
The closer the two fingerprint vectors are, the more likely that they share the same target proteins.
Though sounds simple, many ligand-based methods show high predictive performances,
suggesting that the assumption is indeed valuable. However, limitations exist. They cannot explain
the activity cliff [79], and their performances are suboptimal for novel molecules. Structure-based
methods, also called protein-ligand docking methods, take structural information for both proteins
and ligands and can partially overcome the drawbacks. The physicochemical interactions between
atoms comprising the ligands and the binding pockets of proteins are calculated, and the predefined
energy functions are used to score the protein-ligand pairs of interest. While they can provide
detailed pictures of how the given pair of molecules may interact, they suffer from high false
positives. Also, high computational burden makes them inappropriate for screening protein-ligand
interactions at a large scale. In network-based methods, protein-ligand interactions are treated as a
bipartite graph where nodes are proteins and ligands, and edges are known protein-ligand
associations. Nodes and edges may possess attributes, representing the characteristics of the
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molecules or interactions. The missing edges (e.g. unknown interactions) are predicted using
various kinds of mathematical models. Network-based methods often enjoy high scalability due to
the design of the models. However, they. Rely on high-level features (e.g. only a few numbers
representing a whole protein target) to represent the network, limiting their accuracy and
interpretability. Deep learning-based methods use artificial neural networks to replace the
mathematical models used in the methods of other kinds. With the great success and explosive
interest in deep learning, artificial neural networks, such as convolutional neural network have
been applied to computational protein-ligand interaction predictions. Deep learning-based
fingerprints introduced above can be used to represent molecules. The flexibility of deep learning
architectures makes the number of possible models virtually infinite, and larger and more complex
models are being developed. The field of deep learning is fast-evolving in both its software and
hardware, continuously improving the performances on various tasks. While they enjoy the
greatest flexibility and high performances, their interpretability has been criticized due to the
“black-box” nature of complex artificial neural networks. Deep learning-based methods can also
be classified into the other categories listed above.
Table 1.2. Strengths and weaknesses of protein-ligand interaction prediction methods
Method type Strength

Weakness

Ligand-based

Computational cost is generally low, high
performance on some well-studied
targets, simple to implement

Structure-based

High-resolution details can be obtained,
can make predictions for new targets
(with structure available)

Network-based

Systematically integrates knowledge from
large amount of data across multiple
aspects (multi-omics)

Deep learningbased

Often achieve higher performance
compared to other types of methods,
model flexibility to integrate assumptions
from multiple types of methods

Lack of high-resolution details in predicted
interaction, performance limited for
screening against targets with many known
ligands
High computational cost, scalability also
limited by structural coverage, often suffer
from high false positive
Lack of high-resolution details, scalability
depends on core algorithms and data
requirement, comparing performances of
multiple methods is not trivial
Computational cost is usually high, low
interpretability of models, require large
amount of data to train models

*Appears in a book chapter, Drug repurposing in cancer therapy, Elsevier (in press)
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Ligand-based virtual screening
A traditional assumption in ligand-based virtual screening is that ligands that are similar to
each other are more likely to share common targets. For a given target protein, if a query ligand
turns out to be very similar to a known active ligand, it is likely that the query ligand will also be
active. A systematic approach of this is to decide the numerical representation of ligands (e.g.
molecular fingerprints), define a similarity metric (e.g. Tanimoto coefficient or cosine distance),
and evaluate the pairwise ligand similarity scores for each query ligand against each known
active/inactive ligand. Then, the predicted protein-ligand interaction for the query ligand can be
made simply based on the nearest neighbors [59] or based on the statistical significance of the
similarity [56, 58]. It was shown that with proper measurement, a set of weak ligand similarities
(with statistical significance) may be an indication of common target. Moreover, the similarities
between ligand pairs contain information relevant to the target proteins [56, 80]. Due to the
underlying assumption in the ligand-based virtual screening, however, an adequate number of
known active/inactive ligands must be provided for each target protein. This makes ligand-based
virtual screening inappropriate for cases where insufficient amount of data is available. For
instance, a suboptimal performance is expected if predictions are made for novel mutant target
proteins, where the known active/inactive ligands are available only for the wild-type proteins. An
approach taking advantage of more detailed target features, such as physicochemical interactions
in 3D space, should be considered in such cases.
Riniker et al. performed an extensive comparison of 12 commonly used molecular
fingerprints on DUD, MUV and ChEMBL data sets [59]. For each test compound, its similarity
score to all active molecules in training set were measured. The maximum similarity scores for
each test compound are then used to rank them, and the efficiency of each fingerprint is evaluated
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using the rank. Circular fingerprints performed better when evaluated by early recognition metrics,
whereas path-based fingerprints were better for AUC. It was also found that the performance varies
more cross-target-same-fingerprint than the cross-fingerprint-same-target evaluations.
A popular method in ligand-based virtual screening is Similarity Ensemble Approach,
(SEA) which applies statistical tests on top of the fingerprint-based pairwise ligand similarity
search methods to rank the target proteins [56]. In SEA, each target protein is represented as a set
of its known active ligands. For each query ligand, similarity to the known actives for each target
are calculated, and the sum of the similarity scores above certain threshold are summed to derive
raw scores for the query ligand-target protein association. The raw scores are then statistically
evaluated against randomly populated set of ligands, and the statistical significance is used to rank
the target proteins. In a later study, it was shown that the performance can be improved by using
multiple SEA models, each with different types of fingerprints and by preparing for target-specific
data sets (e.g. kinase dataset) [57].
The SEA method is important in a few aspects. First, it uses all active ligands for a given
target, instead of closest neighbors. The high performance of this method suggests that a set of
weak similarities may indicate significant overall relatedness. Koutsoukas et al. proposed a
probabilistic machine learning model, Parzen-Rosenblaat Window (PRW) method with similar
ideas [81]. Each target protein is represented as a set of ECFP fingerprint features for the active
ligands, and the probability of the query ligand being active is obtained by comparing how many
of the fingerprint features they share. In other words, a target protein is a bag of fingerprint bits
from its active ligands, and the query ligand may have many of the bits-in-bag if it is active. Second,
the similarity scores are statistically tested against randomly populated set of ligands, instead of
simply using the best similarity scores. Awale et al. measured pairwise ligand similarity scores
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based on multiple types of fingerprints, and the statistical significance of the distances between
query and the closest neighbor in the active ligands for a target protein is used to rank the target
proteins [58].
Lauria et al. developed DRUDIT, a ligand-based drug discovery tool that is freely
accessible via web service [82]. Similar to an earlier work by Riniker et al. [59], ligands are
represented as chemical molecular descriptor vectors, which are then used to build templates for
target proteins. Here the chemical descriptors contain not only the presence/absence of certain
substructures but also some other physicochemical properties, such as the autocorrelation values.
The target template represents the distribution of each descriptor from the active ligands. The input
ligand’s descriptors are then compared to the target template, where the score is higher if the input
ligand’s descriptor values are within a small range of the target template distribution. DRUDIT is
strictly based on the ligand property and the known protein-ligand associations, and the easy-touse web service (www.drudit.com) is freely available at the time of writing this review. Such a
user-friendly service of computational drug discovery tool is rare and valuable.
Yang et al. used extreme gradient boost to predict the inhibition strength of compounds
against JAK2. The authors collected active and inactive compounds for JAK2 from PubChem,
BindingDB, and ZINC databases. Molecular fingerprints for the compounds were calculated using
RDKit and fed into extreme gradient boost classification and regression models. It was shown that
models using ECFP4 performed consistently better, and the extreme gradient boost classification
model performed better than virtual docking methods in terms of early enrichment of active
compounds [83].
Sadawi et al. reported that their multi-task regression algorithm outperformed the singletask counterpart, and incorporation of evolutionary distances among protein targets further
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improved the performances in majority of the tasks [84]. In the multi-task regression method, each
target protein is a task, where the protein-ligand affinity data with IC50 measurements were
obtained from ChEMBL. Using 1024-bit pharmacophore fingerprint (FCFP) as ligand
representation, Random Forest regressor was used as the baseline single-task method, and two
types of multi-task methods, namely feature-based and instance-based methods were compared.
In feature-based multi-task method, FCFP was used to represent ligand, and the target proteins are
simply grouped by their family hierarchy manually curated by ChEMBL, forming multi-task data
sets for related tasks. In addition to the feature-based method, instance-based method takes the
target-target similarity profile as an additional input, where the similarity scores are based on
amino acid sequence similarity. While the single-task baseline method has a flaw in that it does
not include any target features, the study clearly showed that the target-target similarity scores help
improve the predictive performances, i.e. instance-based performed better than feature-based
multi-task method. It is important to note that in the study, the evaluation data set contained same
targets that were appeared in the training set.
Ligand 3D feature-based virtual screening
The limited success of ligand-based virtual screening may be partially attributed to the
abstraction of chemical molecular features that cannot fully represent 3D structures of molecules.
Therefore, virtual screening methods that utilize ligand 3D features have been studied to more
accurately predict protein-ligand interactions. For the additional details in molecular representation,
ligand 3D feature-based methods may provide more accurate predictions but may also suffer from
higher computational costs. The requirement of ligand 3D structure also limits the scalability of
models to chemical space.
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Grisoni et al. used ligand 3D features, such as partial charges and 3D shape of compounds
to select a handful of ligands that are likely to show similar interaction profile to (-)-galantamine,
a natural product approved for Alzheimer’s Disease [85]. Potential target proteins for these
selected ligands were predicted and some of them were experimentally validated. Although the
proposed target is not cancer, it is a computational approach to discover multitarget drugs.
Hernandez et al. developed a 3D graph-based molecular similarity search method, which
performed better than conventional fingerprints for classifying active ligands in DUD-E data set
[86]. The ligand molecules are represented as a graph of atoms and ring structures containing
physical and pharmacophore features as node attributes. Then, maximum common substructures
for pair of ligands were heuristically calculated to obtain ligand-ligand similarity scores. The
similarity scores are then used to rank ligands in DUD-E data sets to classify active and inactive
ligands and the early enrichment performances were generally higher than the conventional
fingerprint-based methods. While the gain of performances in early enrichment is noticeable, the
proposed 3D graph-based method did not outperform ECFP for all target classes. This may be due
to that there are many ligands without known 3D conformation specific to the binding targets. As
done in this study, the available standard conformers need to be used for the algorithm, which may
not correctly represent the binding poses of the ligands. In cases where the ligands of interest are
topologically similar but showing different activities, requiring high-resolution comparisons, such
a 3D structure-based method can be more accurate than the 2D topology-based fingerprints.
Fan et al. proposed DStruBTarget, a ligand-based virtual screening method that utilizes 2D
and 3D ligand information as well as protein-ligand binding affinity information [87]. In
DStrubTarget, the prediction scores are calculated by finding a reference ligand that maximizes a
combination of three values: 2D similarity between query and reference ligands, 3D similarity,
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and scaled binding affinity between the reference ligand and the target of interest. The evaluation
demonstrated that incorporation of 3D similarity scores is helpful to improve the predictive
performances.
Structure-based virtual screening
Structure-based virtual screening methods are a class of methods that uses 3D structures of
the ligands and target proteins as input. Using the physicochemical properties of the 3D structures,
the alignment between proteins and ligands are searched and scored. To date, molecular docking
simulation methods are actively developed and applied to predict protein-ligand binding activities.
Molecular docking simulation methods are frequently used to search for such binding poses by
optimizing method-specific scoring functions. Scoring functions are metrics evaluating the
protein-ligand docking poses based on physicochemical interactions (force field), statistics of atom
pairs from known protein-ligand interactions, or some other types of variables designed to
correlate with known binding affinities [88]. A usual workflow in studies based on molecular
docking simulation is first to find the 3D structures for the ligands and targets of interest, where
ligands often outnumbers the targets. Using the structures as input, various molecular docking
simulation approaches can be used to rank the ligands against each target with favorable (e.g. lowenergy) protein-ligand binding complexes. Some of high-ranked binding complexes are obtained
and filtered (e.g. discarding molecules predicted to interact with too many targets). Eventually, a
handful of protein-ligand pairs are considered candidates and may be evaluated in vivo or in vitro
for experimental validation of predicted activities [89, 90]. A number of user-friendly graphic
interfaces are available for molecular docking experiments, including AutoDock [91], UCSF Dock
[92], MTiOpenScreen [93], HADDOCK [94], and SwissDock [95].
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While traditional molecular docking experiments aim to screen a large library of ligands
against a few particular targets of interest, inverse docking methods aim to screen a few ligands of
interest against a large number of target proteins and therefore is “target-fishing.” Inverse docking
is a useful scheme when a ligand with unknown targets is known for certain phenotypes. A
potential target of a known tumor growth inhibitor was suggested by using an inverse docking
method [96]. A general inverse docking approach was presented for multitargeting antibacterial
drug design [97]. Recently, Wang et al. proposed a consensus inverse docking model by utilizing
multiple different docking methods to predict consensus docking conformations [98]. It is
available for web access (http://chemyang.ccnu.edu.cn/ccb/server/ACID/).
One of the key strengths of molecular docking methods is that the simulated protein-ligand
complexes can be used to provide atom-level insights on how the binding occurs, generating
hypotheses about the mechanism of action. For this reason, molecular docking methods can be
used as a supplementary method for other classes of methods to enhance the predictions by
providing finer-resolution view of the interactions [85, 99, 100]. However, due to the requirement
of 3D structures and atom-level detailed computations, molecular docking methods suffer from
computational cost and relatively low scalability. Thus, to date, such methods alone cannot fully
exploit the abundance of archived data from high-throughput biochemical and biomedical
experiments. When appropriate, other 3D structural features with lower resolution may be used to
reduce the computational costs and thus increase scalability of the model [101]. More details of
the strengths and drawbacks of molecular docking methods can be found in the reference [88].
Network-based virtual screening
In network-based virtual screening methods, protein-ligand interactions are viewed as a
network, where proteins and ligands are nodes, and protein-ligand associations are edges
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connecting the nodes. A protein-ligand association network can be represented as an m-by-n
rectangular matrix, where m and n are the number of unique proteins and ligands. In the matrix
form, typically ‘1’ indicates known protein-ligand associations and ‘0’ indicates unknown ones,
thereby representing the adjacency (or connectivity) between one type of nodes to another. While
many databases can be integrated to build a large-scale protein-ligand association network, the
protein-ligand adjacency matrix is usually sparse, noisy, biased, and incomplete. Due to the
incomplete coverage of experiments, many interacting protein-ligand pairs have not been
evaluated and thus are hidden in the ocean of ‘0’s in the adjacency matrix. Thus, the aim of many
network-based virtual screening methods is to predict the hidden associations based on the known
information. For example, the missing links between proteins and ligands can be predicted by
evaluating the degree of shared neighbors within the protein-ligand interaction network [102].
Without using any other information than known protein-ligand associations, the assumption here
is similar to that of ligand-based methods: similar nodes (in terms of shared neighbors) are likely
to interact.
As drug activities, including protein-ligand interactions happen within a complex and
heterogeneous biological environment, many biological features are frequently used to help the
protein-ligand interaction prediction, and the capability to utilize such side information is one of
the key strengths of network-based methods. To be compatible with protein-ligand interaction data,
side information may also be encoded in the form of adjacency matrix or similarity matrix. For
example, drug-induced side effects may be in an n-by-s matrix, where n and s are the number of
unique drugs and side effects, respectively. When a network consists of multiple types of nodes
(e.g. proteins, ligands, diseases, side effects in one network), it is called heterogeneous network,
where special treatments are often required to integrate and process the network for prediction.
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Also, similarities between nodes of same type can be measured and used as features, such as
ligand-ligand similarity or protein-protein similarity. Within a network, the groups of nodes of
same type are often referred as layers (e.g. ligand layer is a group of ligands in the network), edges
connecting nodes of same type are intra-layer (or within-layer) edges, and edges connecting nodes
of different types are inter-layer (or cross-layer) edges. The following examples are heterogeneous
network-based protein-ligand interaction prediction methods.
BANDIT utilizes multiple biochemical and biomedical properties of compounds to identify
target proteins of an orphan ligand [80]. BANDIT takes ligand chemical structure, gene expression
profile upon chemical perturbation, cellular growth inhibition profile, drug-induced side effects,
and other types of biochemical assay results to compare large number of ligands. Each pair of
ligands are represented as a set of similarity scores, where each score is based on the
aforementioned ligand properties. Then, a Bayesian statistic model is used to calculate the
likelihood that two ligands share a target protein given the pieces of evidence. Using BANDIT,
the researchers were able to predict the target protein of ONC201, an anticancer compound in
clinical development whose biological target and mechanisms remained unknown. In addition to
high performance and utility in clinical development, the performance of BANDIT suggests that
it is beneficial to integrate multiple types of large-scale data sets to predict protein-ligand
interactions. While the prediction procedure – that is to compare ligands based on their properties
and shared targets are assumed for similar ligands – is similar to that of many ligand-based virtual
screening methods introduced above, BANDIT is also capable of separating drugs based on their
mechanisms of action, demonstrating its unique strength as a network-based method.
Chu et al. developed DTI-CDF, a network-based machine learning model that uses network
representation of protein-ligand associations with intra-layer similarity information to predict
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unknown drug-target associations [103]. In DTI-CDF, protein-protein and ligand-ligand similarity
scores are used to train different numbers of Random Forest [104] and XGBoost [105] models
stacked multiple times to make final predictions. For each stack of the models, the input contains
the multiple types of similarity information. From the second stack, the output from previous stack
is additionally used as input. The model architecture resembles that of residual network, a popular
CNN architecture that has been very successful in image recognition. DTI-CDF, however, is
trained and evaluated only on KEGG data set [35], which contains a small subset of proteins and
ligands, thus limiting the generalizability of the method to a larger protein-ligand space.
Luo et al. developed a computational framework to repurpose drugs by integrating
heterogeneous network of drugs, diseases, side effects, and target proteins [106]. The
heterogeneous network consists of both cross-layer (drug-protein, drug-side effect, drug-disease,
and protein-disease associations) and within-layer (drug-drug interactions, drug-drug similarities,
protein-protein interactions, and protein-protein similarities) edges, and Random Walk with
Restart (RWR) [107], a popular network propagation method was used to extract the feature
vectors for each nodes. A feature reduction technique was used to compress the size of the node
vectors, and the drug vectors are projected to the target protein space, such that the projection
approximates the known drug-protein interaction matrix. The method identified three drugs as
potential cyclooxygenase inhibitors, and experimental validation confirmed the inhibitory
activities of the drugs. The potential binding modes of the drugs were also predicted using a
molecular docking simulation method.
Utilizing a convenient feature of adjacency matrices, Fu et al. attempted to computationally
parse through the pathways that link proteins with ligands [108]. They first built more than 50
different semantic network relationships represented by commuting matrices – a kind of adjacency
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matrix representing the number of length-n pathways between nodes – from adjacency matrices of
ligands, ligand substructures, side effects, diseases, protein targets, protein functional annotations,
and biological pathways. The commuting matrices can be obtained by matrix multiplication of
adjacency matrices. For example, if matrix A and B represent protein-ligand and ligand-disease
associations, the matrix dot product of A and B (i.e. A∙B) represents the number of unique
pathways connecting proteins and diseases after one intermediate ligand node. The commuting
matrices represent the meta-paths between proteins and ligands, which are used to train Random
Forest and Support Vector Machine models to predict binary protein-ligand associations. While
the report did not include a repositioning of drugs, the high performance suggests that the
incorporation of heterogeneous biological data sets is beneficial for computational predictions.
Notably, the ‘0’s in protein-ligand interaction network do not necessarily indicate noninteracting pairs. Zheng et al. showed that systematically sampling the true negative pairs can
significantly improve performances of many machine learning algorithms for protein-ligand
interaction prediction [109]. On a heterogeneous network of proteins, ligands, side effects, and
protein functions, they applied guilt-by-association assumption – where protein-ligand pairs are
likely negative if they are dissimilar to most of known positives – to obtain high-confidence
negative protein-ligand interactions. The improved performances of machine learning models with
the imputed negative data suggest that it is overly simplistic to use all ‘0’s as negative samples.
Nonnegative matrix factorization (NMF) is also a popular network modeling method that
has been applied to computational drug discovery. REMAP takes protein-ligand interaction
network as well as the intra-layer similarity networks to obtain compressed feature representations
for all proteins and ligands in the network [110]. Liu et al. separately developed a similar method,
called NRLMF [111], where the main difference from REMAP is that REMAP explicitly consider
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the possibility that some of ‘0’s are actually positives. A major restriction in REMAP is that the
compressed feature vectors for proteins and ligands must be of the same dimension. To overcome
the drawback, a tri-factorization version of REMAP, WINTF, was developed [99, 112]. In both
REMAP and WINTF, ligand-ligand and protein-protein similarities can be calculated based on the
2D molecular structures and primary sequence comparisons, respectively. By the design of
REMAP algorithm, once optimized, two structurally similar ligands are assigned similar
compressed feature vectors, and so for proteins. This property of the algorithm provides a useful
way to represent ligand molecules in a way that contains both its chemical structure and its global
target profile in compressed vectors. Wang et al. used the compressed vectors from WINTF to
cluster ligands and applied RWR algorithm to repurpose diazoxide for triple-negative breast cancer
[99]. Ayed et al. used the compressed vectors from REMAP to predict drug sensitivity of cancer
cell lines, which showed superior performances compared to features based only on ligand
structures [113]. A multilayered version of REMAP, FASCINATE method was applied to predict
drug-induced side effects and side-effect-pathway relationships from heterogeneous biological
network data [22]. These methods will be introduced in more detail throughout later chapters.
Deep learning-based biochemical activity prediction
Zakharov et al. proposed a deep learning-based multitask protein-ligand interaction
prediction model, named deep learning consensus architecture (DLCA) [114]. DLCA takes
multiple types of molecular descriptors as inputs, each of which are processed separately by layers
of fully connected artificial neurons, also known as feed-forward neural network, and the outputs
from each of the separate layers are averaged to provide consensus predictions. The authors
adopted both random split and scaffold out validation (i.e. training and test compounds do not
share some predefined chemical substructures). The performance dropped significantly when
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scaffold out validation was performed. However, the consensus model performed better than every
individual component model for both random split and scaffold out validation. DLCA is an
example where the consensus models (or ensemble models) performing better than the individual
component models. It was also shown no single type of molecular fingerprint is superior than the
others in general.
Lee et al. developed DeepConv-DTI, a CNN-based binary classification tool for drugtarget interaction prediction [115]. DeepConv-DTI takes compound 2D structure and target protein
primary sequence as inputs, which are vectorized by ECFP and a simple lookup table (i.e. each
amino acid has a unique integer identifier), respectively. The protein lookup values are then
projected into embedding vectors, which are then pooled by convolutional layers before being
concatenated with the compound vectors. The model was trained on a collection of binary proteinligand associations in some of the databases mentioned above. Importantly, the convolutional
filters applied to the protein sequences seem to highlight the parts of proteins interacting with the
compound, suggesting the capability of convolutional neural network to capture the local features
relevant to the physicochemical interactions.
Moridi et al. applied variational autoencoder and principal component analysis to extract
features for small molecule drugs and diseases to repurpose approved drugs [116]. A small
molecule drug is represented by its chemical structure, target protein sequences, relevant enzyme
sequences, and gene expression profile under the treatment. These features are processed by
variational autoencoders to reduce dimension and extract salient features, and then used to measure
drug-drug similarity scores using cosine distance. On the other hand, a disease is represented by
its phenotypes and genotypes (i.e. disease characteristics and involved genes), compressed by
principal component analysis, which are used to measure disease-disease similarity scores. The
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predicted drug-disease association scores are then calculated by taking the square root of the
maximum product of similarity scores within the drug-drug and disease-disease similarity network.
When evaluated for each distinct disease, the model achieved high AUC values for most of the
reported diseases. One shortcoming is that the model requires the target genes and relevant
enzymes for the input drugs. While it is likely for an approved drug to have known target genes
and enzymes, they are not necessarily the key players for the new indications, limiting the
interpretability and applicability of the method.
Torng and Altman proposed a two-stage graph-CNN method to predict protein-ligand
binding affinity [117]. They first built an unsupervised deep autoencoder to represent the binding
site pockets for druggable proteins. Each protein pocket is a graph of amino acid residues having
any atoms within 6 Å to the bound ligands from PDB co-crystal structures. Residues within 7 Å
are connected to form a binding pocket graph. The second stage comprises two separate graph
CNN models that learns features from proteins and ligands, supervised by the binding
classification labels. Ligand molecules are represented in the second stage using NeuMF graph
CNN [63]. Since the two supervised graph CNNs run in parallel to predict the binding activity, the
model does not require the co-complex structure information. They applied negative sampling
strategy to include both negative binding pockets and negative ligands. From DUD-E database,
randomly chosen binding pockets dissimilar to the active pockets are included as negative pockets.
From ChEMBL database, ligands having measured IC50 is greater than 50 𝜇M are used as negative
ligands. Such negative sampling technique can be critical for successful modeling as the
benchmark data sets are often incomplete, sparse and biased. Zhang et al. developed a deep
learning-based protein-ligand binding affinity predictor, DeepBindRG [118]. DeepBindRG
extracts interacting atom pairs from protein-ligand co-crystal structures similarly to the Torng and
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Altman method. The atom pairs are then featurized based on their chemical and force-field-based
atomic categories to prepare 2D picture-like input data. The popular ResNet architecture [119] was
then trained to predict the protein-ligand affinity values in pKd or pKi.
Karimi et al. developed DeepAffinity, a protein-ligand affinity prediction tool based on
RNN and CNN [120]. The inputs for DeepAffinity are the protein primary sequence and ligand
2D structures in SMILES string format, which are then processed by Recurrent Neural Network
(RNN)-based encoder [121] and pairwise attention mechanism. Before feeding into RNN, protein
primary sequences are used to represent their structural properties, such as secondary structure
elements and physicochemical properties, while SMILES strings are k-hot encoded (i.e. binary bit
vector indicating the individual characters). The RNN-encoded protein and ligand vectors are then
further processed by pairwise attention mechanism, followed by CNN layers and fully connected
layers to predict pIC50 values. It is noted that the authors split the protein-ligand affinity data for
novel protein family prediction cases. In other words, the model performances were measured for
protein targets that were not included in the training data. Also, it was shown that the attention
mechanism assigned higher scores for protein segments that are closer to the binding sites although
the input did not contain 3D structures. DeepAffinity does not require 3D structure data, making
it more appropriate for larger-scale, early-stage predictions, where limited information is available
for the proteins and ligands of interest.
Wan et al. proposed NeoDTI, a prediction tool for binary protein-ligand interactions based
on graph convolutional neural network that is designed to learn from heterogeneous network,
which showed superior performances compared to multiple types of methods [122]. Using the
same datasets as Luo et al. [106], heterogeneous network was built to consist of intra-layer and
inter-layer relationship edges between drugs, proteins, side effects, and diseases (nodes). Using
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graph convolutional neural network, similar to that of NeuMF [63], the information about nodes
are collected to reflect the nodes themselves and their neighbor nodes connected by different edge
types. The update of node information is governed by a loss function that is specially designed to
drive the feature vectors of related nodes can be correctly identified after appropriate projection.
The idea of the loss function is similar to that of matrix factorization methods – that is, the feature
vectors of proteins and ligands reproduce the protein-ligand network. NeoDTI integrates graphbased neural network and matrix factorization to predict protein-ligand interactions.
Other computational drug repurposing methods
The methods mentioned above are mainly for predicting protein-ligand or drug-target
interactions and thereby proposing new indications of existing drugs. While such methods are
critical, computational drug repurposing in general includes other classes of methods that do not
necessarily predict protein-ligand interactions. Computational methods that directly predict drugside effect or drug-disease associations are useful tools for drug repurposing, where the core
assumption is that similar drugs are likely to share therapeutic effects [123-125]. Gene expression
perturbations have also been used to predict therapeutic effects where a drug is assumed to be
efficient if the gene expression signatures under treatment are in opposite direction of those from
diseased states [126, 127]. Although relatively less explored and potentially raising questions
regarding security and privacy, electronic health records are also useful resources to
retrospectively explore clinical data to mine undiscovered opportunities [128]. These classes of
methods are out of the scope of this dissertation. Interested readers are referred to the references
[129-131].
1.6 Discussion
We discussed a few important subtypes of computational drug discovery approaches with
a focus on anticancer therapeutics. A typical workflow of artificial intelligence-based drug
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discovery project contains a few steps, including problem definition, data set preparation,
computational model building, training and evaluating the performance of the model, statistical
analyses of the performance and predictions, and the inference and validation by assays.
Depending on the problem definition, a project can be classified as ligand-based, (target) structurebased, or network-based. As reviewed above, ligand-based models mostly rely on the ligand
homophily effect – ligands that are similar to each other are likely to share targets, which makes
the ligand-ligand similarity measurement a key component for the models. Structure-based models
consider more about the physicochemical interface of protein-ligand binding, often containing a
sub-model to represent binding pockets or interacting residues extracted from the 3D structures of
protein-ligand interaction complexes. Network-based models treat protein-ligand binding as a
network with edges (binding) connecting vertices (proteins and ligands) and aim to predict the
unknown edges based on known edges. It is noted that these strategies are applicable to diseases
other than cancers when appropriate inputs pertinent to the diseases of interest are available.
There is no one size fits all solution in computational drug discovery. Ligand-based models
are often simple and scalable, but their dependency to the ligand-ligand similarity measure make
them less suitable to predict and overcome the activity cliff – a small change in ligand structure
leading to dramatic differences in bioactivity [79]. Structure-based methods can perform better for
the activity cliff as they consider the physicochemical properties of both protein and ligand.
However, they require the 3D structure of the target and suffer from higher computational
complexity. Network-based models often integrate information from both proteins and ligands by
building protein-protein and ligand-ligand intra-layer networks in addition to the protein-ligand
inter-layer network. They are designed to overcome the high computational complexity and the
requirement of protein 3D structures by using sequence-based features. Nevertheless, network-
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based models suffer from the sparsity, incompleteness, biases, and noises in the known proteinligand interaction network, and they are prone to the loss of information. For instance, it is not
guaranteed that the solely sequence-based protein features are sufficient to accurately predict the
physical interactions between proteins and ligands. Thus, it is desirable to combine multiple types
of models to overcome the drawbacks for each class of methods as in a recent drug repositioning
study [100].
To date, most cancer therapies focused on directly removing or killing the tumor cells.
While such removal of growing seeds may exert some therapeutic effects, it is noted that less
attention has been paid to the soil, called the tumor microenvironment (TME) [132]. So far, the
inhibitors of aforementioned immune checkpoint proteins are one of few available TME-based
therapeutic options whose inefficiency have not yet been fully understood [2]. Although
incomplete, extensive biological research has revealed that there are subtypes of TMEs that either
promote or inhibit tumor progression [133]. While the majority of computational drug discovery
research in cancer therapies have focused on discovering molecules that can kill or inhibit the
growth of cancer cells, a shift to target the specific subtypes of TMEs may result in novel
therapeutic agents. The potential therapeutic targets that can possibly enhance quantity and quality
of neutrophils – the most abundant circulating leukocytes that are responsible for innate immune
response – have been recently reviewed [134]. It is also discussed that a variety of cells in TME,
such as stromal, endothelial, and myeloid cells, can prevent T cells from exerting their antitumor
immunity by either physically blocking T cells around solid tumors or biochemically depriving
their activities [135]. Reported cases of drugs targeting cancer associated fibroblasts (CAFs), a
major stromal component of TME in pancreatic cancer have been discussed in a recent review
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[136]. While individual therapies have been of limited success, a number of potential CAF-related
targeted therapies have been proposed.
Polypharmacology theorizes that inhibiting two or more of the intended targets will be
more beneficial than single-targeting drugs. A dual-action agent inhibiting both mevalonate
pathway and sterol regulatory element-binding protein activity may provide unprecedently
efficient antitumor effects by avoiding the resistance mechanism, as suggested in reference [18].
A recent study demonstrated that PD-1 proteins on myeloid cells may have different roles from
those on T-cells [137], partially explaining the limited success of the immunotherapies. A
hypothetical dual-action drug can be designed to inhibit both CAF-tumor crosstalk (e.g. TGF-𝛽
inhibitor [138]) and CAF-produced tumor-promoting signals (e.g. Interleukin-33, which induces
tumor-promoting M2 macrophages [139]). An existing CAF-derived extracellular matrix-targeting
drug, sonidegib [140], can be optimized to also intervene the above mentioned TME biological
networks or cellular metabolic pathways. Another hypothetical, multi-targeting drug that
efficiently inhibits BCL-XL and MCL-1 (BCL-2 family multidomain anti-apoptotic proteins) may
enjoy maximum benefits by reverting the adaptive resistance-based tumor cell survival with low
toxicity [9]. Ligand-based screening methods can help identify chemical scaffolds that are potent
against the multiple targets of interest, structure-based methods can help iteratively optimize the
scaffolds, and network-based methods can identify the global bioactivity profiles at early stage.
Biological interaction networks within and across cells have been actively revisited to reveal more
potential therapeutic targets. Computational approaches should also be newly developed, revised,
and fine-tuned to accelerate the discovery of drugs that can induce therapeutic effects from
multiple interactions.
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CHAPTER TWO

REMAP: A Dual Regularized One-class Collaborative Filtering Algorithm for Large-scale
Off-target Identification and Its Application to Dual-action Anticancer Drug Repurposing
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2.1 Introduction
Drug discovery has been of limited success under the conventional one-drug-one-geneone-disease paradigm. It suffers from high attrition rate and possible unexpected post-market
withdrawal [11]. It has been recognized that drug off-target interactions (i.e. interactions between
the drug and unintended targets) frequently occur [141], which may lead to adverse drug reactions
(ADRs) [142], as demonstrated by the deadly adverse reaction of a Fatty Acid Amide Hydrolase
(FAAH) inhibitor in a clinical trial [13]. On the other hand, off-target interactions may be of
therapeutic values, thus providing new opportunities for drug repurposing and polypharmacology
[141]. Therefore, identifying off-target interactions is a critical step in drug discovery, which can
reduce the drug attrition rate and to accelerate the drug development process, and ultimately to
provide safer and more affordable therapeutic options.
A more recent paradigm in drug discovery is called polypharmacology, where multitargeted therapies through either drug combination or a single polypharmacological agent are
developed to better treat diseases. It has been suggested that a single polypharmacological agent
has advantages over the combination of multiple drugs [16]. Although there have been
serendipitous success cases in polypharmacology, target selection and lead compound
identification are two major challenges in the rational design of polypharmacological therapeutics.
Existing efforts mainly focus on one-drug-multi-target-one-disease paradigm, selecting multiple
targets involved in a single disease. It is not trivial, however, to choose the right target combination
for the disease of interest due to the limited knowledge in gene-disease associations. In terms of
lead compound identification, a typical approach is to merge two or more distinct molecular
substructures each having a desired activity towards the targets of interest, designing a single
molecule [143-145]. This approach may be too simplistic and often results in poor drug-likeness
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properties, making subsequent lead optimization processes a serious bottleneck in the development
of multi-targeting drugs [146]. Moreover, additional challenges in polypharmacology remain to be
solved: the genome-wide drug-target interactions and multi-indications are rarely considered.
Many efforts have been made to develop statistical machine learning methods for the
prediction of unknown drug-target associations by screening large-scale chemical and protein data
sets [147]. The fundamental assumption in applying statistical machine learning methods to drugtarget interaction prediction is called similarity principle or homophily effect, where similar
compounds tend to bind to similar protein targets, and vice versa. Based on the similarity principle,
both semi-supervised and supervised machine learning techniques have been developed and
applied. The semi-supervised learning methods either build statistical models for the k nearest
neighbors (k-NN) of the query compound with similar compounds in the database (e.g. ParzenRosenblatt Window (PRW) [81] and Similarity Ensemble Approach (SEA) [56] are examples).
Although a large number of 2D and 3D molecular fingerprint representations of chemical
compounds have been developed, molecular structure similarity that is measured by Tanimoto
coefficient (TC) or other similarity metrics of fingerprints do not show continuous correlations
with the binding activity. Activity cliff is known to exists in the chemical space, where a small
modification of a compound structure can dramatically change its binding activity [148]. Thus, the
chemical structural similarity alone is insufficient to capture genome-wide interaction profile, as
protein-ligand interaction is determined by both protein and chemical structures. New deep
learning techniques that can learn nonlinear, hierarchical relationships may provide new solutions
for representing chemical space [149-152]. However, few works have been done to incorporate
protein relationships into a deep learning framework. It remains to be seen whether deep neural
networks are applicable to genome-wide target prediction.
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A number of statistical machine learning techniques, such as Gaussian Interaction Profile
(GIP), Weighted Nearest Neighbor (WNN), Regularized Least Squares (RLS) classifier [153, 154],
and matrix factorization [155-157] have been developed to integrate chemical and genomic space.
Neighborhood Regularized Logistic Matrix Factorization (NRLMF) [157] and Kernelized
Bayesian Matrix Factorization (KBMF) [156] are two of the most successful methods among those
methods. However, several drawbacks exist in these methods limiting their applications in
genome-wide off-target predictions. First, several high-performing algorithms such as KBMF are
computationally intensive, requiring prohibitive time and memory when applied to whole genome
scale tasks. Second, these supervised learning methods require well-annotated negative samples.
While publicly available biological and/or chemical databases (e.g. ZINC [27], ChEMBL [28],
DrugBank [36], PubChem [29], and UniProt [38]) have enabled large-scale computational
screening of chemical-protein interactions, the known interactions are sparse, and the number of
reported negative samples (i.e. chemical-protein pairs do not interact with each other) is too small
to optimally train a prediction algorithm [158]. Randomly generated negative cases will adversely
impact the performance of these algorithms, and algorithmically derived negative cases are often
unrealistic [158]. Finally, the performances of these methods have been mainly evaluated for the
prediction of the off-targets within the same gene family (e.g. within GPCRs or protein kinases)
using a small benchmark with hundreds of drugs and targets. Their performances in predicting offtargets across different gene families on a large scale are not guaranteed. Indeed, drug crossreactivity is known to occur across protein fold spaces [159]. Thus, in silico prediction methods
that are fast and accurate enough to explore the available large-scale data sets is urgently needed.
In this chapter, we describe our contributions to address the aforementioned issues. We
present a scalable and efficient method, REMAP, which formulates the genome-wide off-target
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predictions as a dual-regularized One Class Collaborative Filtering (OCCF) problem. By the
design of the OCCF, negative data annotations are not required for the training, but can be used if
available. We demonstrate that REMAP is highly scalable with promising accuracy; thus, it can
be applied to large-scale off-target predictions. We introduce a new benchmark set to evaluate the
performance of drug-target interactions across gene families, comparing performances of REMAP
with other state-of-the-art methods. In our subsequent study, we apply REMAP to repurpose
existing drugs for new indications [100]. We integrate REMAP with 3D structure-based prediction
methods, thus naming it 3D-REMAP. Using 3D-REMAP, we design a dual-indication anti-cancer
therapy by integrating multi-omics data with different classes of systems pharmacology algorithms.
We repurpose levosimendan, an FDA-approved drug for heart failure, as an anticancer treatment.
The kinase binding activity and anticancer activities of levosimendan were validated in subsequent
experiments. The details about 3D-REMAP with experimentally validated drug repurposing
outcomes are available in the reference [100]. Our findings present a new computational tool for
drug repurposing and may shed a new light in the anti-cancer drug discovery and demonstrate the
potential of genome-wide multi-target screening in precision medicine [160].
2.2 Methods and Materials
Definition of off-target prediction method REMAP and its benchmark
Problem formulation for REMAP method
The problem we try to solve here is to predict how likely a pair of protein and ligand interact
with each other, given a protein-ligand association network, protein sequences and chemical
structures of the proteins and ligands. Note that we use the terms interactions and associations
interchangeably. We define a bipartite network for protein-ligand associations as a sparse 𝑚 × 𝑛

44

matrix 𝑅, where m is the number of unique ligands and n is the number of unique protein targets.
𝑅#,% = 1 if the 𝑖 !" and the 𝑗!" protein are associated, and 𝑅#,% = 0 , otherwise. The chemical
structural similarity scores are in an 𝑚 × 𝑚 square matrix 𝐶, with 𝐶#,% representing the similarity
score between the 𝑖 !" and 𝑗!" ligands 70 ≤ 𝐶#,% ≤ 19 for total m ligands. The target protein
sequence similarity scores are in the same format for total n proteins 70 ≤ 𝑇#,% ≤ 19. We consider
this problem analogous to the user-item purchase prediction, such that users and items represent
ligands and proteins, respectively. Therefore, the problem is to provide an 𝑚 × 𝑛 matrix 𝑃, in
which 𝑃#,% indicates the score for the predicted association between the 𝑖 !" ligand and the 𝑗!"
protein.
Overview of off-target prediction method REMAP
Our new method REMAP is based on a one-class collaborative filtering algorithm that
recommends previously unknown user-item preferences based on the profiles of users and items
[161]. The underlying assumption is that similar users tend to prefer similar items, and an unknown
preference does not necessarily indicate a downvote. In our formulation, protein-ligand association
prediction problem is analogous to the user-item preference prediction task. Assuming that a fairly
low dimensional features (i.e. smaller number of features than the number of total ligands or
protein targets) can sufficiently capture the characteristics determining the protein-ligand
associations, two low-rank feature matrices, U (ligand side) and V (protein side), were
&
approximated by minimizing ∑(# ∑'
% 7𝑅 − (𝑈 ∙ 𝑉 )9, where R is the matrix for known protein-

ligand interactions, and 𝑉 & is the transposition of the protein side low-rank matrix V. The two lowrank feature matrices, 𝑈 and 𝑉 are optimized by iteratively minimizing the objective function
below in Eq. 2.1. The overall process of REMAP is in Figure 2.1
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Figure 2.1 Overall process of the REMAP method. Known protein-ligand associations, protein sequence
similarity, and ligand structural similarity information are incorporated in the matrices R, T, and C,
respectively. After iterative updates, optimized low-rank matrices UUP and VUP are obtained, whose dot
product forms the prediction score matrix, P.
https://doi.org/10.1371/journal.pcbi.1005135.g001

All symbols used in this chapter are summarized in Table 2.1 Here, 𝑤 is the penalty weight
on the observed and unobserved associations which indicates the reliability of the assigned
probability of true associations, 𝑄 is the imputation matrix (i.e. the probability of unobserved
associations as real associations for each entry), 𝛼 is the regularization parameter to prevent
overfitting, 𝛽 is the importance parameter for the ligand structural similarity, 𝛾 is the importance
parameter for the sequence-based protein similarity, and tr(A) is the trace of matrix A (Table 2.1).
In this work, we use global weight and imputation values. However, the weight and imputation
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values may be determined by a priori knowledge or from the prediction of other machine learning
algorithms. In other words, 𝑤 can be a matrix with the same dimension as the matrix R, and the
matrix 𝑄 can be filled by other predictive methods. For example, we used protein-ligand docking
methods to partially fill in the matrix R. The weight values corresponding to the docking-predicted
associations were set to a lower score, while the corresponding imputation values were set to zeros.
This reflects our a priori knowledge that the predicted associations to be true with a lower
confidence. Such an approach is the focus in the later parts of this chapter, which introduces 3DREMAP and its application to dual-action drug repurposing.
The raw prediction score for the 𝑖 !" ligand to bind the 𝑗!" protein are calculated by 𝑃(#,%) =
&
𝑈+,(#,:) ∙ 𝑉+,(%,:)
. The raw scores, however, do not necessarily mean the probability or likelihood

of the given associations. Moreover, the input matrix is significantly unbalanced in terms of
positive/negative samples. Hence, the raw scores were adjusted based on the ratio of observed
positive and negative cases when the negative data are available (explained in the prediction score
adjustment section in this chapter). Also, the matrix 𝑈'×/ contains low-rank profiles for ligands
since its 𝑖 !" row represents the ligand feature in the protein-ligand association network with
consideration of the drug-drug similarity information. Analogously, the matrix 𝑉(×/ contains the
low-rank features for each protein target, compressed into 𝑟-dimensional vectors. The REMAP
code was originally written in Matlab and modified for the drug-target predictions. A python
implementation

of

REMAP

is

also

freely

available

https://github.com/hansaimlim/REMAP/tree/master/scripts.

We

at

the

note

same
that

the

repository
python

implementation shows comparable speed for processing moderately sized datasets. As data
matrices get larger, the python implementation requires significantly more memory than Matlab
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implementation due to the advantage of highly optimized sparse matrix operations in Matlab. The
users may choose the right implementation for their use cases.
Table 2.1. The symbols and the descriptions for numerical calculations
Symbol
𝑅
𝐶, 𝑇
𝐶 (1. ,1/ )
𝑑 &4(# (1. ,1/ )
𝑇(52,53)
𝑑6#! (52,53)
𝐷7 , 𝐷&
𝑈, 𝑉
𝑅(#,%)
𝑅(#,:)
𝑅(:,%)
𝑅&
𝑡𝑟(𝑅)
𝑄
𝑚
𝑛
𝑤
𝛼
𝛽
𝛾
𝑟
𝑝#!8/
𝑃(#,%)

Definition and Description
The adjacency matrix of the known drug-target associations, 𝑅 ∈ ℝ'×( .
The chemical-chemical and the target-target similarity matrices,
𝐶 ∈ ℝ'×' , 𝑇 ∈ ℝ(×( .
The chemical-chemical similarity score for the chemicals 𝑐2 and 𝑐3 .
The Tanimoto dissimilarity coefficient for the chemicals 𝑐2 and 𝑐3 .
The target-target similarity score for the query protein 𝑝2 and the target
protein 𝑝3 .
The bit score for the query protein 𝑝2 and the target protein 𝑝3 .
The degree matrices of C and T, respectively, 𝐷7 ∈ ℝ'×' , 𝐷& ∈ ℝ(×( .
The chemical-side and the target-side low-rank approximation matrices,
𝑈 ∈ ℝ'×/ , 𝑉 ∈ ℝ(×/ .
The element of 𝑅 at its 𝑖 !" row and 𝑗!" column.
The 𝑖 !" row of 𝑅.
The 𝑗!" column of 𝑅.
The transpose matrix of 𝑅.
The trace of matrix 𝑅.
The imputation matrix (i.e. the probability of unobserved associations as real
associations for each entry in the matrix 𝑅), 𝑄 ∈ ℝ'×( .
The number of unique ligands.
The number of unique protein targets.
The penalty weight on observed and unobserved associations which indicate
the reliability of assigned probability of true association.
The regularization parameter to prevent overfitting.
The importance parameter for chemical-chemical similarity.
The importance parameter for protein-protein similarity.
The rank of the low-rank approximation matrices, i.e. dimension of the
compressed protein and ligand features.
The number of maximum iterations to minimize the objective function.
The raw prediction score by REMAP for the 𝑖 !" chemical and the 𝑗!" protein.
Table partially from https://doi.org/10.1371/journal.pcbi.1005135.t001
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Ligand structural similarity calculation
Ligand-ligand similarity score matrix is one of the required inputs of REMAP. We define
the similarity between a pair of ligands based on their chemical molecular 2-dimensional
structures. We first calculate chemical molecular fingerprints for each ligand and evaluate the
similarity between the two molecular fingerprints using Tanimoto coefficient [162]. The
fingerprint of choice in this study is the Extended Connectivity Fingerprint with maximum
diameter of 4 (ECFP4), which has been successfully applied to ligand-based virtual screening
method, PRW [81]. The use of the same fingerprint also allows for a fair comparison of REMAP
with PRW. It is interesting to compare the different fingerprints in the future study.
To calculate a similarity score between two ligands, c1 and c2, the Tanimoto distance
𝑑 &4(#(1. ,1/ ) was obtained using JChem software from ChemAxon with the Tanimoto metric for the
ECFP4 molecular descriptor type using the command in the Unix environment,
“ChemAxon/JChem/bin/screenmd target_smi query_smi -k ECFP -g -c M Tanimoto” [163]. Then, the ligand structural similarity score, 𝐶(1. ,1/) is simply 𝐶(1. ,1/ ) = 1 −
𝑑 &4(#(1. ,1/ ) . Briefly, two ligands have a higher structural similarity if they have more of the same
chemical substructures (e.g. functional groups) at more similar relative positions. Ligand similarity
scores below 0.5 were treated as noise and set to 0.
Protein primary sequence similarity
Protein-protein similarity matrix is also one of the required inputs for REMAP. The
similarity of a pair of proteins was calculated by algorithmically comparing the primary sequences
of the proteins. NCBI BLAST [164] with an e-value threshold of 1 × 109: and its default options
(e.g. 11 for gap open penalty and 1 for its extension, BLOSUM62 for the scoring matrix, and so
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on) are used to calculate the bit-scores for each pair of proteins. Based on our 10-fold cross
validation (see below), e-value thresholds from 1 to 1 × 1093; did not significantly affect the
performance (data can be found in Supplementary Figure 1 in [110]). Therefore, we decided to use
a moderate e-value threshold of 1 × 109: . Note that the BLAST default is 1 × 109< . A similarity
score for a pair of protein 𝑝2 and protein 𝑝3 was calculated by the ratio of the bit scores for the
pair, 𝑑6#!(5. ,5/) , compared to the bit score of the self-alignment, 𝑑6#!(5. ,5.) . Specifically, the
protein sequence similarity score between the protein 𝑝2 and the protein 𝑝3 is defined as 𝑇(52,53) =
=012(3.,3/)
=012(3.,3.)

.

Benchmark test and data preparation
We used ZINC dataset for the benchmark [27]. The protein-ligand associations were
filtered at IC50 ≤ 10 µM, which yielded 31,735 unique protein-ligand associations for 3,500
proteins and 12,384 ligands. Cell-based assay results or protein complex targets were excluded.
As required for protein sequence similarity calculation, proteins whose primary sequence is
unavailable were also excluded. Protein primary sequences were obtained from UniProt database
[38]. The whole protein primary sequences were used to calculate protein-protein similarity scores
as defined above.
To evaluate REMAP, we performed a 10-fold cross validation on the ZINC dataset
described above. We set the hyperparameters as follows: 𝑤 = 𝛼 = 0.1, 𝑟 = 300, 𝛽 = 0.75, 𝛾 =
0.1, and 𝑝#!8/ = 400 . The optimized values determined by the 10-fold cross validation of
benchmark are shown in Figure 2.2. Figure 2.2B indicates that the best performance is achieved
when 𝛽 = 0.25 and 𝛾 = 0.5. To further assess REMAP, we compared REMAP with several other
methods on ZINC dataset: PRW [81], a ligand-based virtual screening method, NRLMF [111], a
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matrix factorization-based method similar to REMAP, and KBMF with twin kernels (KBMF2K)
[165], WNNGIP [154, 166], a combination of nearest neighbor and Gaussian interaction profile
methods, and another new type of matrix factorization method (Collaborative Matrix Factorization

Max. Iteration

(CMF) [167]) for different types of chemicals and proteins.

Factorization rank (r)

100
200
300
400
500

100
0.76
0.7926
0.8002
0.8008
0.8009

200
0.7606
0.7938
0.7985
0.8
0.8008

300
0.7615
0.7933
0.8005
0.8004
0.802

400
0.7595
0.7934
0.7992
0.8009
0.8015

500
0.7623
0.7925
0.8
0.8017
0.8008

p_prot (p7)

p_chem (p6)
0
0.25
0.5
0.75
1

0
0.6028
0.7713
0.7741
0.7774
0.7773

0.25
0.6343
0.7959
0.7967
0.7961
0.7956

0.5
0.624
0.7774
0.7778
0.7781
0.7779

0.75
0.6063
0.7452
0.7442
0.7424
0.7427

1
0.5809
0.698
0.6915
0.6882
0.6846

3.0483
3.7878
3.7843
3.7822
3.7781

Figure 2.2 Heatmap for REMAP hyperparameter grid search. 10-fold cross validation performances on
ZINC dataset are shown with color bars. Performances indicate the true positive rate at the top 1%
predicted protein-ligand associations. In B, p_chem is 𝛽 and p_prot is 𝛾.
https://doi.org/10.1371/journal.pcbi.1005135

Next, we divided the ZINC dataset into different categories based on the connectivity of
known protein-ligand associations and the degree of uniqueness of the ligands. First, all the ligands
in the dataset were categorized based on the number of known target proteins into ligands having
only one known target, two known targets, and three or more known targets. As a separate
category, the ligands were clustered based on the structural similarity of the most similar ligand in
the dataset with maximum similarity score increment of 0.1, starting from 0.5. Also, all protein
targets in the dataset were categorized based on the number of known interacting ligands into
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proteins having 1-5, 6-10, 11-15, 16-20, and 21 or more interacting ligands. The protein-ligand
association samples were divided using at least one of the two ligand filters. Thus, samples were
divided by number of targets and number of ligands filter, or number of targets and maximum
structural similarity filter. The data categories were used to evaluate predictive performances of
algorithms in various scenarios in drug discovery. Note the different numbers of known targets for
ligands reflect novel and off-target prediction tasks. For example, samples for ligands having only
one known target can be used to evaluate novel target prediction performances in cross validation
settings. Samples for ligands having at least one known target can be used to evaluate performances
in off-target predictions. Our focus is off-target prediction, and it is expected that REMAP is
suboptimal in novel target prediction tasks. This is analogous to the new user or new item problem,
also called cold start problem reviewed by Su et al. [168].
Evaluation of prediction accuracy of REMAP by TPR vs. Cutoff Rank
Our benchmark dataset is heavily unbalanced with much smaller number of known
associations than unknown ones. Moreover, the unknown ones are not necessarily negative. Thus,
a typical metric, such as Receiver Operating Characteristic curve (ROC) cannot reliably evaluate
the performance. Thus, we define a performance measurement that is analogous to ROC curve
without dependencies to the true negatives. We evaluate the performances by the true positive rate
∑ &/?8 ,@A#!#B8A

(∑ 7@(=#!#@( ,@A#!#B8A; TPR, Recall or Recovery) at the top 1% of predictions for each ligand. To be
specific, the top 35 target proteins out of 3,500 for each ligand are considered positively predicted
for our datasets. Thus, for instance, a TPR of 0.965 at the 35th cutoff rank (top 1%) means that
96.5% of the total hidden positive pairs were ranked 35th or better for the ligands in test set.
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Scalability of REMAP as a matrix factorization algorithm
In order for REMAP to be practically applied to whole genome-scale protein-ligand
interaction prediction tasks, its speed on a reasonably sized dataset should be fast enough. We
measured its running time by varying the rank parameter or the size of dataset for both Matlab and
python implementation of REMAP. On the ZINC dataset (12,384 ligands and 3,500 proteins),
from 𝑟 = 100 to 1000 with an increment of 100 and from 𝑟 = 1000 to 2000 with and increment
of 250. 10 replicative tests were performed for each condition. Also, a synthetic protein-ligand
interaction network containing 50,000 ligands and 20,000 proteins with 1% known interactions
are built and used to evaluate the running time of REMAP. The maximum number of iterations
(𝑝#!8/ ) was fixed to 100. A 15-inch MacBook Pro (2018) with 2.2 GHz Intel Core i7 and 32 GB
memory was used to evaluate running time of REMAP in both Matlab and python implementation.
We also compared the speed of different matrix factorization methods with ours. However, due to
the large time complexity and memory requirement for other algorithms, we needed to use a larger
machine. A multi-core node with up to 700 GB of shared memory system in CUNY HPCC for
them on the ZINC dataset. It is noted that the main purpose of this experiment is to show that
REMAP is scalable to whole genome-scale off-target predictions.
Genome-wide chemical-protein association dataset for benchmark study
For performance comparison, protein-ligand associations were obtained from the ZINC
[27], ChEMBL [28] and DrugBank [36] databases and integrated into a larger set of association
data. Assays with IC50 or pIC50 (negative log of IC50 in molarity) information available were
extracted from the databases, and IC50 ≤ 10 𝜇M (equivalent to pIC50 ≥ 5.0) were considered the
activity threshold. The lower IC50 value (greater pIC50), the more potent the association is. UniProt
Accessions and InChI Keys were used to remove duplicate proteins and ligands, respectively. For
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assay recorded with IC50 in µg/L (found in ChEMBL database), the full molecular weights of the
compounds listed on ChEMBL database were used to convert µg/L to µM and applied the same
threshold. After merging the databases, protein-ligand pairs were considered ambiguous if records
exist in both ranges and unobserved otherwise. A total of 198,712 unique ligands and 3,549 unique
target proteins were obtained from the combination of ChEMBL and ZINC with 228,725 unique
protein-ligand active pairs, 76,643 inactive pairs, and 4,068 ambiguous pairs. Of the 198,712
ligands, 722 were found to be FDA-approved small molecular drugs. Furthermore, drug-target
relationships were extracted from the DrugBank database and integrated into the ZINC_ChEMBL
dataset above. As a result, a total of 199,338 unique ligands and 6,277 unique proteins were
obtained from the combination of the three databases with 233,378 unique active associations.
3D-REMAP, integration of 3D structures into REMAP for drug repurposing
REMAP method itself is scalable to genome scale off-target prediction. However, it lacks
structural components, which is an important aspect for successful protein-ligand interaction
prediction. Thus, ligand binding site similarity search across human structural proteome was
performed and integrated into the REMAP method described above. The computational
procedures have been reported in previous studies [23, 169-174]. Briefly, we used PDE3B (PDB
ID 1SO2) as the template structure for the binding site analysis. PDE3B is a reported target for
levosimendan, a candidate for dual-indication precision anticancer treatment in this study. The
SMAP software [175-177] was applied to characterize ligand-binding potential from the
geometric, physiochemical, and evolutionary characteristics of the binding pocket of PDE3B, and
to computationally predict the binding site similarity between the template and 10,472 nonredundant human protein structures in PDB database. The p-value of binding site similarity was
normalized by structural classes (e.g. all-alpha, all-beta, and mixed alpha-beta). The structures
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whose ligand binding sites were predicted to be similar to that of PDE3B with the p-value < 0.002
were selected as the initial off-targets of PDE3B inhibitors. Autodock Vina was used to predict the
binding energy between the selected off-targets and levosimendan, milrinone, anagrelide,
amrinone, and enoximone. Drug-target interactions that had docking scores less than -7.5 were
incorporated into the genome-wide chemical protein interactions network in the next step.
Using REMAP method described above, we incorporated the 3D structure-based
predictions into REMAP, and we further integrated the pipeline with other machine learning
methods. Hence, we name the new pipeline, 3D-REMAP. As described above, genome-wide
drug-target interactions were predicted using 3D-REMAP. 3D-REMAP takes four network
matrices as input: protein-ligand associations (matrix R), structurally predicted off-target
associations (matrix Q), ligand structural similarity, and protein sequence similarity. Note that 3DREMAP takes the structurally predicted association matrix in addition to the other required inputs
to REMAP method. The protein-ligand associations were obtained by integrating three publicly
available resources: 1) large-scale databases, ChEMBL [28] (v23.1) and DrugBank [36] (v5.5.10),
2) four data sets from recent publications about kinome assays [178-181], and 3) protein structurebased off-target prediction from previous step. From ChEMBL, inhibition assays having 𝐼𝐶:; ≤
10 𝜇𝑀 were considered positive. Assays with suboptimal confidence scores (i.e. confidence < 9)
were excluded. From DrugBank database, all available protein-ligand associations, including
drug-target, drug-enzyme, drug-carrier, and drug-transporter associations were collected. The
kinome assays datasets provide protein-ligand associations in different types of activity
measurement. Christmann-Franck et al. collected kinase-ligand binding assays from multiple past
publications and presented the activity standardization protocol in the manuscript, which assumed
an activity with 𝐾# ≤ 5 𝜇𝑀 is active [178]. If the original publication reported percent inhibition
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(or percent activity) at a given compound concentration, the corresponding Ki value was calculated
as follows:

𝐾# =

𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 × (100 − %𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛)
%𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛

If the original publication reported the pKi value, Ki is simply 𝐾# = 1095C1 . For this study,
we followed the above standardization protocol to consistently integrate kinome assays with the
public databases. We considered kinase-ligand associations active if 𝐾# ≤ 5 𝜇𝑀 𝑜𝑟 𝑝𝐾# ≥ 5.3. As
done in REMAP benchmark study above, InChIKey and UniProt Accession are used to remove
duplicate ligands and proteins, respectively. In case the dataset does not provide InChI Keys, we
used OpenBabel to convert all chemical molecules to InChI Key. Assays for low confidence targets
from reference [180] were excluded. Structure-based off-target network was obtained using the
procedure described in the previous section. Ligand-ligand and protein-protein similarity scores
were calculated as described above. MadFast software developed by ChemAxon (Budapest,
Hungary. https://chemaxon.com/) was used to calculate ligand structural similarity matrix, and
BLAST was used to calculate protein-protein similarity matrix. The integrated protein-ligand
association network contains 650,581 positive associations for 1,656,274 unique ligands and 9,685
unique target proteins. The ligand-ligand and protein-protein similarity score matrices contain
122,421,717 and 31,266 nonzero scores, respectively.

2.3 Results
REMAP is highly effective in predicting off-targets even for novel chemicals
We evaluated the performances of algorithms for chemicals having one, two, or more than
three known targets with varying maximum ligand structural similarity ranges or with proteins
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having a certain number of known ligands in the databases (dataset prepared as explained in the
methods and materials section). In general, the performances improve as the number of known
ligands per protein or the maximum ligand structural similarity value increases. In product
recommendation scenarios, it is easier to make better recommendations when there are more of
previous purchase history or more users or items of similar kinds are known in the database. On
the other hand, it is possible to see a decreased performance when there are more of correct answers
to predict. It is important to note that, however, some methods may benefit more from the available
information, reflecting the proper design of the methods for the given problem.
It was noticeable that REMAP performed significantly better than PRW and NRLMF when
there was at least one known target for a chemical whose targets are predicted (Figure 2.3).
REMAP consistently showed greater than 90% recall at the top 1% except in one category where
REMAP is still the best. While PRW and NRLMF also reached reasonably high recall for some
categories (e.g. more than 11 known ligands per proteins, or max7𝐶(1. ,1/) 9 > 0.7 ), REMAP
showed that it can still perform well when there are limited structural similarities between training
and test ligands (Figure 2.3B). In other words, REMAP is applicable to chemicals that are
structurally distant to the ligands already in the dataset. In all cases with at least one known target
for the tested chemicals, REMAP performed best among the three algorithms (Figure 2.3 and
Figure 2.4). Therefore, in practice, REMAP can predict potential drug targets for chemicals with
at least one known target as training data, even when the chemicals are structurally dissimilar to
the training chemicals.
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Figure 2.3 Performance comparison for REMAP, PRW, and NRLMF on the dataset for ligands having
two known targets. L1to5 means 1-5 known ligands per target, and L21more means 21 or more known
ligands per target. Tc0.5to0.6 means 0.5 ≤ max*𝐶("! ,"") , < 0.6. Note that during cross-validation, the
dataset is equivalent to off-target prediction problem, where there is only one known target, and the
other is hidden. Asterisks represent statistical significance based on one-tail t-test (* 𝑝 < 0.05, ** 𝑝 <
0.001).
https://doi.org/10.1371/journal.pcbi.1005135.g003

As shown in Figure 2.3, REMAP outperforms the state-of-the-art NRLFM algorithm in
most of the tested cases. As NRLMF is sensitive to the rank parameter, we carried out
optimizations to determine optimal rank and iterations for NRLMF (Supplemental Figure S4). The
optimal rank and iterations used in the evaluation were 100 and 300, respectively. Moreover, in
the current implementation, REMAP is approximately 10 times faster and uses 50% less memory
than NRLMF. Consistent with the results by Liu et al. [111], the accuracies of NRLFM are
significantly higher than KBMF2K, CMF, and WNNGIP in all of ZINC benchmarks (data not
shown). Overall, REMAP is one of the best-performing methods for the genome-wide off-target
predictions.
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Figure 2.4 Performance comparison for REMAP, PRW, and NRLMF on the dataset for ligands having
three or more known targets. L1to5 means 1-5 known ligands per target, and L21more means 21 or
more known ligands per target. Tc0.5to0.6 means 0.5 ≤ max*𝐶("! ,"" ), < 0.6. Note that during crossvalidation, the dataset is equivalent to off-target prediction problem, where there is only one known
target, and the other is hidden. Asterisks represent statistical significance based on one-tail t-test (* 𝑝 <
0.05, ** 𝑝 < 0.001).
https://doi.org/10.1371/journal.pcbi.1005135.g004

Ligand structural similarity significantly improves REMAP performance, while protein
sequence similarity information contains significant noise
To test whether the ligand structural similarity matrix helps prediction, we performed 10fold cross validation on the ZINC dataset with the contents of the ligand-ligand or the proteinprotein similarity matrix controlled. In other words, about half of the nonzero similarity scores in
ligand similarity matrix were randomly chosen and set to zero for the “half-filled chemical
similarity” matrix, and all entries are set to 0 for the “zero-filled chemical similarity” matrix. The
predictive power of REMAP was noticeably improved when all available ligand similarity pairs
were used, compared to the half-filled or the zero-filled similarity matrix (Figure 2.5A). Similarly,
the contents of the protein similarity matrix were controlled (e.g. half-filled protein sequence
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similarity, and zero-filled protein sequence similarity) while the full ligand similarity matrix was
used. Unlike the ligand similarity experiment, the protein-protein similarity information did not
necessarily improve the performance (Figure 2.5B). Best performance was achieved when a half
of the protein-protein similarity information was used together with the full ligand similarity
matrix, suggesting that there is significant noise in the protein sequence similarity matrix. It is note
that the information is still helpful as seen in the Figure 2.5B compared to the zero-filled matrix
curve. A careful examination of the BLAST-based protein sequence similarity matrix may give an
insight for the design of a novel protein-protein similarity metric for drug-target binding activities.

Figure 2.5 Impact of ligand and protein similarity information on the performance of REMAP,
evaluated by true positive rate at a given cutoff prediction rank. A. Performances evaluated by varying
degree of information in ligand structural similarity matrix. B. Performances evaluated by varying
degree of information in protein sequence similarity matrix.
https://doi.org/10.1371/journal.pcbi.1005135.g005

We also performed grid searches for 𝛽 and 𝛾 on ZINC dataset. Although the performance
was slightly better when the ligand structural similarity importance was maximum (Figure 2.6A),
the difference was too small to conclude that it is best to fix 𝛽 = 1. Instead, the prediction may
rely too much on the ligand structural similarity scores. Therefore, to allow flexibility on utilizing
ligand similarity information, we set 𝛽 = 0.75 at which the performance was almost as accurate
as 𝛽 = 1. On the other hand, the best performance was achieved when the protein sequence
similarity importance, 𝛾, was set to 0.1 (Figure 2.6B), further supporting our claim that proteinprotein sequence similarity is not an optimal choice for the prediction of protein-ligand
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interactions. When jointly optimizing 𝛽 and 𝛾 , their optimal values were 0.25 and 0.5,
respectively, as seen in the 10-fold cross validation benchmark evaluation (Figure 2.2B).

Figure 2.6 Impact of the importance weights for ligand and protein similarity on the performance of
REMAP, evaluated by true positive rate at a given cutoff prediction rank. A. Performances evaluated
by varying degree of importance score for ligand structural similarity. B. Performances evaluated by
varying degree of importance score for protein sequence similarity. p_chem = 𝛽, p_prot = 𝛾.
https://doi.org/10.1371/journal.pcbi.1005135.g006

Our result supports a recent study [162] which showed that Tanimoto coefficient is an
efficient metric for ligand structural similarity calculation for virtual screening tasks. A chemical
molecular fingerprint-based virtual screening method, PRW, was developed by Koutsoukas et al
[81]. PRW defines protein targets as bins that can contain molecular fingerprint features for
interacting ligands. While the fundamental idea of dissecting ligand molecules into functional
fragments is similar to that of our method, it should be noted that PRW does not consider the
information from proteins, as well as the interactome.
REMAP is readily scalable for large-scale protein-ligand interaction networks
In our benchmark studies, REMAP showed great speed without losing its accuracy. On our
benchmark dataset (ZINC; 12,384 chemicals and 3,500 proteins), it took approximately 260
seconds and 380 seconds to run 100 iterations at the rank of 200 (𝑟 = 200, 𝑝#!8/ = 100) for Matlab
and python implementations of REMAP, respectively. The time complexity is approximately
linearly dependent on the rank in both Matlab and python implementation of REMAP (Figure 2.7).
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The scalability of REMAP is superior when compared to KBMF2K, a state-of-the-art matrix
factorization-based protein-ligand interaction prediction algorithm that is also implemented in
Matlab [165]. It took more than 10 days for KBMF2K to run on the same-sized matrix using even
more powerful, high-performance computer system with up to 24 cores and 700 GB shared
memory for the ZINC benchmark (data not shown). Moreover, REMAP was capable of
factorizations with higher ranks while KBMF was limited to rank of 200 in our system due to the
high memory requirement (over 100 GB of memory). Even at a much higher rank (𝑟 = 2,000),
less than one hour was required for REMAP on the same dataset (Figure 2.7).

Figure 2.7 Scalability of REMAP method in both Matlab and python implementation. Running times
for REMAP algorithm for ZINC dataset were recorded 5 times for each low-rank parameter (x-axis).
Average running times for Matlab and python implementations are shown in seconds (y-axis). Error
bars represent ± 7 times standard deviation. Intel Xeon E5-1603 v3 having 4-cores at 2.80 GHz CPU
with 32 GB memory was used for both implementation.

Low-rank profile-based ligand structural similarity analysis
As expected, the percentage of pairs of ligands sharing common targets decreases with the
decrease of the ligand structural similarity measured by the Tanimoto coefficient of ECFP
fingerprints (𝐶(1. ,1/ ) ). The percentage of target-sharing ligand pairs drops below 50% and 20%
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when the Tanimoto coefficient is between 0.5 and 0.6, and less than 0.5, respectively (Figure 2.8).
Thus, a model is less likely reliably detect novel protein-ligand binding pairs by ligand structural
similarity alone, especially when the structural similarity between ligands is limited.

It is

interesting to see how REMAP performs when the ligand structural similarity fails.

Figure 2.8 Percentage of ligand-ligand pairs sharing common targets with different types of similarity
between them. A. Percentage of ligand-ligand pairs (y-axis) with varying ligand structural similarity (xaxis). B. Percentage of structurally dissimilar ligand-ligand pairs (y-axis, 𝐶("! ,"") < 0.5) with varying
low-rank profile similarity (x-axis). Ligand chemical similarities are measured by Tanimoto coefficient.
Ligand profile similarities are measured by 1 − 𝑆%&',(%! ,%" ) . [0.5,0.6) means 0.5 ≤ 𝐶("! ,"") < 0.6.
https://doi.org/10.1371/journal.pcbi.1005135

We analyzed the low-rank ligand profile (matrix UUP) to see whether it represented the
target-binding behavior of the ligands. When filtered by low ligand structural similarity (𝐶(1. ,1/ ) <
0.5), there are 899,871 ligand-ligand pairs. Among them, the cosine similarity between profiles
(𝑆1@A,(1. ,1/) ) of 91,888 ligand-ligand pairs are higher than 0.3. With high profile similarity (0.99 ≤
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𝑆1@A,(1. ,1/ ) ≤ 1), a total of 1,327 ligand-ligand pairs were found of which 1,033 pairs shared at least
one commonly known target. Figure 2.8B shows the percentage of pairs that share the common
target in different profile similarity bins for FDA-approved drugs. This suggests that REMAP can
provide a protein-ligand binding profile that cannot be captured by ligand structural similarity
alone.
When the ligand profile similarity is limited to 𝑆1@A,(1. ,1/ ) ≤ 0.3, the percentage of ligand
pairs that share a common target drops below 50% (Figure 2.8B). We constructed a ligand-ligand
similarity network by filtering out ligand pairs with 𝑆1@A,(1. ,1/ ) ≤ 0.3, then applied the MCL
algorithm on the ligand-ligand network to find clusters of similar ligands. The largest cluster of
ligands contained a total of 313 ligands, and their relationships to diseases were examined based
on the known associations annotated in CTD database [182]. As a result, we found ligands are
drug molecules that are related to mental disorders, including hyperkinesis, dystonia, catalepsy,
schizophrenia and basal ganglia diseases as the mostly related diseases. The most frequent known
protein targets by the ligands were GPCRs. It is comparable that GPCRs were targeted 1,924 times
while kinases were targeted only 55 times. While it is interesting to further examine the cluster,
validating all possible protein-ligand pairs in the largest cluster is inefficient.
A smaller cluster of drugs consists of a total of 31 FDA-approved drugs 26 of which are
known to target kinases or interact with microtubule (Table 2.2). Seven drugs in the cluster have
not been used for anticancer treatment and were found to be closely related to the anticancer drugs
(Figure 2.9 and Table 2.2). Interestingly, several of them have been tested for their anticancer
activity. For instance, colchicine (also known as colchine), an FDA-approved drug for gout
treatment, has been shown to have anti-proliferative effects on several human liver cancer cell
lines at clinically acceptable concentrations [183]. Griseofulvin is an antifungal antibiotic drug,
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which appears to be effective as an anticancer drug when used together with other anticancer
treatments [184]. The three anthelmintic drugs, albendazole, mebendazole and niclosamide, have
been studied and repurposed for their anticancer therapeutic effects on different types of cancers.
Albendazole has been shown to be effective in suppression of liver cancer cells both in vitro and
in vivo [185], and recently has been repurposed for ovarian cancer treatment with a bovine serum
albumin-based nanoparticle drug delivery system [186]. Mebendazole showed anticancer activities
in human lung cancer cell lines [187] and human adrenocortical cancer cell lines [188], and it has
been repurposed as a treatment for colon cancer [189]. Niclosamide and mebendazole showed
beneficial effects in glioblastoma in different studies [190, 191]. Use of aprepitant was proposed
in combination with other compounds to improve the efficiency of temozolomide, the current
standard treatment for glioblastoma [192]. Anticancer activity of carbidopa hydrate has not yet
been reported. These literature evidence support the utility of REMAP to repurpose existing drugs
for another uses, especially as an anticancer treatment. Experimental validations of predicted
anticancer activities will further demonstrate the strength and promise of REMAP as a systems
pharmacology approach.

Figure 2.9 Clusters of ligands based on the low-rank profile similarity A. Overview of the ligand
clusters with the anticancer drug cluster highlighted. B. Inset of the anticancer drug cluster highlighted
in A. 25 known anticancer drugs are in light blue boxes, and 7 other FDA-approved that are closely
linked to the known anticancer drugs are in dark blue boxes.
https://doi.org/10.1371/journal.pcbi.1005135.g008
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Table 2.2 The known uses and target information for the anticancer drug cluster in Figure 2.9 obtained
from DrugBank. The known targets are in UniProt Accession.
Drug name

Approved treatment(s)

Known binding target(s)

Albendazole

Parenchymal neurocysticercosis

F1L7U3, Q71U36, P68371, P83223

Principal mode of action
Tubulin polymerization inhibitor

Aprepitant
Carbidopa
hydrate
Colchine

Antiemetic

P25103

Substance P/Neurokinin NK1 receptor
antagonist

Reduce adverse effects of levodopa in Parkinson
disease treatment

P20711

DOPA decarboxylase inhibitor

Gout

Q9H4B7, P07437

N/A (depolymerize microtubule)

Griseofulvin

Ringworm infection

P10875, P87066, Q99456

N/A

Mebendazole

Anthelmintic

Q71U36, P68371

Tubulin polymerization inhibitor

Niclosamide

Anthelmintic against tapeworm infections

P40763, O60674, P12931

disrupt oxidative phosphorylation

Aza-epothilone B

Breast cancer

Q13509

Microtubule stabilizer

Bosutinib

Chronic Myelogenous Leukemia

P11274, P00519, P07948, P08631, P12931,
P24941, Q02750, P36507, Q9Y2U5,
Q13555

Tyrosin kinase inhibitor

Cabazitaxel

Prostate cancer

P68366, Q9H4B7

Microtubule stabilizer

Crizotinib

Non-small cell lung cancer

Q9UM73, P08581

Anaplastic lymphoma kinase inhibitor

P15056, P04049, P57059, Q8NG66,
P53667
P00519, P12931, P29317, P06239, P07947,
P10721, P09619, P51692, P24684, P06241
Q9H4B7, P10415, P11137, P27816,
P10636, O75469

Inhibitor of some mutant BRAF
kinases
BRC/ABL and Src family tyrosine
kinase inhibitor

P00533, O75469

N/A (EGFR inhibitor)

Dabrafenib

Metastatic melanoma

Dasatinib

Chronic myeloid leukemia

Docetaxel

Breast, ovarian and non-small cell lung cancer

Erlotinib

Non-small cell lung cancer, pancreatic cancer

Gefitinib

Non-small cell lung cancer

P00533

EGFR inhibitor

Imatinib

Chronic myelogenous leukemia

A9UF02, P10721, O43519, P04629,
P07333, P16234, Q08345, P00519, P09619

Tyrosine kinase inhibitor

Nilotinib

Various leukemias (investigational)

P00519, P10721

Tyrosine kinase inhibitor

Paclitaxel
Pazopanib
Ponatinib
Regorafenib
Ruxolitinib
Sorafenib
Sunitinib
Trametinib
Vandetanib
Vinblastine
Vincristine
Vindesine
Vinorelbine

P10415, Q9H4B7, O75469, P27816,
Lung, ovarian and breast cancers
P11137, P10636
P17948, P35968, P35916, P16234, P09619,
Renal cell cancer and soft tissue sarcoma
P10721, P22607, Q08881, P05230,
Q9UQQ2
P00519, P11274, P10721, P07949,
Q02763, P36888, P11362, P21802,
Chronic myeloid leukemia
P22607, P22455, P06239, P12931,
P07948, P35968, P16234
P07949, P17948, P35968, P35916, P10721,
Metastatic colorectal cancer and gastrointestinal
P16234, P09619, P11362, P21802,
stromal tumors
Q02763, Q16832, P04629, P29317,
P04049, P15056, P15759, P42685, P00519

Microtubule stabilizer

Microtubule stabilizer
Tyrosine kinase inhibitor

Bcr-Abl tyrosine kinase inhibitor

Multiple kinases inhibitor

Janus Associated Kinases (JAK) 1 and
2 inhibitor
P15056, P04049, P35916, P35968, P36888,
Inhibitor of Raf kinase, PDGF,
Renal cell carcinoma
P09619, P10721, P11362, P07949, P17948
VEGFR 2 and 3
Renal cell carcinoma and gastrointestinal stromal P09619, P17948, P10721, P35968, P35916, Multi-targeted receptor tyrosine kinase
tumor
P36888, P07333, P16234
inhibitor
Allosteric inhibitor of mitogenMetastatic melanoma
Q02750, P36507
activated extracellular signal regulated
kinase 1 and 2
Myelofibrosis

Broad range tumor types
Breast, testicular cancers, lymphomas,
neuroblastoma
Acute lymphocytic leukemia, lymphomas,
neuroblastoma, rhabdomyosarcoma
Acute leukemia, malignant
lymphoma, Hodgkin’s disease, acute
erythraemia, acute panmyelosis

P23458, O60674

P15692, P00533, Q13882, Q02763

Inhibitor of VEGFR

Q71U36, P07437, Q9UJT1, P23258,
Q9UJT0, P05412

N/A (mitosis inhibition, metaphase)

P07437, P68366

N/A (mitosis inhibition, metaphase)

Q9H4B7

mitosis inhibition, metaphase

P07437

N/A (mitosis inhibition, metaphase)

Non-small cell lung carcinoma

https://doi.org/10.1371/journal.pcbi.1005135.t002
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Rational polypharmacology strategy for discovering dual-indication cross-gene family multitarget agents
With the promising utility of REMAP method for protein-ligand off-target prediction, we
propose a new strategy that can systematically utilize off-targets to maximally benefit from multitargeting drug molecules. The rationale of our multi-target drug repurposing strategy is that the
serious side effect caused by therapeutic target(s) (i.e. on-target effect) or anti-target(s) (i.e. offtarget effect) of a drug can be mitigated by its or another drug’s interaction with an off-target,
which is against the side effect, as shown in Figure 2.10. The drug-off-target interaction can come
from a single polypharmacological agent or multiple drug combination. In this chapter, we focus
on searching for marketed drugs that may act as a dual-indication agent that can mitigate the
cardiotoxicity of anticancer therapy and present anticancer potency at the same time.
Contemporary anticancer therapeutics, such as tyrosine kinase inhibitors, anthracycline
chemotherapy, and immunotherapy, are all known to be associated with cardiotoxicity [193].

Figure 2.10 Illustration of our rational design of dual-action drug repurposing. A. Concept figure for
dual-action drug levosimendan, which targets both RIOK1 and PDE3 for therapeutic and mitigating side
effects. B. Our 3D-REMAP pipeline that integrates structural systems pharmacology with chemical
genomics, bioinformatics, and statistical machine learning tools for drug repurposing.
https://doi.org/10.1371/journal.pcbi.1006619.g001
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Hypothesis generation using 3D-REMAP, a genome-scale multi-target screening platform
The rational discovery of the dual-indication drug was performed using a novel genomescale multi-target screening platform, 3D-REMAP, as illustrated in Figure 2.10B. In our
subsequent study, we introduce 3D-REMAP framework, which integrates diverse data from
structural genomics and chemical genomics, as well as synthesized tools from bioinformatics,
cheminformatics, biophysics, and machine learning [100]. We briefly introduce the 3D-REMAP
framework in this chapter. Interested readers are referred to the published manuscript [100]. Since
each data set alone is biased, incomplete, and noisy, and a single computational or experimental
tool has its inherited advantages and limitations, the integrative analysis may provide more
comprehensive and reliable outcomes. 3D-REMAP takes four networks as input: a protein-ligand
interaction network, represented by the matrix R in Eq. 2.1. In this study, the matrix R contains
650,581 positive protein-ligand pairs for 1,656,274 unique ligands and 9,685 unique target
proteins. In addition to R, two other input networks are a ligand structural similarity network and
a protein sequence similarity network (Figure 2.1). The details in the construction of protein-ligand
association, chemical-chemical similarity, and protein-protein similarity networks are described in
the Materials and Methods section.
Since observed protein-ligand interaction matrix from chemical genomics databases is
highly sparse, one of the unique features of 3D-REMAP is to apply ligand-binding site similarity
search and protein-ligand docking to screen off-targets of given ligands across human structural
proteome [23, 169-174]. The putative ligand-off-target interactions are predicted by structural
comparisons for the binding pockets (SMAP software [175-177]) and protein-ligand docking
[194]. The predicted ligand-off-target interactions serve as imputations to fill in the unobserved
entries in the matrix R. The structural genomics data are complementary with the chemical
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genomics data and may provide additional information on genome-wide protein-ligand
interactions.
Using the matrix R and Q along with ligand-ligand and protein-protein similarity networks
as input, 3D-REMAP algorithm described above was then applied to predict the binding profiles
of the given drugs against the 9,685 targets. To reduce the impact of the potential false positives
from the off-target prediction, a confidence weight can be supplied to quantify the uncertainty of
the prediction, making 3D-REMAP robust to noisy data. Finally, atomic-level details of the
prioritized drug-off-target interactions are analyzed for lead optimization using flexible proteinligand docking. Because 3D-REMAP integrates cheminformatics, SMAP, protein-ligand docking,
and machine learning and is scalable to tens of thousands of protein targets on genome-scale tasks,
it may predict off-targets that are overlooked by protein structure-based approaches and other
cheminformatics methods alone. The integrated 3D-REMAP pipeline showed unmatched accuracy
in predicting drug-off-target interactions compared to the accuracy of each component method
without integration. The potential of such combinational framework is strongly supported by the
experimental validations of our predicted drug-off-target interactions between levosimendan and
multiple kinases. The proprietary KinomeScan assay confirmed the strong binding affinity of
levosimendan against RIOK1 (Kd = 0.82 𝜇M) and several other kinases. Downstream analyses
using statistical machine learning methods predicted the use of levosimendan as an anticancer
therapy, which is also experimentally validated using cancer proliferation inhibition assays [100].
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2.4 Discussions
REMAP improves the predictive power of off-target prediction and drug repurposing
In this chapter, we first developed REMAP, a one-class collaborative filtering application
to predict off-target interactions from protein-ligand association network. Our extensive
benchmark studies show that REMAP outperforms existing methods in most of the cases for the
off-target prediction. Compared with other state-of-the-art matrix factorization algorithms, the
performance of REMAP comes from several improvements. First, we formulated the proteinligand interaction prediction as a one-class collaborative filtering problem; thus, the negative data
are not required for the training. Second, a priori knowledge including known negative data can
be incorporated into the matrix factorization framework with imputation and weight matrices.
Finally, the imputation and weight values can be either simplified as scalars or detailed to
incorporated a priori knowledge from other methods. REMAP boasts unmatched computational
scalability when the imputation and weight values are simplified, and its performance can be
significantly improved when they are carefully filled based on other classes of data sets and
computational methods as shown in 3D-REMAP.
The efficiency and effectiveness of REMAP allows us to predict proteome-wide target
binding profiles of hundreds of thousands of ligands. As the proteome-wide target binding profile
is more correlated with phenotypic response than a single target-binding activity, REMAP can
facilitate linking molecular interactions in the test tube with in vivo drug activities. When using a
multitarget binding profile predicted by REMAP as the signature of a ligand molecule, 7 drugs
were found to be associated with anticancer therapeutics, although they do not have detectable
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ligand structural similarity. Among them, the anticancer activities of 6 drugs were supported by
literature evidence. Thus, REMAP itself could be a great tool for drug repurposing.
Using our new systems structural polypharmacology pipeline, 3D-REMAP, we
computationally predicted and experimentally validated that levosimendan – a marketed drug for
heart failure – can inhibit the growth of multiple cancer cell lines, notably, lymphoma. The
anticancer activity of levosimendan mainly comes from the modulation of RNA processing
pathway through the inhibition of atypical kinase RIOK1. RIOK1 represents a new anticancer
target [195, 196], and the chemical space of its inhibitors has just emerged. Tyrosine kinase
inhibitors have been previously approved for treatment of lymphoma [197, 198]. Our findings
suggest that levosimendan could be used as a combination therapy or a potential lead compound
for new multitarget drugs for lymphoma. On one hand, levosimendan may be combined with other
tyrosine kinase inhibitors that are associated with cardiotoxicity. Different from inhibitors
generated from high-throughput screening or de novo design from a single target, it is known that
levosimendan interacts with other protein targets for therapeutic effects than RIOK1. The
combination of levosimendan and tyrosine kinase inhibitors may not only reduce the cardiotoxicity
of tyrosine kinase inhibitors but also enhance the anticancer efficacy since they act on different
cancer-associated pathways. On the other hand, levosimendan interacts with multiple kinases that
are associated with cancers as well as proteins that are responsible for heart failure. The
promiscuity of levosimendan may allow us to utilize it as a lead compound to design a new type
of dual-action agent by modulating multiple targets that are involved in both side effects and
disease mechanisms. In many cases, disease-causing genes have pleiotropic effects on biological
systems, thereby making on-target side effect(s) unavoidable. In contrast to the conventional drug
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discovery processes that design highly selective ligands, it is possible to mitigate the side effect by
designing a drug molecule that binds to an off-target that is against the side effect [199].
Remaining issues and future directions
Although REMAP showed its great potential on genome-wide off-target predictions as
discussed above, two issues remain: the cold start problem and suboptimal protein similarity
metrics. Similar to other matrix factorization algorithms such as NRLMF, REMAP suffers from
cold start problem, also known as new user or new item problem. In other words, difficulty is
expected when recommending a product for a new user if the new user has never purchased or
reviewed a product in the database [168]. For novel ligands that do not have any known targets in
the dataset, REMAP did not show better performance than PRW. Moreover, if the target of a novel
ligand has 10 or fewer known ligands, the recovery of REMAP drops below 0.5 (Figure 2.11A).
When the novel ligand is similar to those ligands in the database, the recovery of REMAP reached
above 90% (Figure 2.11B). These suggest that, in practice, existing matrix factorization-based
methods, including REMAP, are suboptimal if the ligands of interest do not have any known
interactions. To resolve, it is possible to design an algorithm that combines the benefits of PRW
or other algorithms with REMAP. The use of confidence weights and a priori imputation makes
it straightforward yet powerful for REMAP to incorporate additional information, as shown in our
3D-REMAP pipeline. In addition, the computational efficiency of REMAP makes it possible to
apply active learning to overcome the cold start problem [200-202].

72

A
True Positive Rate

1

*

0.9
0.8
0.7

**
**

*
**

**
*
**

0.6
0.5
0.4
0.3
0.2
0.1
0

B
True Positive Rate

1
0.9
0.8

*

*
*

0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

Figure 2.11 Performance comparison for REMAP, PRW, and NRLMF on the dataset for ligands having
only one known target in the network. L1to5 means 1-5 known ligands per target, and L21more means
21 or more known ligands per target. Tc0.5to0.6 means 0.5 ≤ max*𝐶("! ,"") , < 0.6. Note that during
cross-validation, the dataset is equivalent to cold start problem, where the ligands are new in the dataset.
Asterisks represent statistical significance based on one-tail t-test (* 𝑝 < 0.05, ** 𝑝 < 0.001).
https://doi.org/10.1371/journal.pcbi.1005135

The suboptimal performance of REMAP may arise from the lack of molecular-level
biochemical details in deriving the protein similarity metrics. When testing the ZINC dataset, we
found that REMAP performs better as lower weight was assigned for protein-protein sequence
similarity data (Figure 2.6B). In addition, the predictive power of REMAP improved when about
half of the randomly selected protein-protein similarity scores were set to zero, further confirming
that the noisy metric confounds relating global sequence similarity to ligand binding activities
(Figure 2.5B). It is not surprising that proteins with similar sequences do not necessarily bind to
similar ligands, as protein-ligand interaction is governed by the spatial organization of amino acid
residues in the 3D protein structure [203]. Amino acid mutations/post-translational modifications
and conformational dynamics may alter the ligand-binding activity through direct modification of
the ligand-binding site or allosteric interaction. A protein may also consist of multiple binding sites
73

that can accommodate different types of ligands. Thus, two proteins with high sequence similarity
do not necessarily share ligands because the they may possess different 3D conformations,
especially in their binding sites [203]. In contrast, two proteins with low sequence similarity can
still bind to the same ligands if their binding pockets are similar [176, 204]. The binding site
similarity can be a more biologically sensitive measure of protein-protein similarity for the offtarget prediction [169-174]. While such work is on-going, it also inspired the development of our
new pipeline, 3D-REMAP, which integrates structural genomics into the REMAP algorithm.
In our subsequent work, we published our new pipeline, 3D-REMAP, which integrates
structural genomics and other types of methods into REMAP to repurpose levosimendan, a heart
failure treatment as an anticancer treatment [100]. To further improve the potential of
levosimendan in cancer treatment, several points remain to be investigated. First, the anticancer
potency of levosimendan can be further enhanced by designing personalized derivatives. The
binding pose analysis may provide valuable clues to the molecular design. Second, a patent has
shown that PDE3 inhibitors may be active against HeLa cell line [205]. It will be interesting to test
the sensitivity of levosimendan and other PDE3 inhibitors on more cancer types. Finally, in vivo
anticancer activity of levosimendan need to be verified.
Despite the promising results, the rational design of multi-indication multitarget drugs is
an extremely challenging task. It requires modeling drug actions on a multi-scale, from genomewide protein-ligand associations to system-level drug responses. We showcase that 3D-REMAP
is a promising tool towards designing polypharmacological agents and drug repurposing. 3DREMAP provides a framework to integrate heterogeneous data from chemical genomics, structural
genomics, and functional genomics, and synthesize a variety of computational biology tools from
bioinformatics, machine learning, biophysics, and systems biology for the multi-scale modeling of
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drug actions. An emerging paradigm of systems pharmacology enables the understanding of
cellular mechanism of drug action at organismal resolutions, but it lacks the potential to screen
and design new chemical entities. Structure-based drug discovery has been successful in
identifying novel drug molecules with fine-tuned binding properties to specific targets. However,
the designed protein-ligand interactions may not transform well into the desired organismal level
drug response. 3D-REMAP may bridge the structure-based drug design and systems
pharmacology; thus, it facilitates drug development for complex diseases. Nevertheless, many
aspects of 3D-REMAP could be improved. First, the performance of each individual algorithm,
such as protein-ligand docking and protein-ligand interaction prediction in the computational
pipeline needs to be improved. Second, we use REMAP to integrate different experimental data
sets and computational predictions into one pipeline. Other machine learning techniques such as
deep learning could provide more powerful integration. Third, there still exists a big gap between
in vitro drug activity and clinical phenotype. More data types and modeling techniques, such as
quantitative systems pharmacology and pharmacokinetics modeling as well as data mining of
electronic health records should be incorporated into the pipeline for more comprehensive
prediction pipeline. With the knowledge of genome-wide protein-ligand interaction profiles and
their associations with diseases, significant time and cost could be saved in the lead optimization,
pharmacokinetics, pre-clinical, and other downstream research activities using pro-target strategy
for drug discovery.
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CHAPTER THREE

WINTF: An Extension of REMAP Using Matrix Tri-factorization for Target Gene
Prediction for Transcription Factors
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3.1 Introduction
Transcription factors (TFs) regulate gene expression via complex interactions with the
target genes, and the regulations are critical for cellular organizations and development. TFs can
activate or deactivate their target genes by binding to the recognition DNA sequences, also known
as motifs. In addition, TFs can interact with each other or recruit other protein components to form
a protein complex to perform transcriptional regulations [206]. Such complex regulations explain
the relative complexity of higher metazoans compared to lower organisms, such as unicellular
eukaryotes or prokaryotes, where the organismal complexity cannot be fully explained by the
number of distinct genes alone. It is established that the human genome contains only about twice
as many genes as Drosophila, and the difference is largely from the duplication of the same genes
rather than new ones [207]. Thus, the incredibly high complexity of humans cannot be understood
without considering that human genome contains approximately one TF per every ten genes [208].
The complicated transcriptional regulations by TFs seems to play an important role in development.
In Drosophila, for example, deletion of one TF gene (Antennapedia) cause a serious phenotypic
defect – legs are on the head where antennae is supposed to be [209]. Thus, understanding the
associations between TFs and target genes is an important research topic in the biological and
biomedical sciences.
Recent advancement of sequencing and molecular biology technology has led to
developments of laboratory techniques to identify TF-gene associations on a large scale, and the
output data have been utilized for computational studies to integrate results from different
experiments [210]. Chromatin immunoprecipitation (ChIP)-based techniques include ChIP-chip
[211], ChIP-seq [212], and ChIP-PET [213]. The sequences from ChIP techniques are enriched
around the binding sites for the TFs. Therefore, the target genes can be inferred by mapping the
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sequence read peaks to the genome. Several studies have focused on identifying the true
associations from the ChIP data by statistical comparison with the sequence peaks to the
background signal [214-216]. DamID is an alternative technique to ChIP techniques to identify
TF-DNA interactions [217]. ChIP Enrichment Analysis (ChEA) [218] is a freely available tool
that combines TF-DNA associations manually curated and automatically collected from 115
publications for the ChIP-X experiments, including the three ChIP techniques and DamID. ChEA
takes a set of genes (whose expression levels are significantly altered) and finds the potential TFs
that are predicted to interact with most of the genes. ChEA represents a reliable but incomplete
resource for known TF-target gene associations; thus, it can serve as a benchmark for algorithm
development.
Although the laboratory techniques mentioned above are essential for studying TF-DNA
associations, they are imperfect. Sequencing data from experiments contain noisy reads that are
not necessarily indications of the corresponding TF-DNA interactions. In addition, ChIP protocols
are often dependent on the quality of the antibody used in the experiments [219]. The antibody
may not be specific enough, or it could even block successive interactions between TFs, making
it difficult to observe indirect interactions. DamID is largely limited by its resolution as the GATC
motifs are required, although the use of antibodies is not required and therefore has advantages
over the ChIP protocols [220]. Thus, the currently known TF-gene associations represent
incomplete, biased, and noisy dataset due to the limitations of experimental techniques.
Computational methods to infer missing TF-gene associations are needed to reveal a
comprehensive picture of the gene regulations.
Collaborative filtering methods are a group of computational algorithms that have been
widely used in a broad range of areas to infer unobserved associations based on the observed ones
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with or without additional information [168]. The early generations of collaborative filtering
methods are based on probabilistic models and aimed for business concerns, such as
recommending products for users in commercial platforms, such as Amazon.com and Barnes and
Noble [221, 222]. First proposed by Paatero and Tapper in 1994, nonnegative matrix factorization
(NMF) [223] has been adopted for recommendation problems, especially after the development of
the fast multiplicative update rules by Lee and Seung [224]. One of the most successful
applications is the popular Netflix challenge, where unknown user-video preferences are predicted
using the past activities of the users [225]. The early collaborative filtering methods heavily rely
on the availability of the information about the users’ past activities, and it is difficult to make
predictions for new users, called cold start problem. To overcome the drawback, more advanced
collaborative filtering methods attempt to utilize additional information, including user-user or
item-item similarities [168]. Recently, Yao et al. developed a one-class collaborative filtering
algorithm, wiZAN-dual, that utilizes both user-user and item-item similarity information as well
as regularization and imputation techniques applied to improve prediction accuracy [161].
FASCINATE is an extension of wiZAN-dual on a multilayered network [226]. REMAP is an
application of wiZAN-dual for biomedical problems introduced in Chapter 2. REMAP predicts
off-targets of ligands based on the ligand structural similarity and protein sequence similarity as
well as the information about the known protein-ligand interactions. In the comprehensive
benchmark studies shown in Chapter 2, REMAP outperforms other state-of-the-art methods. Thus,
we will only use REMAP as a baseline for the performance evaluation in this chapter.
As shown in Chapter 2, biomedical and biochemical association predictions can be
modeled as collaborative filtering problems by replacing users with ligands and items with proteins.
Similarly, the unobserved TF-gene associations can be inferred using REMAP. However, one
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limitation of REMAP is that the factorized low-rank matrices for both ligands and proteins must
have the same rank. That is, the TF-side and gene-side latent features must be in the same
dimensional latent space, which is unrealistic, particularly if the number of TFs and genes are very
different. Moreover, the relationship between the TF and the gene will be modeled by the inner
product between two latent features. The inner product could be too simple to capture complex
nonlinear relationships between TFs and genes. In this chapter, we present a new weighted imputed
neighborhood-regularized tri-factorization algorithm (WINTF), an extension of REMAP, which
allows us to set different feature sizes for TFs and genes as well as increase the power of modeling
complex relationships among them. We apply WINTF to the target gene prediction of TFs, in
which the latent features of TFs and genes have different ranks. In the benchmark, WINTF
achieves better prediction accuracy for TF-gene association prediction, compared with REMAP
and vanilla tri-factorization method that do not use the advanced features of REMAP and WINTF,
such as weight, imputation, and neighborhood-regularization. Many of our inferred novel
associations are supported by literature evidence. Further applications to tissue-specific TF-gene
association prediction will significantly enhance our knowledge in transcriptional regulation.
3.2 Related Works and Contributions
Here we review the existing methods for target gene identification tools and relevant
databases, followed by methods in the similar mathematical framework. Existing TF-related
studies mainly focus on prioritizing the TF-DNA binding peaks to collect the putative TF-gene
associations from ChIP-X experiments and the databases for the known TF-gene associations. To
the best of our knowledge, there are few artificial intelligence and machine learning-based TFgene prediction tools that take known TF-gene associations as input to infer unknown ones.

80

Therefore, WINTF is the first machine learning algorithm for the target gene prediction of
transcription factors.
Target identification from profile (TIP) is a probabilistic model that ranks target genes for
TFs based on the relative strengths of binding signals from ChIP experiments, with an assumption
that the binding signal is normally distributed [227]. Identifying target genes (iTAR) is an online
server, which is designed to overcome the limitation from the normality assumption in TIP by
applying a Gaussian mixture model to estimate p-values [228]. Covariance based extraction of
regulatory targets using multiple time series, CERMT, infers TF target genes based on an
assumption that the true target genes for TFs will show similar response pattern to the TFs [229].
Targetfinder is a computational tool to predict target genes with an assumption that the genes with
similar expression profiles are likely to be regulated by the same TFs [230]. These methods either
take ChIP experimental data as input or rely on the gene expression data to compare the input
genes. A recent study combining these ideas infers functional TF-gene associations by correlating
ChIP data and gene expression profiles [231].
TRANSFAC is a database for TF-gene interactions from experimental data, which has been
managed and updated to adopt new data across different organisms as well as tissue-specific
regulations [232, 233]. In addition to the information about TFs, their binding sites, and target
genes, the new TRANSFAC database contains information about the control of gene expressions,
the source cell line for TFs, and binding sites for different experimental conditions, if available
[234]. JASPAR is another TF-gene association database for matrix-based TF binding sites from
published experiments [235]. The updated version of JASPAR includes multiple species in six
taxonomic groups [236]. The famous encyclopedia of DNA elements (ENCODE) project, initiated
in 2004, aimed to identify all functional elements in the human genome, which includes TF-gene
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associations [237]. ChEA presents a large collection of TF-gene associations that are manually
curated and computationally extracted from over 100 published ChIP-X experiments [218].
TRRUST is a more recent database for human TF-gene associations by text-mining a large volume
of literature abstracts [238]. TRRUST version 2 includes TF-gene interactions in mice as well as
more for humans [239]. TRANSFAC, JASPAR, ENCODE project and ChEA databases are also
available in Harmonizome, an integrated knowledgebase about genes and proteins, developed to
facilitate easy and reproducible access to and learning from a large amount of biomedical data [43].
Human transcriptional regulation interactions database (HTRIdb) is a publicly available database
containing experimentally validated human TF-gene associations [240].
As mentioned in the introduction, NMF-based models have been applied to predict
unknown associations such as unobserved protein-ligand binding. SymNMF is an NMF-based
method to integrate and infer missing similarity information between proteins and ligands from
multiple sources [241]. Matrix Tri-factorization (MTF) differs from NMF in that the input matrix
is factorized into three latent feature matrices (e.g. matrices 𝐹, 𝐺, and 𝑆 in Table 3.1), instead of
two (e.g. matrices 𝐹 and 𝐺 where 𝑟 = 𝑠). Unlike aforementioned NMF or MTF-based ranking
methods that heuristically optimize the feature sizes (e.g. 𝑟 and 𝑠 in Table 3.1), MTF-based
supervised clustering requires prior knowledge to determine the feature sizes. Hwang et al.
developed an MTF-based supervised clustering method (R-NMTF) for disease phenotypes and
genes regularized by phenotype similarity and protein-protein interaction network [242]. Park et
al. developed NTriPath to cluster cancer types and genes regularized by protein-protein interaction
data [243]. While the output clusters may be utilized for certain ranking tasks, these methods
require prior knowledge in the number of clusters and correct cluster labels in addition to the
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regular inputs for NMF- or MTF-based ranking methods. MTF has been applied to gene function
prediction, patient stratification, and disease module detection in other studies [244, 245].
Our contributions in this chapter are mainly threefold. First, we develop a new algorithm WINTF,
which incorporates sample weight, imputation, and side information into the existing trifactorization frameworks for the first time [244, 245], making it better handle noisy and sparse
data. Second, we present an efficient optimization algorithm based on the multiplicative update
rule. Finally, we develop an accurate machine learning method for the target gene prediction of
TFs for the first time.
3.3 Methods
Prediction Method Description
We first present in this section a mathematical formulation of the one-class collaborative
filtering problem. The optimization function for our prediction algorithm, weighted and imputed
neighborhood-regularized tri-factorization (WINTF) in Eq. 3.1 with the symbols described in
Table 3.1. Then, we describe how WINTF differs from REMAP, a single-ranked counterpart of
WINTF. We also present the update rules for our algorithm, based on the multiplicative update
rule by Lee and Seung [224].
3

𝐽 = i𝑊⨀7𝑅 + 𝑃 − (𝐹𝑆𝐺 & )9i + 𝛼(‖𝐹‖3 + ‖𝑆‖3 + ‖𝐺‖3 )
+𝛽𝑡𝑟(𝐹 & (𝐷D − 𝑀)𝐹) + 𝛾𝑡𝑟(𝐺 & (𝐷E − 𝑁)𝐺)

(3.1)

WINTF algorithm is designed to find the nonnegative low-rank feature matrices 𝐹, 𝑆, and
𝐺 that minimizes the optimization function in Eq 3.1. The optimization function 𝐽 consists of four
terms as shown in Eq. 3.1. Although the formula is slightly different from that for REMAP, most
ideas remain the same. The shared ideas are described in the following paragraph.
As mentioned, WINTF is an extension of REMAP in Chapter 2. REMAP was applied to
predict off-target protein-ligand associations based on the wiZAN-dual algorithm, which was
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originally designed to predict user-item preferences [161]. REMAP and WINTF share several
design ideas. They both take the known user-item (protein-ligand in REMAP application)
associations with user-user similarity scores and item-item similarity scores. The inputs are
therefore three network matrices: user-item association, user-user similarity, and item-item
similarity network matrices. The core MF algorithm attempts to find the latent matrices containing
the feature vector representations of users and items, such that the dot product of the matrices
reconstructs the known association network. Both WINTF and REMAP also commonly take a
penalty weight, an imputation value, a regularization parameter, and importance weights for useruser and item-item similarity information as user-defined parameters. The penalty weight is to
indicate the reliability of the known associations, and the imputation value indicates the probability
of unknown associations to be positive. They can be either obtained from a priori knowledge, such
as the false positive rate of high-throughput experiments or tuned as hyperparameters, or as
described in the Chapter 2 for 3D-REMAP. The last two terms in Eq. 3.1 accounts for the similarity
principle (i.e. similar users prefer similar items, also called homophily effect). The two importance
parameters control how much the corresponding similarity scores should affect the optimization.
In both WINTF and REMAP the similarity principle is critical. The similarity scores, which can
be measured by external methods (e.g. ligand structural similarity for different drugs introduced
in Chapter 2), are used to reflect the similarity principle by updating the low-rank matrices so that
the feature vectors for two similar users or items are closer in Euclidean space. Further details
about the design of the optimization function are available in Chapter 2.
The key difference between WINTF and REMAP is that WINTF is designed to calculate
three low-rank matrices to approximate the known association matrix, as opposed to only two
matrices for REMAP and other traditional NMF methods. The optimization function for REMAP
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can be obtained by removing the matrix 𝑆 in the Eq. 3.1. Without the matrix 𝑆, however, one can
easily see that the matrix inner product 𝐹𝐺 & must be in the same dimension as the known
interaction matrix 𝑅. Therefore, the matrices 𝐹 and 𝐺 must have the same rank. In other words,
the feature sizes for both users and items must be the same. This single-rank constraint is
undesirable unless the actual feature sizes are coincidentally identical. The feature interaction
matrix 𝑆 alleviates the single-rank constraint, making it possible to set the rank of 𝐹 different from
that of 𝐺 . With an additional matrix 𝑆 into traditional NMF methods, better predictive
performances are expected due to more flexible choices for feature sizes. Introduction of an
additional feature interaction matrix inevitably increases the running time for the algorithm. We
also show that the increased computational cost is affordable in most modern computers.
Table 3.1 Symbols and definitions
Symbols
𝑚, 𝑛
𝑟, 𝑠
𝑤
𝑝
Θ, Θ1

Definition
Number of unique genes and TFs.
Feature sizes for genes and transcription factors, respectively. 𝑟 < 𝑚, and 𝑠 < 𝑛.
Scalar reliability weight. 𝑤 ∈ [0, 1]
Scalar imputation score. 𝑝 ∈ [0, 1]
Set of observed and unobserved associations.
Element atrow andcolumn of matrix 𝑅.
Known association matrix.
𝑅
𝑅(#,%) = 1 𝑖𝑓 (𝑖, 𝑗) ∈ Θ, 0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒. 𝑅 ∈ ℝ'×(
𝐹
Low-rank feature matrix for genes. 𝐹 ∈ ℝ'×/
𝐺
Low-rank feature matrix for TFs. 𝐺 ∈ ℝ(×A
𝑆
Low-rank feature interaction matrix. 𝑆 ∈ ℝ/×A
𝑀
Gene-gene similarity score matrix. It is a symmetric, positive matrix. 𝑀 ∈ ℝ'×'
𝑁
TF similarity score matrix, defined similarly to 𝑀. 𝑁 ∈ ℝ(×(
𝐷D , 𝐷E Degree matrices for 𝑀 and 𝑁, respectively. 𝐷D and 𝐷E are diagonal, positive matrices.
𝑊
Weight matrix. 𝑊(#,%) = 1 𝑖𝑓 (𝑖, 𝑗) ∈ Θ, 𝑤 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒. 𝑊 ∈ ℝ'×(
𝑃
Imputation matrix. 𝑃(#,%) = 0 𝑖𝑓 (𝑖, 𝑗) ∈ Θ, 𝑝 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒. 𝑃 ∈ ℝ'×(
𝟏'×( Indicator matrix containing 1 at every position. 𝟏'×( ∈ ℝ'×(
α
Regularization parameter. 𝜆/ ∈ [0, 1]
𝛽, 𝛾 Importance weights for genes and TFs, respectively.
𝑡𝑟(𝑀) Trace of matrix 𝑀.
‖𝑀‖3 Frobenius norm of matrix 𝑀.

Matrices are capitalized and italicized, and scalars are in lower cases
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The optimization algorithm for WINTF is based on the multiplicative update rule [224],
similar to that of REMAP algorithm described in Chapter 2. As in other NMF problems, the
optimization problem in Eq. 3.1 is not convex due to the coupling of 𝐹, 𝑆, and 𝐺. Therefore, the
multiplicative update rule is to find a fixed-point solution for a local optimum of the problem with
nonnegativity constraint. The update rules for each of the three low-rank matrices are below.

[(1 − 𝑤𝑝)𝑅𝐺𝑆 & + 𝑤𝑝1'×( 𝐺𝑆 & + 𝜆F 𝑀𝐹](?,/)
𝐹(?,/) ← 𝐹(?,/) v
w(1 − 𝑤) 𝑅xG 𝐺𝑆 & + 𝑤𝐹(𝑆𝐺 & 𝐺𝑆 & ) + 𝜆/ 𝐹 + 𝜆F 𝐷D 𝐹y(?,/)
𝐺(#,A)

[(1 − 𝑤𝑝)𝑅& 𝐹𝑆 + 𝑤𝑝1'×( 𝐹𝑆 + 𝜆H 𝑁𝐺](#,A)
← 𝐺(#,A) v
w(1 − 𝑤)𝑅xG 𝐹𝑆 + 𝑤𝐺(𝑆 & 𝐹 & 𝐹𝑆) + 𝜆/ 𝐺 + 𝜆H 𝐷E 𝐺y

𝑆(/,A) ← 𝑆(/,A)v

(3.2)

(3.3)
(#,A)

[(1 − 𝑤𝑝)𝐹 & 𝑅𝐺 + 𝑤𝑝(𝐹 & 1'×( 𝐺)](/,A)
w(1 − 𝑤)𝐹 & 𝑅xG 𝐺 + 𝑤𝐹 & (𝐹𝑆𝐺 & )𝐺 + 𝜆/ 𝑆y

(3.4)

(/,A)

The predicted score matrix for known associations, 𝑅xG , is defined as follows.
(𝐹𝑆𝐺 & )(?,#) 𝑖𝑓 (𝑢, 𝑖) ∈ 𝛩
𝑅xG (?,#) = z
0
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

(3.5)

Algorithm 3.1 WINTF
1. Input matrices: M, N, and R
Input scalars: Ω = {𝑟, 𝑠, 𝑤, 𝑝, 𝛼, 𝛽, 𝛾} and max_iter
2. Define: 𝑓3 , 𝑓< , 𝑓I , 𝑓: from equations 3.2, 3.3, 3.4, and 3.5 above
3. Initialize: 𝐹; , 𝑆; , 𝐺; = 𝑅𝑎𝑛𝑑𝑜𝑚𝑈𝑛𝑖𝑓𝑜𝑟𝑚𝑀𝑎𝑡𝑟𝑖𝑥 ∈ [0,1]
4. for 𝑖 = 0 to (max_iter −1)
5.
𝑅xJ,# = 𝑓: (𝑅, 𝐹# , 𝑆# , 𝐺# )
6.
𝐹#K2 = 𝑓3 7𝐹# , 𝑆# , 𝐺# , 𝑅xJ,# , Ω9
7.
𝐺#K2 = 𝑓< 7𝐹# , 𝑆# , 𝐺# , 𝑅xJ,# , Ω9
8.
𝑆#K2 = 𝑓I 7𝐹# , 𝑆# , 𝐺# , 𝑅xJ,# , Ω9
9.
replace NaNs in 𝐹#K2 , 𝐺#K2 , 𝑆#K2 with 0
10. Return: real-valued matrices 𝐹#K2 , 𝐺#K2 , 𝑆#K2
The update rules are derived by taking the partial derivatives with regard to each low-rank
matrix, while fixing the other two low-rank matrices as constant. Thus, we update one low-rank
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matrices at a time, while fixing the other two. The update process under the multiplicative update
rules can also be described as a gradient descent method with specially tailored learning rates. The
pseudocode for our method is below in Algorithm 3.1. Note the use of a global scalar weight 𝑤
and a global scalar imputation 𝑝, instead of position-specific weight matrix 𝑊 and imputation
matrix 𝑃. With a priori knowledge, it is possible to use position-specific matrices as shown in our
3D-REMAP pipeline in Chapter 2.
Once the updates are completed, 𝑅x , the prediction matrix for all TF-gene associations can
be obtained by the inner product of the three low-rank matrices. The prediction score matrix for
unknown interactions, 𝑅xG4 , can be obtained by 𝑅xJ4 = 𝑅x − 𝑅xJ , which contains prediction scores
for both known and unknown associations.
𝑅xG4 = 𝑅x − 𝑅xG , where 𝑅x = 𝐹𝑆𝐺 &
Figure 3.1 summarizes the process of WINTF for predicting an unknown gene-TF
association (Gene3 and TF1 in the figure). The mathematical justifications, including derivation
and proof of the update rules with the use of scalar weight and imputation values are in the
following section.
Gene1
Gene2

Gene4

Gene3

Gene3

score

score
TF1
TF3

TF1
TF2

Figure. 3.1 WINTF process for gene-TF association prediction. WINTF takes gene-TF, gene-gene, and
TF-TF networks as input, and updates the three low-rank feature matrices, F, S, and G. Once WINTF
update process is completed (Algorithm 1), the prediction score for an unknown gene-TF association
(Gene3-TF1) is obtained by a dot product of the corresponding low-rank features. Blue and yellow
rectangles represent the feature vectors for the gene and TF, respectively. In other words, blue rectangle
is 𝐹((,:) and yellow rectangle is 𝐺(*,:) .
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Theorems and Proofs
In the section above, we proposed the update rules for the three low-rank matrices to
calculate a local minimum of the cost function 𝐽, defined in Eq. 3.1. As mentioned, 𝐽 is nonconvex.
Thus, we update one low-rank feature matrix at a time, while fixing the others as constant. When
𝑆 and 𝐺 are fixed, the cost function can be simplified into 𝐽F .
3

𝐽F = i𝑊⨀7(𝑅 + 𝑃) − 𝐹𝑆𝐺 & 9i + 𝛼‖𝐹‖3 + 𝛽𝑡𝑟(𝐹 & (𝐷D − 𝑀)𝐹),

𝑠. 𝑡. 𝐹 ≥ 0

(3.6)

The partial derivative of the with regards to F is the following.
1
1 𝜕𝑦
∇F 𝐽 =
= −𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & − 𝛽𝑀𝐹 + 𝑊⨀𝑊⨀𝐹𝑆𝐺 & 𝐺𝑆 & + 𝛼𝐹 + 𝛽𝐷D 𝐹
2
2 𝜕𝐹

(3.7)

Based on the multiplicative update rule developed by Lee and Seung [224], we derive the update
rule for F as follows.

𝐹(?,/) ← 𝐹(?,/)v

[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & + 𝛽𝑀𝐹](?,/)
[𝑊⨀𝑊⨀(𝐹𝑆𝐺 & )𝐺𝑆 & + 𝛼𝐹 + 𝛽𝐷D 𝐹](?,/)

(3.8)

In the section 3.1, we showed simplified update rules that reduce the computational
complexity by replacing the large dimension of the weight and imputation matrices with scalar
values. The simplified update rule for Eq. 3.8 is the Eq. 3.2.
In the remainder of this section, we first show that the fixed-point solution of Eq. 3.8
satisfies the KKT condition, and that Eq. 3.2 and Eq. 3.8 are mathematically equivalent. Then, we
show that the cost function, 𝐽F in Eq. 3.6 monotonically decreases under the update rule in Eq. 3.8.
THEOREM 1. The fixed-point solution of Eq. 8 satisfies the KKT condition.
PROOF. The Lagrangian of Eq. 3.6 is the following, where Λ is the Lagrange multiplier.
3

𝐿L5 = i𝑊⨀7(𝑅 + 𝑃) − 𝐹𝑆𝐺 & 9i + 𝛼‖𝐹‖3 + 𝛽𝑡𝑟7(𝐹 & 𝐷D 𝐹) − (𝐹 & 𝑀𝐹)9 − 𝑡𝑟(Λ𝐹)
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(3.9)

Let

M
𝐿
MF L5

= 0, we get the following.

2(−𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & + 𝑊⨀𝑊⨀𝐹𝑆𝐺 & 𝐺𝑆 & + 𝛼𝐹 + 𝛽𝐷D 𝐹 − 𝛽𝑀𝐹) = Λ

(3.10)

From the KKT complementary slackness condition, we derive the following.
[−𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & + 𝑊⨀𝑊⨀𝐹𝑆𝐺 & 𝐺𝑆 & + 𝜆/ 𝐹 + 𝜆F 𝐷D 𝐹 − 𝜆F 𝑀𝐹 ](?,/) ∙ 𝐹(?,/)
=0

(3.11)

Eq. 3.12 is the fixed-point solution of Eq. 3.8. It is trivial to show that Eq. 3.12 satisfies Eq. 3.11.
[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & + 𝛽𝑀𝐹 ](?,/) = [𝑊⨀𝑊⨀(𝐹𝑆𝐺 & )𝐺𝑆 & + 𝛼𝐹 + 𝛽𝐷D 𝐹 ](?,/)

(3.12)

Next, we show that Eq. 3.2 is mathematically equivalent to Eq. 3.8. We use 𝟏N , 𝟏G , and
4

𝟏G as the indicator matrices for all, observed, and unobserved associations, respectively, so that
4

1'×( = 𝟏N = 𝟏G + 𝟏G , and 𝟏G = 𝑅. Note that the weight and imputation values are applied only
for unobserved associations, the equations below turn the weight matrix W and imputation matrix
P into scalar weight w and scalar imputation value p, respectively, significantly reducing the
computational costs. Note that the weight matrix W contains the square root of the global weight
w, on unobserved positions and zero on observed ones.
𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 &
6
= 7𝟏J ⨀𝑅 + 𝑤𝑝 ∙ 𝟏J 9𝐺𝑆 & = (𝑅 + 𝑤𝑝 ∙ 𝟏N − 𝑤𝑝 ∙ 𝟏J )𝐺𝑆 &
= (1 − 𝑤𝑝) ∙ 𝑅𝐺𝑆 & + 𝑤𝑝 ∙ 𝟏'×( 𝐺𝑆 &
and
(𝑊⨀𝑊⨀𝐹𝑆𝐺 & )𝐺𝑆 &
4
= 𝑊⨀𝑊⨀7𝑅xJ + 𝑅xJ4 9𝐺𝑆 & = 7𝑅xJ + 𝑤 ∙ 𝟏J ⨀𝑅xJ𝒄 9𝐺𝑆 &
= (1 − 𝑤) ∙ 𝑅xJ 𝐺𝑆 & + 𝑤 ∙ 𝐹𝑆𝐺 & 𝐺𝑆 &
Substituting the two equations above into Eq. 3.8 completes the proof that Eq. 3.2 is
mathematically equivalent to Eq. 3.8.
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THEOREM 2. The cost function in Eq. 3.6 monotonically decreases under the update rule
proposed in Eq. 3.8.
PROOF. To prove the theorem 2, we start from the cost function Eq. 3.6.
Based on the auxiliary function strategy [246], 𝐻7𝐹, 𝐹‡ 9 is an auxiliary function of J(F) if
it satisfies the following conditions.
𝐻(𝐹, 𝐹) = 𝐽(𝐹), and 𝐻7𝐹, 𝐹‡ 9 ≥ 𝐽(𝐹)

(3.13)

Defining 𝐹 (!K2) = 𝑎𝑟𝑔 𝑚𝑖𝑛 𝐻7𝐹, 𝐹 (!)9 proves that 𝐽7𝐹 (!) 9 monotonically decreases since the
F

following condition is satisfied by the design of the auxiliary function.
𝐽7𝐹 (!) 9 = 𝐻7𝐹 (!) , 𝐹 (!) 9 ≥ 𝐻7𝐹 (!K2) , 𝐹 (!) 9 ≥ 𝐽7𝐹 (!K2) 9

(3.14)

We first define an auxiliary function that satisfies the conditions in Eq. 3.13, and solve for the
auxiliary function, which is the global minimum of the auxiliary function.
'

/

𝐹(?,O)
𝐻7𝐹, 𝐹‡ 9 = −2 ‰ ‰w7𝑊⨀𝑊⨀(𝑅 + 𝑃)9𝐺𝑆 & y(?,O) 𝐹‡(?,O) Š1 + log Š
••
𝐹‡(?,O)
'

'

/

?P2 OP2

'

𝐹(B,O) 𝐹(?,O)
3
− ‰ ‰ ‰ 𝛽𝑀(?,B) 𝐹‡(B,O) 𝐹‡(?,O) Š1 + log Š
•• + ‰ 𝛼 𝐹(?,O)
𝐹‡(B,O) 𝐹‡(?,O)
?P2 BP2 OP2
' /

+‰‰
?P2 OP2

3
w7𝑊⨀𝑊⨀𝐹‡ 𝑆𝐺 & 9𝐺𝑆 & y(?,O) 𝐹(?,O)

𝐹‡(?,O)

'

(3.15)

?P2

/

3
[𝛽𝐷D 𝐹‡](?,O) 𝐹(?,O)
+‰‰
𝐹‡(?,O)
?P2 OP2

It is trivial to show that 𝐻(𝐹, 𝐹) = 𝐽(𝐹). To show 𝐻7𝐹, 𝐹‡9 ≥ 𝐽(𝐹), we name the five terms
in Eq. 3.15 as H1, H2, H3, H4, and H5, respectively. Then, using the inequality 𝑥 ≥ 1 + 𝑙𝑜𝑔 (𝑥),
the H1 becomes the following.
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'

/

𝐻1 ≥ −2 ‰ ‰w7𝑊⨀𝑊⨀(𝑅 + 𝑃)9𝐺𝑆 & y(?,O) 𝐹(?,O)

(3.16)

?P2 OP2

= −2𝑡𝑟w7𝑊⨀𝑊⨀(𝑅 + 𝑃)9𝐺𝑆 & 𝐹y
'

'

/

𝐻2 ≥ − ‰ ‰ ‰ 𝛽𝑀(?,B) 𝐹(B,O) 𝐹(?,O) = −𝛽𝑡𝑟(𝐹 & 𝑀𝐹)

(3.17)

?P2 BP2 OP2

(3.18)

Then, for H3 we obtain 𝐻3 = 𝛼 ∙ 𝑡𝑟(𝐹𝐹 & )
For H4, first define 𝐹(?,O) = 𝐹‡(?,O) 𝑄(?,O) and we have the following.
'

(

/

/

3
3
(𝐺𝑆 & )(#,O) 𝐹(?,O)
𝐹‡(?,Q) (𝑆𝐺 & )(#,Q) 𝑊(?,#)
𝐻4 = ‰ ‰ ‰ ‰
𝐹‡(?,O)
'

?P2 #P2 OP2 QP2
(
/
/

3
3
(𝐺𝑆 & )(#,O) 𝐹‡(?,O) 𝑄(?,O)
= ‰ ‰ ‰ ‰ 𝐹‡(?,Q) (𝑆𝐺 & )(#,Q) 𝑊(?,#)
?P2 #P2 OP2 QP2
' (
/
/

= ‰ ‰ ‰ ‰ 𝐹‡(?,Q)

(𝑆𝐺 & )

3
𝑄(?,O)
3
&
‡
(#,Q) 𝑊(?,#) (𝐺𝑆 )(#,O) 𝐹(?,O) Š

?P2 #P2 OP2 QP2
' (
/
/

3
+ 𝑄(?,Q)
•
2

(3.19)

3
(𝐺𝑆 & )(#,O) 𝐹‡(?,O) 7𝑄(?,O) + 𝑄(?,Q)9
≥ ‰ ‰ ‰ ‰ 𝐹‡(?,Q) (𝑆𝐺 & )(#,Q) 𝑊(?,#)
?P2 #P2 OP2 QP2
' (
/
/
3
(𝐺𝑆 & )(#,O) 𝐹(?,O) = 𝑡𝑟w7𝑊⨀𝑊⨀(𝐹𝑆𝐺 & )9𝐺𝑆 & 𝐹 & y
= ‰ ‰ ‰ ‰ 𝐹(?,Q) (𝑆𝐺 & )(#,Q) 𝑊(?,#)
?P2 #P2 OP2 QP2
∗
We derive Eq. 3.20 with the use of the following inequality , where 𝐴(×( , 𝐵O×O , 𝑆(×O , and 𝑆(×O

are nonnegative, and A and B are symmetric matrices [247].
(

O

3
(𝐴𝑆 ∗ 𝐵 )𝑆(#,5)
‰‰
≥ 𝑡𝑟(𝑆 & 𝐴𝑆𝐵)
∗
𝑆(#,5)
'

#P2 5P2
/
3
[𝛽𝐷D 𝐹‡ ](?,O) 𝐹(?,O)

𝐻5 = ‰ ‰

?P2 OP2

𝐹‡(?,O)

≥ 𝛽𝑡𝑟(𝐹 & 𝐷D 𝐹)

(3.20)

Substituting Eq. 3.16 – Eq. 3.20 into Eq. 3.15 shows that the auxiliary function satisfies the second
condition in Eq. 3.13. The gradient of the auxiliary function is the following.
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1 𝜕𝐻(𝐹, 𝐹‡ )
2 𝜕𝐹(?,O)
[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & ](?,O) ∙ 𝐹‡(?,O) [𝛽𝑀𝐹‡ ](?,O) ∙ 𝐹‡(?,O) 𝛼𝐹(?,O) ∙ 𝐹‡(?,O)
−
+
𝐹(?,O)
𝐹(?,O)
𝐹‡(?,O)
[𝑊⨀𝑊⨀𝐹‡ 𝑆𝐺 & 𝐺𝑆 & ](?,O) ∙ 𝐹(?,O) [𝛽𝐷D 𝐹‡ ](?,O) ∙ 𝐹(?,O)
+
+
𝐹‡(?,O)
𝐹‡(?,O)
[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & + 𝛽𝑀𝐹‡ ](?,O) ∙ 𝐹‡(?,O)
=−
𝐹(?,O)
&
&
[𝑊⨀𝑊⨀𝐹‡ 𝑆𝐺 𝐺𝑆 + 𝛼𝐹‡ + 𝛽𝐷D 𝐹‡ ](?,O) ∙ 𝐹(?,O)
+
𝐹‡(?,O)
=−

(3.21)

The Hessian of 𝐻7𝐹, 𝐹‡ 9 is a diagonal matrix with positive diagonal elements. Therefore, we obtain
the global minimum by setting Eq. 3.21 to be zero, which results in the following solution.

3
3
𝐹(?,O)
= 𝐹‡(?,O)
∙

[𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & + 𝛽𝑀𝐹‡ ](?,O)
[𝑊⨀𝑊⨀7𝐹‡ 𝑆𝐺 & 𝐺𝑆 & + 𝛼𝐹‡ + 𝛽𝐷D 𝐹‡ ](?,O)

(3.22)

Setting 𝐹 (!K2) = 𝐹 and 𝐹 (!) = 𝐹‡ proves that the update rule Eq. 3.8 monotonically decreases the
cost function. With the equivalence between Eq. 3.2 and Eq. 3.8, Eq. 3.6 monotonically decreases
under the update rule Eq. 3.2.
The proof for the update rule for G can be derived analogously to the proof above. The
matrix S-equivalent of the cost function Eq. 3.6 is the following.
𝐽(𝑆) = 𝑡𝑟(−2𝑊⨀𝑊⨀(𝑅 + 𝑃)𝐺𝑆 & 𝐹 & ) + 𝑡𝑟(𝑊⨀𝑊⨀(𝐹𝑆𝐺 & )𝐺𝑆 & 𝐹 & ) + 𝛼𝑡𝑟(𝑆 & 𝑆)
Therefore, we choose an auxiliary function for the matrix S, which is missing two terms
corresponding to H2 and H5 in Eq. 3.15. The auxiliary function and its gradient are the following.
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Setting the gradient to zero, we obtain the global minimum solution.
3
𝑆(#,%)

3
= 𝑆‘(#,%)
∙

w𝐹 & 7𝑊⨀𝑊⨀(𝑅 + 𝑃)9𝐺y(#,%)
’𝐹 & “𝑊⨀𝑊⨀7𝐹𝑆‘𝐺 & 9” 𝐺 + 𝛼𝑆‘•

(#,%)

Combining the theorems 1 and 2, we proved that the proposed update rules satisfy the KKT
condition and converge to the solution. We use the proposed update rules to iteratively update the
low-rank matrices in alternating manner to find the solution.
Experimental Setup
We use the TF-gene interaction data from ChEA, which contains manually curated as well
as computationally extracted associations from more than 100 publications for ChIP-X
experiments [218]. The ChEA dataset contains 386,776 TF-gene interactions for 21,585 genes and
199 TFs for human. Since the density is approximately 9%, it is expected that a random guess
would have a 9% chance to correctly pick a true interaction. The gene-gene and TF-TF similarity
matrices are prepared by assuming two interacting proteins are related to each other. The proteinprotein interaction (PPI) data is obtained from the STRING database, which contains
experimentally known and computationally predicted protein-protein physical interactions and
functional associations (e.g. co-expressed genes) with reliability scores [248]. The similarity score
between the and genes (or TFs) is calculated by the PPI reliability score divided by the maximum
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available score (1,000). If multiple reliability scores exist for a pair of proteins, average value is
used. This makes all similarity scores in between 0 and 1, for minimum and maximum similarity,
respectively. Sequence-based protein-protein similarity scores can be used as it was done in the
REMAP application as described in Chapter 2. Two proteins will have a high similarity score if
their BLAST [249] alignment returns a high score. As a result, 9,207,162 and 12,775 PPI-based
nonzero similarity scores are obtained for gene-gene and TF-TF networks, respectively.
To compare WINTF with REMAP, we evaluated the performances of them for the ChEA
dataset described above. We conducted 5-fold cross validations to measure four different
performance metrics: area under receiver operating characteristic curve (AUROC, or AUC), mean
average precision (MAP), half-life utility (HLU), and mean percentile rank (MPR). AUROC is
one of the most frequently used performance measurements that measures how quickly an
algorithm achieves a high true positive rate while keeping low false positive rates. HLU measures
the likelihood that a user accepts recommendation assuming that the likelihood decreases
exponentially with the ranking of the recommended items [250]. MAP measures the average
precision for all users at varying true positive rates [251]. MPR is the average percentile rank of
positive associations in the test samples [252]. The higher AUC, MAP, HLU, and the lower MPR,
the better performance. We compared the performances with and without the PPI-derived
similarity score matrices.
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3.4 Results
Time complexity
Compared to REMAP, WINTF has an additional feature interaction matrix, necessarily
requiring longer computational time. As we describe in Chapter 4 and in our previous application
using WINTF algorithm [253], we measured computational time of WINTF using the ChEA data
set. Figure 2 shows the average running time as increasing number of total elements in the matrices
F, S, and G. The empirical time complexity of WINTF suggests that the running time
approximately linearly dependent on the number of matrix elements. It also shows that WINTF on
ChEA data set takes approximately 1,100 seconds at the default rank parameters (𝑟 = 1000, 𝑠 =
100).
2166
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Figure. 3.2 Time complexity of WINTF using ChEA dataset. Average running time (blue squares) from five
runs of WINTF are plotted according to the total number of elements in the three low-rank matrices, F, S,
and G. The x-axis is the total number of elements in the three matrices in millions (i.e. 𝑚 × 𝑟 + 𝑟 × 𝑠 +
𝑛 × 𝑠). Within the tested range of elements, WINTF shows approximately linear time complexity (green
dashed line). Error bars represent ± five times the standard deviations.

Benchmark evaluation of prediction accuracy
Our benchmarks under different conditions (e.g. different hyperparameters and
with/without similarity information) show WINTF outperforms REMAP under all tested
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conditions (Table 3.2 and Table 3.3). Table 3.2 shows that WINTF performs significantly better
than REMAP in all four metrics, regardless of the use of similarity matrices. Table 3.3 shows that
the rank parameters affect the performances of both methods, and that WINTF outperforms
REMAP under all tested hyperparameters. Due to the number of hyperparameters for both
algorithms, it is impractical to compare them with all possible combinations. Thus, we tested a
limited number of combinations, evaluating the potentials of different similarity measurements,
and the effect of the additional low-rank matrix in WINTF. In our previous study with REMAP as
described in Chapter 2, we performed extensive grid searches on the hyperparameter space, where
we found that the optimal parameters are 𝑤 = 𝑝 = 𝛼 = 0.1, and max_iter=100. In our previous
study, alterations on these hyperparameters did not significantly affect the performance, unless w
is set to 1.0 and p, or 𝛼 is set to 0, respectively (Table 3.2, Condition E), or max_iter is fewer than
50. We found similar trends from grid searches on WINTF hyperparameter space. Similar to our
benchmarks in Chapter 2, small, nonzero w, p, and 𝛼 values showed reliable performances with
max_iter=100. The dimension of the feature interaction matrix (e.g. r, s) are important
hyperparameters and known to be data-dependent. Our experiments suggest that it is best to keep
𝑟 ≥ 500 and 𝑠 ≤ 150, further supporting the power of our new algorithm for setting the ranks
differently (Figure 3.3). Therefore, we set the default hyperparameters as 𝑤 = 𝑝 = 𝛼 = 0.1,
max_iter=100, 𝑟 = 1000, and 𝑠 = 100. With these default parameters, we observed that 𝛽 ≅
0.01 works best, and 𝛾 has less impact on performances compared to other hyperparameters.
Therefore, we set 𝛽 = 0.01 and 𝛾 = 0.7 as the default hyperparameters. Both of the gene-gene
and TF-TF similarity matrices used for our WINTF application are based on protein-protein
interactions from STRING, as described in the method section.
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Figure. 3.3 Low-rank parameters and performances of WINTF. The two low-rank parameters, r and s, were adjusted
together and the average AUC values were evaluated while the other hyperparameters were set to default. X-axis
represents the pair of r and s, and y-axis represents the average AUC from 5-fold cross validation. Error bars represent
± 5 times the standard deviation.
Table 3.2 Performance comparison for WINTF and REMAP with different similarity information
1

Con.
A
B
C
D
E

Algorithm
WINTF
REMAP
WINTF
REMAP
WINTF
REMAP
WINTF
REMAP
Vanilla MTF

AUC
0.763(8.0e-4)
0.717(0.001)
0.766(6.0e-4)
0.726(1.7e-3)
0.762(7.8e-4)
0.727(0.002)
0.762(7.8e-4)
0.717(0.001)
0.500(0.0)

HLU
40.7(0.394)
31.1(0.667)
40.7(0.23)
32.0(1.7)
40.7(0.394)
33.6(0.150)
40.7(0.394)
30.1(0.672)
5.96(0.06)

MAP
0.295(0.003)
0.231(0.002)
0.295(2.6e-3)
0.237(7.4e-3)
0.295(0.003)
0.243(0.001)
0.295(0.003)
0.231(0.002)
0.155(5.0e-4)

MPR
0.259(5.0e-4)
0.300(0.001)
0.259(4.6e-4)
0.294(1.5e-3)
0.259(5.0e-4)
0.291(0.002)
0.259(5.0e-4)
0.300(0.001)
0.320(6.6e-4)

Values are mean and (standard deviation) for 5-fold cross validation
1
Condition A: TF similarity scores are based on sequence similarity only, and gene similarity scores are not used. Condition B: TF similarity scores
are the average of sequence-based and protein-protein interaction-based scores, and gene similarity scores are based on PPIs only. Condition C:
TF similarity scores are based on PPIs only, and gene similarity scores are not used. Condition D: No similarity information used. Condition E:
Vanilla MTF ( w = 1.0, p = λr = λ F = λG = 0 ). r = 1000 and s = 100 for WINTF and vanilla MTF, and r = 100 for REMAP, respectively.

Table 3.3 Performance comparison for WINTF and REMAP with different hyperparameters
1

Con.
A
B
C
D

Algorithm
WINTF
REMAP
WINTF
REMAP
WINTF
REMAP
WINTF
REMAP

AUC
0.766(6.0e-4)
0.726(1.7e-3)
0.764(5.1e-6)
0.726(2.9e-3)
0.765(7.6e-4)
0.730(1.8e-3)
0.762(6.6e-4)
0.717(3.2e-3)

HLU
40.7(0.23)
32.0(1.7)
40.7(0.09)
32.2(1.6)
40.7(0.10)
29.8(0.30)
40.7(0.09)
30.9(1.7)

MAP
0.295(2.6e-3)
0.237(7.4e-3)
0.295(1.6e-3)
0.238(3.7e-3)
0.295(1.5e-3)
0.233(1.6e-3)
0.295(1.6e-3)
0.231(4.2e-3)

MPR
0.259(4.6e-4)
0.294(1.5e-3)
0.259(1.1e-6)
0.294(2.7e-4)
0.259(6.4e-4)
0.292(1.6e-3)
0.259(6.4e-4)
0.300(3.0e-3)

Values are mean and (standard deviation) for 5-fold cross validation
1
Condition A: Default parameters. Condition B: WINTF ranks=(100,100), REMAP rank=100. Condition C: WINTF ranks=(100,50), REMAP
rank=50. Condition D: 𝜆! = 𝜆" = 0.
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The results in Table 3.2 further demonstrates that the novelty and strength of our method
comes from the weight, regularization, imputation, and side information parameters. It is noted
that when 𝑤 = 1, 𝑝 = 𝛼 = 𝛽 = 𝛾 = 0, the optimization problem in Eq. 3.1 is equivalent to that
of the plain matrix tri-factorization (vanilla MTF), 𝐽 = ∑(𝑅 − 𝐹𝑆𝐺 & )3 . We observe clearly
improved performances when the weight, regularization, imputation, and side information
parameters are introduced into the vanilla MTF.
Evaluation on independent test data
With the choice of hyperparameters and similarity score matrices described above, we
performed WINTF on the full ChEA TF-gene dataset. We first calculated the predicted score
matrix 𝑅x as described in the method section. To evaluate the statistical significance of the
predicted scores, we randomly picked 1,000,000 scores in 𝑅x . Removing the scores for 90,076
known interactions, we plotted a histogram of the 909,924 predicted scores, which suggested that
the predicted scores are not following a simple distribution, such as Gaussian or exponential
distribution (Fig. 3.4). Thus, we first removed the prediction scores for TF-gene interactions that
were found in ChEA dataset, and we used Epanechnikov kernel to create a distribution that fits the
sampled scores as shown in Figure 3.4. Then, we picked the predicted TF-gene pairs that ranked
approximately within the top 2% (i.e. cumulative density above 0.9808 under the kernel
distribution). Our prediction and filtering method returned 495 TF-gene interactions that were not
included in ChEA dataset. We searched for TRANSFAC [234], ENCODE [237], and TRRUST2
[239] databases to evaluate the final prediction accuracy. As a result, 187 of the 495 (37.8%)
associations were found in at least one of the three databases (Appendix B in [112]). Recalling that
the chance of correct prediction for a random guess is 9.0% based on the density of the ChEA data
set, our enrichment factor is 4.19 (37.8% divided by 9.0%) for our prediction accuracy.
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Figure 3.4 Probability density of 909,924 randomly sampled WINTF prediction scores for TF-gene
associations that are excluded from the training data. Epanechnikov kernel fits to the sampled scores.
Table 3.4 Predicted TF-gene interactions by WINTF
1

TF
MYC
MYC
MYC

Gene
NOTCH2
ZMIZ1
ARID5B

CDF
0.99213
0.99906
0.99928

Database
ENCODE
ENCODE
ENCODE
ENCODE,
TRANSFAC

Reference
[254, 255]
[256]
[257]

MYC

BCL6

0.99909

MYC

NDRG1

0.98982

ENCODE, TRRUST2

[260]

MYC

ST3GAL1

0.9992

ENCODE, TRRUST2

[261]

MYC
SPI1

EFNA5
BCL6

0.99607
0.99864

ENCODE
ENCODE, TRRUST2

[262]
[263]

SOX2
SOX2
CREM
AR

HES1
NOTCH2
MEIS1
RUNX1

0.99993
0.99335
0.99955
0.99837

None
None
None
None

[264, 265]
[265]
[266]
[267]

[258, 259]

1

Cumulative distribution function of the Epanechnikov kernel fitted to the WINTF prediction scores

Among the 495 predicted novel associations that are not found in the ChEA training data,
a number of them are strongly supported by published studies. The associations are listed in Table
3.4. While the association between NOTCH1 and MYC was previously studied regarding T-cell
acute lymphoblastic leukemia and included in ChEA dataset, NOTCH2-MYC association was not
included. Our prediction suggests that NOTCH2 may also be associated with MYC. Indeed, it was
suggested that NOTCH2 and MYC are related in terms of cellular proliferation in mouse thymic
lymphoma without strong evidence to conclude their association [254]. More recently, a study
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concerned with hypoxia-induced signaling pathway showed that NOTCH2-knockdown murine
mesenchymal stem cells cannot properly proliferate, which can be reverted by overexpression of
MYC [255]. The collaboration of ZMIZ1 and activated NOTCH1 was found to cause T-cell acute
lymphoblastic leukemia in mouse models, which was proposed to be a result of the interaction
between ZMIZ1 and MYC at downstream [256]. ARID5B gene, whose role in T-cell acute
lymphoblastic leukemia has been unknown, was found to directly bind MYC enhancer to promote
the MYC expression, which is a required step for the disease [257]. The concept of double protein
lymphoma, characterized by the co-expression of MYC and BCL2 or BCL6, is known to be
aggressive [258], although the MYC/BCL6 biomarker is of less prognostic value [259]. Possibly
due to rarity of studies involving MYC/BCL6, the association was not included in the ChEA
dataset, while the MYC-BCL2 association was included. NDRG1, whose overexpression in tumor
cells decreases the proliferation rate [268], is known to be suppressed by MYC in embryonic cells
[260]. In a study about the genetic linkage in colon cancer cells, upregulation of
glycosyltransferase genes, including ST3GAL1 by MYC was observed [261]. It was also found
that EFNA5 was upregulated along with other genes in MYC-knockout mice neural stem and
precursor cells [262]. The physical interaction between SPI1 and BCL6 is reported. Interestingly,
BCL6 acts as a repressor that binds to SPI1 in germinal center B cells [263]. Although the direct
association is unknown and thus excluded from ChEA dataset, SOX2 and HES1 (with other genes)
have been studied as markers of neural stem cells [264]. A more recent study added evidence that
SOX2 and HES1 are at least members of the same regulatory pathway in rat anterior pituitary cells
[265]. In the study, it was also found that SOX2-expressing cells have significantly lower levels
of NOTCH2 expression, suggesting a potential repression of NOTCH2 by SOX2 [265]. The direct
association between CREM and MEIS1 was not known although they are involved in the
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myogenesis, the growth of skeletal muscle. A recent study suggests that although CREM and
MEIS1 may not directly interact, they seem to regulate the growth process through another
transcription factor, NF-Y [266]. In a recent ChIP-seq experiment, it was shown that RUNX1 is a
target of AR, which is important for AR-dependent transcription and cell growth in androgendependent prostate cancer [267]. These research activities support our claim that WINTF can
predict unobserved, but positive associations based on the known associations. NOTCH2-MYC,
ZMIZ1-MYC, BCL6-MYC, and EFNA5-MYC associations are in the ENCODE database [237],
but not in the TRANSFAC [234] or TRRUST2 [239] database. MYC-NDRG1, MYC-ST3GAL1,
and MYC-BCL6 associations are found in both ENCODE and TRRUST2 databases. ARID5BMYC, SOX2-HES1, and CREM-MEIS1 associations are not found in any of the three databases,
suggesting that our method can predict novel TF-gene associations from known ones with proper
TF-TF and gene-gene similarity measurements.
3.5 Discussions
It is suggested in Table 3.2 that TF-gene associations may be better modeled by using both
protein-protein interaction network and sequence comparison. An important note is that using only
one type of them (e.g. sequence-based similarity only) does not improve the predictive power of
WINTF. In addition, the predictive performances were insensitive to the PPI-based TF-TF network
importance weights, which implies that the canonical PPIs included in the database are insufficient
to model gene regulation scenarios where multiple TFs form a complex to regulate a gene. A more
comprehensive list of PPIs may address such issue. For better performance as well as
interpretability, other types of gene-gene similarity scores may be used. The similarity may be
based on the sequence alignment scores of the regulatory elements of the genes, which presumes
that the DNA sequences of the regulatory elements have evolved to efficiently recruit the TFs.
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Differential gene expression data can also be a way to measure similarities between genes with the
hypothesis that two genes showing similar patterns of expression under the same conditions are
likely to be regulated by the same TFs. A combination of these two types of similarity scores may
improve the predictions. Other biological constraints, including the relative location of TF and
gene in the genome can be incorporated into the weight and imputation matrices. However, many
of such similarity measurements are tissue- and context-specific. Unfortunately, we do not have
large-scale tissue-specific TF-gene association data yet. It is noted the canonical PPIs used in this
study are mainly functional associations including the co-expressed genes. Although they are not
perfect measurement for the gene-gene similarity, our benchmark studies and independent
validations demonstrate their potential utility.
Our benchmarks in Table 3.2 demonstrate that the weight, regularization, imputation, and
side information parameters are critical for WINTF. Without these parameters, the vanilla MTF
method shows no predictive power. Table 3.3 also suggest that the improved performance of
WINTF compared to REMAP is from the introduction of the matrix S. While the main purpose of
introducing the matrix S is to set different ranks for genes and TFs, it is not clear whether the ranks
must be very different. The Condition B in Table 3.3 shows that WINTF performs better than
REMAP even if all rank parameters are set to 100. In practice, the rank parameters are heuristically
optimized. On the other hand, the matrix S can be viewed as a hidden layer introduced to REMAP.
Thus, the matrix S may have worked similarly to the hidden layers for the popular deep learning
methods, characterized by multiple layers of neural networks with activation functions and
regularization steps. Increasing the number of low-rank matrices in WINTF to mimic deep learning
may be an interesting future study. A more interesting combination is to integrate neural network
techniques with matrix factorization, as shown in a recent study where the matrix inner product is
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considered an additional layer to a multilayer neural network [269]. The time complexity due to
the introduction of an additional low-rank matrix as well as large number of parameters from
multilayer neural network can be overcome by factorizing smaller submatrices and projecting to
the original feature space [270]. In addition, the algorithm to optimize the cost function of matrix
factorization may be improved. Simultaneous perturbation stochastic approximation is a potential
algorithm to improve the performance as well as the speed of optimization since it requires a
dramatically low number of evaluations per iteration and randomness to potentially find the global
minimum solution [271, 272]. Such work will enable larger scale applications of the association
prediction method with improved accuracy and interpretability.
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CHAPTER FOUR

Application of WINTF for Targeted Anticancer Therapy
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4.1 Introduction
The cost of bringing a drug to the market has risen to approximately 2.6 billion dollars
(Tufts Center for the Study of Drug Development, 2015), and the failure rate is intimidating: only
about one third of drugs in phase III clinical trials reach the market. The limited success of the
conventional drug discovery process is largely attributed to the wide adoption of a reductionist
paradigm, “one-drug-one-gene-one-disease model” [273-275]. The onset and progress of many
complex diseases such as cancer are systematic processes that involve multiple interacting genes
in biological network. Therefore, it is important to design drugs that target gene interaction
networks instead of a single gene. Furthermore, drug repurposing that reuses existing safe drugs
for another indication has emerged as a new paradigm to accelerate drug discovery. As the safety
profiles of existing drugs has already been well documented, the time and cost of clinical trials can
be significantly reduced.
Recent advancements in high-throughput laboratory techniques have generated abundant
chemical genomics data on drug actions and disease genes. These big, complex, heterogeneous
data sets provide unprecedented opportunities for identifying genome-wide drug-gene-disease
associations, thereby facilitating multi-targeted drug design and drug repurposing. However,
several challenges remain in successfully utilizing chemical genomics and disease association data
for drug discovery. First, chemical genomics data from high-throughput screening experiments are
not only extremely large but also highly noisy, biased, and incomplete. Many existing data mining
algorithms are not directly applicable to build a reliable model for chemical genomics data. Second,
drug action is a result of complex processes. Drug-gene interactions at the molecular level initiate
the processes, and molecular interplay between biological network manifests the clinical outcomes.
A single genomics data set can only capture a small part of the whole drug actions. Therefore, it
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is critical to integrate multiple data sets for protein-ligand interactions, gene-disease associations,
and ligand-disease associations to model the drug action on a multi-layer. Finally, one of the
fundamental problems remaining in biomedical data mining: how to assess the reliability of a
specific prediction from a data mining pipeline under a rigorous statistics framework. The reliable
and unbiased assessment of the prediction for quality control is critical for cost-sensitive drug
discovery projects. For instance, the selection of a novel ligand that is structurally different from
patented drugs as a lead compound from a ranked list of candidate ligands is a billion-dollar
decision. Information on the reliability of individual prediction of a novel chemical entity based
on its weak chemical similarity to existing drugs in terms of bioactivity is invaluable. Most existing
data mining tools can only provide an averaged predictive accuracy based on the population of
training data, but not reliability for a specific instance. For example, when using ranking-based
predictive methods, it is not straightforward to determine what the threshold is to select top-ranked
hits. The top ranked hit could be a false positive, or the top-N (N>1) ranked hits could all be true
positives.
To address aforementioned challenges in the predictive modeling of drug-gene-disease
associations as well as unmet needs in the treatment of complex diseases such as cancer, our
contributions in this work are in both methodology development and translational medicine.
Our contribution in the methodological part starts from revisiting the WINTF method
introduced in Chapter 3. In Chapter 3, we have developed a novel algorithm WINTF based on trifactorization to optimize matrix completion problem in which rows and columns have significantly
different ranks. In this chapter, we formulate the protein-ligand interaction predictions as a multirank dual-regularized weighted and imputed One Class Collaborative Filtering (OCCF) problem.
Negative data, which are sparse and often unavailable, are not necessary for the training under the
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OCCF problem formulation. By using element-specific weights and imputation values as in
Chapter 2, WINTF can handle noisy chemical genomics data in which the label is often uncertain.
Finally, unlike conventional OCCF algorithm that applies a single rank to all layers, WINTF
assigns a different rank to a different layer. It is crucial since different layers can have dramatically
different dimensions to optimally capture the layer-specific features. For example, the dimension
of a ligand layer is in the order of millions, while the dimension of a protein layer is only thousands.
Our benchmark in this chapter clearly show that WINTF outperforms its single-rank counterpart,
REMAP, which is introduced in detail in Chapter 2. Second, to tailor the nature of protein-liganddisease association data sets where observed ligand-disease associations are far sparser than known
protein-ligand interactions and few three-way protein-ligand-disease associations exist, we have
developed a multi-rank, multi-layered framework, ANTENNA, for inferring novel protein-liganddisease associations. ANTENNA has three main components. (1) ANTENNA takes multiple
chemical genomics and disease association data set, and integrate them as a multi-layered network
[226], as shown in Figure 4.1. (2) ANTENNA uses WINTF algorithm to predict genome-wide
novel protein-ligand associations. (3) Based on the genome-wide protein-ligand association
network, ANTENNA applies Random Walk with Restart (RWR) and a statistical framework,
Enrichment of Topological Similarity (ENTS) [276], to infer unobserved ligand-disease
associations and assess their reliabilities.
Arguably, the most important contribution of this work is to discover a potentially safe and
effective targeted therapy for triple negative breast cancer (TBNC). Using ANTENNA, we
predicted that an FDA-approved drug diazoxide may inhibit multiple kinases. Kinase malfunctions
are known to be associated with many diseases such as cancer and Alzheimer’s disease. Among
the kinases with the highest percentage of inhibition by diazoxide, TTK gene is specifically over-
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expressed in TNBC patients [277, 278]. Therefore, we hypothesized that diazoxide may be
cytotoxic against TNBC cells. We outsourced experimental validations, which are introduced in
detail in our published work [99]. Multiple experimental evidence supports our prediction. TNBC
is the most aggressive subtype of breast cancers. No targeted therapy is currently available for
TNBC, supporting that our finding has a great potential toward developing an effective targeted
therapy for TNBC.

Figure 4.1 Illustration of Multilayered network model that integrates multiple genomics data sets into a
large protein-ligand-disease association network.

4.2 Relevant Works
In principle, tensor factorization is a powerful method to predict three-way multilayer
relationships. However, observed protein-ligand-disease triplet associations are extremely sparse.
Majority of observed protein-ligand pairs are not associated with any diseases. Thus, tensor
factorization may be an optimal solution. REMAP algorithm, a kind of OCCF has been applied to
a bipartite graph for predicting protein-ligand interactions as introduced in Chapter 2, but not to
inferring multiple protein-ligand-disease associations. Moreover, existing OCCF algorithm is
mainly based on the formulization of matrix factorization that only allows a single rank for feature
compression. FASCINATE is an algorithm that can jointly infer missing links from a multilayer
network model, which is introduced in Chapter 5. However, FASCINATE is based on the
formulation of a single-rank collective OCCF. Moreover, it can only rank predicted relations,
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without providing any reliability measures. The WINTF algorithm, which is described in detail in
Chapter 3, can address the drawbacks in matrix factorization, OCCF, and FASCINATE when
applied to inferring protein-ligand-disease associations.

4.3 Experimental and Computational Details
Overview of Computational and Experimental Procedure
Our primary purpose is to mine chemical genomics and disease association data to identify
novel targeted therapies for unmet biomedical problems such as the treatment of TBNC. As shown
in Figure 4.2, the input of ANTENNA is the association networks in chemical genomics, drug, and
disease databases including DrugBank [36], ZINC [27], ChEMBL [28], and CTD [182]. We first
integrate these data sets into a multilayered protein-ligand-disease network, MULAN. Then we
apply WINTF, a multi-rank dual-regularized weighted and imputed OCCF algorithm introduced
in Chapter 3, to infer novel protein-ligand associations. Next, we used ENTS to infer liganddisease associations and to assess the reliability for each predicted association. The output of
ANTENNA is a list of predicted ligand-disease associations ranked by their statistical significance.
Finally, we outsource to experimentally validate the top-ranked predictions. In this chapter, we
discuss the construction of MULAN and application of WINTF algorithm. The full details about
integration with ENTS and the experimental validations are described in our published work [99].
Construction of Multi-Layered Chemical-Gene-Disease Network (MULAN)
We combined heterogeneous data sets from genomics into a multilayered network model,
MULAN. Each node in MULAN is a chemical entity (ligands, drugs and other chemicals), a
biological entity (genes or proteins that it encodes), or a phenotypic entity (disease and side effect).
Nodes in the same entity class are linked together by within-layer similarities (e.g., ligand-ligand
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structural similarity or protein-protein sequence similarity) or known interactions (e.g., proteinprotein interactions). Nodes that belong to different entity classes reside in different network layers
and are linked by cross-layer associations (e.g., known drug-target interactions, disease-gene
associations). Integration of genomics data into a bipartite graph is of a proven value [279].
MULAN can be regarded as the union of multiple bipartite graphs. Thus, our new method is likely
to be more robust than traditional approaches.
Protein-ligand associations including drug-target associations were obtained from the
ZINC [27], ChEMBL [28] and DrugBank [36] databases as shown in Chapter 2. To obtain reliable
protein-ligand association pairs, binding assays records with IC50 (concentration of the chemical
needed to inhibit 50% of the activity of the target protein) information were extracted from the
databases, and the cutoff IC50 value of 10 µM was used where applicable. Protein-ligand pairs
were considered positively associated if IC50 ≤ 10 µM (active pairs), negatively associated if IC50
>10 µM (inactive pairs), ambiguous if records exist in both ranges (ambiguous pairs), and
unobserved otherwise (unknown pairs). A total of 198,712 unique ligands and 3,549 unique
proteins were obtained from the combination of ChEMBL and ZINC with 228,725 unique active
protein-ligand pairs, 76,643 inactive pairs, and 4,068 ambiguous pairs. Of the 198,712 ligands,
722 were found to be FDA-approved drugs. Furthermore, drug-target relationships were extracted
from the DrugBank and integrated into the ZINC_ChEMBL dataset above. A total of 199,338
unique ligands and 6,277 unique proteins were obtained from the combination of ZINC, ChEMBL,
and DrugBank with 233,378 unique active protein-ligand pairs. Ligand-disease and proteindisease associations were obtained from the CTD database [182].
We describe the required inputs to WINTF method first. As WINTF is a direct extension
of REMAP, the same inputs are required as described in Chapter 2. Ligand structural similarity
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scores are calculated based on Tanimoto coefficient of the radius-2 ECFP (ECFP4) for ligand
molecules. Protein sequence similarity scores are calculated using BLAST sequence alignment
scores as described in Chapter 2.

Figure 4.2 Workflow of ANTENNA, a multilayer recommender system for drug repurposing.

In addition to the same inputs as REMAP, disease-disease similarity is also required for
WINTF to infer ligand-disease associations, and can be calculated using distributed word
representations [280]. In this chapter, we do not infer the ligand-disease associations directly using
WINTF, since only less than 0.4% of ligands have observed associations with any diseases. Instead,
we use ENTS and target binding profile of a ligand, which is derived from WINTF, to predict
ligand-disease associations.
WINTF Algorithm
Our prediction method WINTF is described in detail with mathematical justifications in
Chapter 3. We apply WINTF to predict unknown associations in protein-ligand interaction
network in this Chapter. As introduced in earlier chapters, the prediction algorithm assumes that
similar ligands are likely to share common target proteins. Also, unobserved associations do not
necessarily indicate negative associations as they may simply be unobserved positives. Taking the
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necessary inputs, WINTF algorithm returns the two low-rank feature matrices F and G for ligands
and proteins, respectively, based on the Eqs. 3.2, 3.3, 3.4, and 3.5, and Algorithm 3.1 in Chapter
3. The predicted protein-ligand associations are obtained by removing scores for known
associations from the dot product of the feature matrices. For benchmark purpose, we use the
predicted protein-ligand associations to evaluate the performance of WINTF in comparison with
REMAP. To combine WINTF into ANTENNA pipeline, we use the ligand-side low-rank feature
matrix F to obtain feature vectors for each ligand. The feature vectors are used to build ligandligand latent similarity network as described below.
Combining WINTF and ENTS to Predict Drug-Disease Association
In ANTENNA, we first use WINTF to generate ligand-side low-rank feature matrix F and
protein side low-rank feature matrix G. The 𝑖 !" row of F contains the protein association profile
for the 𝑖 !" ligand. Then, we calculated ligand-ligand cosine similarities based on the vectors in the
matrix F and construct a ligand-ligand similarity graph. For each row of F for FDA-approved
drugs, the cosine similarity of drug c1 and drug c2 can be calculated by, 𝑆1@A,(1. ,1/ ) =

S+4. ∙+4/ U
VW+4. WVW+4/ W

.

To search for possibly undiscovered uses of the FDA-approved drugs, we focus on drugs that are
found to have high cosine similarity but low ligand structural similarity (< 0.5). Finally, we cluster
drugs based on their directly or indirectly associated diseases found in CTD database [182], and
use ENT to assess and rank the statistical significance of novel drug-disease associations. The final
output of ANTENNA is a list of inferred drug-disease association based on the ranking of false
discovery rate.
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4.4 Results and Discussions
Performance evaluation of WINTF
As shown in Chapter 2, single rank REMAP outperformed state-of-the-art methods: a
chemical similarity-based method (PRW [81]), the best performed matrix factorization methods
so far (NRLMF [111] and KBMF with twin kernels (KBMF2K) [165]), combination of WNN and
GIP (WNNGIP [154]), and another type of matrix factorization-based collaborative filtering
algorithm (Collaborative Matrix Factorization (CMF) [167]). Here, we compare the performance
of WINTF with that of REMAP using two benchmarks. The first benchmark includes 3,494
chemicals, 25 G-protein coupled receptors (GPCRs), and 4,494 observed chemical-GPCR
associations. The second benchmark includes 33,684 chemicals, 31 Cytochrome P450 enzymes
(CYP450), and 51,699 observed chemical-CYP450 associations.
As shown in Figure 4.3, WINTF clearly outperforms REMAP when evaluated by both
benchmarks. WINTF identifies around 96% and 87% true associations ranked on the top 3 for
GPCR and CYP450, respectively, while REMAP can only identify around 78% and 60% true hits
at the same ranks, respectively. When evaluated by the application to sequence-structure similarity
search, ENTS is shown to be superior to Hidden Markov Model and RWR [276].

Figure 4.3 Performance evaluations for WINTF and REMAP on GPCR dataset (A) and CYP450 dataset
(B). Performance measured by the recall at the top-K ranked predictions.
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Time complexity of WINTF
Our empirical result shows that the running time of WINTF is linearly dependent on the
number of proteins and ligands, as shown in Figure 4.4. When evaluated in a machine with 2 cores
of 2.18 GHz CPU. It takes around 1,000 seconds to converge for a matrix with 15,000 ligands, 200
proteins, ligand-side rank of 1,000, and protein-side rank of 200. This demonstrates that WINTF
algorithm is scalable to decent-sized protein-ligand association networks.

Figure 4.4 Running time of WINTF according the number of items in the matrices. The computational
time was measured using a 2-core 2.18 GHz CPU, for a matrix with 200 proteins and varying number of
ligands. The ranks for ligands and proteins are fixed to 1,000 and 200, respectively

ANTENNA Predictions
By combining WINTF with ENTS, ANTENNA predicted a total of 21,921 novel drugdisease associations with Benjamini-Hochberg adjusted false discovery rate (FDR) less than 0.02
as described in [99]. Since it is impractical to experimentally evaluate all the predictions, we
selected drug-disease pairs for further experimental evaluation based on the following criteria.
First, predicted kinase-binders are preferred since the genome-wide binding assay for kinases is
accessible. Second, the associated disease does not have effective therapy yet, so that the
repurposed drug will have the maximal clinical impact. Third, cell-based disease models should
be available, so that we can further evaluate the efficacy of the drug.
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Based on above criteria, diazoxide, a safe FDA-approved drug for hypertension, was
chosen for further evaluations. Diazoxide was predicted to interact with protein kinases.
Furthermore, ANTENNA predicted that diazoxide was associated with Triple Negative Breast
Cancer (TNBC) with Benjamini-Hochberg adjusted FDR of 0.0108. Thus, diazoxide may be
repositioned as a treatment for TBNC which is the most aggressive type of breast cancer and cannot
be effectively treated by any existing targeted therapy. It notes that the FDR of predicted diazoxideTNBC association did not show particularly statistically significant. If this prediction can be
experimentally validated, we will have more confidence in predictions with lower FDRs.
As discussed in the reference [99], our predicted drug activities of diazoxide were
experimentally validated by proprietary KinomeScanTM assay and cell proliferation inhibition
assay. Briefly, diazoxide was found to inhibit multiple kinases, including DRYK1A, IRAK1, and
TTK, which are associated with multiple cancer drug-resistance, and TNBC, Alzheimer’s disease.
In cell viability assays, diazoxide showed stronger inhibition for the MDA-MB-368 (TNBC) cell
line (IC50 = 0.87 ± 0.39 𝜇M) than for the MCF-7 (ER-positive breast cancer) cell line (IC50 =
130.0 ± 70.0 𝜇M). The inhibition of diazoxide against TNBC cell line is clearly stronger than the
clinically accepted cutoff value of IC50 = 10 𝜇M, indicating that diazoxide may be a potential
treatment for TNBC.
4.5 Conclusions
In summary, we have developed a reliable and accurate multi-rank, multi-layered
recommender system ANTENNA. Using ANTENNA, we predicted that an FDA-approved safe
medicine, diazoxide, could bind to multiple kinases whose malfunction is associated with TNBC,
a deadly subtype of breast cancer. We outsourced to perform the proprietary KinomeScanTM assay,
which confirmed the kinase-binding activities of diazoxide. Cell viability assay – also outsourced
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– further validated that diazoxide is highly potent in inhibiting the proliferation of TNBC cancer
cells. These findings suggest that diazoxide can be repositioned as an effective targeted therapy
for TNBC. Furthermore, diazoxide may be effective in the treatment of other diseases such as liver
cancer and Alzheimer’s disease. We are carrying out experiments to validate these predictions.
This chapter demonstrates that big data analytics provides new opportunities for accelerating drug
development and realizing the full potential of precision medicines.
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CHAPTER FIVE

A Multi-rank Multilayer Extension of REMAP Applied to Drug-Target-Disease-Side Effect
Association Network
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5.1 Introduction
Severe side effects or adverse drug reactions are the 2nd leading cause for drug attrition,
and the 4th leading cause of death in the US. Adverse drug reactions and side effects limit the use
of the drugs, decrease their value, and negatively affect patients [281, 282]. Despite the importance
of identifying potential side effects of a drug molecule in advance, it is intimidating and prohibitive
to experimentally test them. As a result, our knowledge in biological and biomedical associations
of side effects and adverse drug reactions is biased, sparse and noisy. To tackle the difficulty in
studying drug-induced side effects, systematic, large-scale methods have been developed to
computationally predict drug-induced side effects [283-286]. Although these approaches provide
acceptable performances for predicting common side effects of existing drugs, challenges remain
to predict rare side effects as well as to systematically predict missing multi-scale drug-proteinpathway-side effect associations. It is important to computationally model drug actions in multiple
aspects since the drug responses result from complex interplay among biological pathways that are
modulated by drug-target interactions.
It is not trivial for a machine learning method to predict novel drug-protein-pathway-side
effect associations based on incomplete, biased, and noisy data. In Chapter 2, we proposed
REMAP to address the challenge of learning from such data. As shown in Chapter 2, REMAP has
several unique features, making it particularly applicable to predict missing relations from
incomplete and noisy data sets such as drug-side effect network. First, REMAP does not require
negative data annotations for training as it utilizes the imputation strategy. The drug-side effect
association network in existing databases are mainly collections of reported side effects. As a
result, known negative associations are extremely sparse as they are rarely tested or reported. These
limitations impose hurdles for most classification methods, which require positive and negative
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samples. Second, REMAP can handle mislabeling by assigning a confidence score to each label.
Mislabeling is common in biological and clinical data sets due to systematic and random errors in
experiments. Finally, by applying neighborhood regularization on drug, protein, and side effect
information, REMAP partially alleviates the cold start problem, where predicting new protein
targets or side effects is difficult for ligands without any known target proteins or side effects. In
our earlier study, we have showed that REMAP can be successfully applied to predict unknown
drug-protein interactions [110]. In this chapter, we extend its application to drug side effect
prediction.

Figure 5.1 A multilayered network view of drugs causing side effects. Drugs may bind protein targets that
are associated with side effects or relevant biological pathways. Therefore, drugs may cause side effects
as results of complex interplay of molecules within biological networks. Solid lines: known associations
used as training sets in this chapter. Dashed lines: no known associations used.

While REMAP shows high accuracy and great potential in understanding drug actions, it
has limitations. One of the most important limitations is that REMAP can take only two distinct
types of biological entities (e.g. drugs and proteins) and their relationship as a bipartite graph. As
mentioned above, however, drug actions involve multiple biological entities that are linked with
each other on a multi-scale. Therefore, integrating information from more than two types of
biological entities may be crucial for predicting drug actions and drug-induced side effects. For
example, a drug often interacts with off-targets. The off-targets are involved in biological
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pathways, and the pathways may be associated with side effects. These biological entities (e.g.
drug, target, pathway, and side effect) and their relationships can be modeled as a multilayer
network (Figure 5.1). To predict missing associations in the multilayer network, most conventional
methods model multiple pairwise associations independently, and integrate these binary relations
subsequently. Such an approach ignores the within-layer dependency among the binary
associations. FASCINATE algorithm was proposed to predict novel missing relationships from
multilayer networks by jointly optimizing multiple bipartite graphs [287]. In the benchmark,
FASCINATE outperforms state-of-the-art methods in predicting multilayer associations [287].
In this chapter, we apply REMAP and FASCIANTE to predict drug-side effect associations
and identify pathways associated with the side effects, respectively. We first show that REMAP
outperforms state-of-the-art multi-target learning methods for predicting drug-side effect
associations. Then, we perform random permutation analysis with the FASCINATE algorithm to
infer statistically significant protein-side effect associations based on known associations among
drug-protein, drug-side effect, and protein-side effect associations. The gene overrepresentation
analysis is carried out to predict associations among biological pathways and side effects. The
predicted results suggest that the biological pathways associated with cataracts, glaucoma,
depression, and other side effects. These putative associations are supported by existing clinical
evidence. Therefore, FASCINATE has demonstrated great potential for identifying novel
associations between side effects and biological pathways systematically from drug-protein-side
effect networks. Our method relies on the known associations and node similarity information,
such as chemical structural similarity between drugs. It is expected that the use of a more accurate
similarity measurement as well as more complete drug-protein-side effect association datasets can
discover more novel associations, which may be directly applied to clinical studies.
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5.2 Related Works
In this section, we review the existing methods for side effect-pathway association
prediction, and the core artificial intelligence and statistical machine learning methods that have
been applied to drug-induced side effect predictions, followed by applications of nonnegative
matrix factorization methods for association prediction.
To the best of our knowledge, only a few studies have focused to infer the associations
between side effects and biological pathways. Using the frequent subgraph discovery method
Fukuzaki et al. proposed Cooperative Pathway Enumerator, CREPE, to predict associations
between biological conditions (e.g. heat shock condition) and pathways [288]. Wallach et al.
presented a method to infer associations between side effect and pathways by a combination of
protein-ligand docking and logistic regression methods, assuming that drugs affecting the same
pathway may induce the same side effects [289]. More recently, Shaked et al. developed Array of
Model-based Phenotype Predictors, AMPP, to infer drug-protein interactions using Support Vector
Machine, and extended it to connect key metabolic reactions and biomarkers to side effects, by
applying Random Forest-based feature selection on the biomarker features [104, 290].
Similarity Ensemble Approach (SEA) is a popular method to predict whether a drug will
bind to a target protein based on a set of chemical structural similarity scores [56, 291, 292].
Lounkine et al. applied SEA to predict drug-induced side effects by connecting the predicted drugtarget associations to the known target-side effect associations [283]. The strength of SEA is that
it can capture information possibly hidden in sets of weak similarities.
Multilabel learning is a class of statistical machine learning methods suitable for predicting
multiple labels that are not necessarily mutually exclusive, and its applications on several domains
have been developed [293]. Zhang and Zhou developed k-nearest neighbor-based multilabel

121

learning method (MLKNN) [294] and refined it by applying mutual information-based feature
selection on top of MLKNN (FS-MLKNN) to infer drug-induced side effects [286]. FS-MLKNN
can be categorized as an ensemble learning method, which combines weak/moderate base learners
to build a strong predictor.
Canonical Correlation Analysis (CCA) is used to find the weights that maximize the
correlation across the feature vectors [295]. Pauwels et al. proposed a chemical substructure-based
method that applies CCA and refined it to Sparse CCA (SCCA) for easier interpretation [285, 296].
In addition to the inference outcomes, SCCA can also return to the optimized importance weights
for each feature. Liu and Altman applied CCA and found correlations among binding affinities of
drugs to essential target genes and side effects of drugs. They integrated CCA with singular value
decomposition to extract features representative of biological signals, carefully excluding the
frequency of information in the dataset [297].
While these sophisticated computational methods are reasonably accurate, each class of
methods has clear drawbacks. First, SEA, FS-MLKNN and SCCA only use chemical features from
drugs. Thus, these methods are incapable of utilizing other side information, such as proteinprotein similarity unless integrating into other methods. Second, these methods are not suitable to
handle the activity cliff, where a small change in a molecular structure results in a dramatic change
in the biological outcome [148]. Third, these methods are based on the assumption that the
unobserved associations are negative. However, the unobserved associations may not necessarily
be negative, the idea which the weighted imputation-based method tries to adopt.
Nonnegative matrix factorization (NMF), first introduced by Paatero and Tapper in 1994,
became a widely adopted method for recommendation tasks with the development of the
multiplicative update algorithm by Lee and Seung [298, 299]. One of the most successful NMF
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applications is perhaps the Netflix competition, where the unknown user-video preferences are
inferred by NMF [225]. To better predict the user-item preferences, advanced NMF algorithms
take side information, such as user-user and item-item similarities to reflect homophily effect, the
idea that similar users tend to choose similar items. Advanced NMF methods such as wiZAN-dual
can also apply weights and imputation strategies to reflect that some of the unknown associations
may be positive [161]. Based on the mathematical framework of wiZAN-dual, REMAP and its
variation COSINE were developed to make predictions on unobserved protein-ligand associations
[110, 300]. FASCINATE is an extension of REMAP on a multilayer network. In this chapter, we
utilize REMAP and FASCINATE to predict unknown drug-protein-pathway-side effect
associations. REMAP and its another extension in data-driven, structure-aided computational drug
repurposing pipeline, 3D-REMAP, are described in detail in Chapter 2.

Figure 5.2 Illustration of FASCINATE algorithm for drug-gene(protein)-side effect multilayer network.
Latent features of drugs, genes, and side effects are calculated based on the observed associations and
side information. The latent features are utilized to reconstruct the complete association matrices for each
layer of the network.
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5.3 Methods
Overview of REMAP and FASCIANTE algorithms
As illustrated in Figure 5.2, the hypothesis of FASCINATE algorithm is that the observed
sparse and noisy drug-gene profiles and drug-side effect profiles rise from the latent features
(hidden variables) of drugs, genes (proteins), and side effects. Similar drugs, proteins, or side
effects will have similar latent features as the optimization proceeds. The dot product operation
between drug and gene latent features will restore the complete drug-gene associations; similarly
for drug-side effect and gene-side effect associations. Note that when we focus only on one of the
cross-layer dependencies (e.g. only drug-gene, or only drug-side effect), the application is identical
to REMAP in Chapter 2. Also, it is important to note that FASCINATE jointly optimizes each
layer; thus, the result is different from just combining the output matrices after applying REMAP
separately to the layers.
Dataset description
Our method has three distinct types of nodes: drugs, genes (or proteins), and side effects.
We collected known associations from several publicly available databases. Drug-side effect
associations for small molecular drugs were obtained from SIDER4.1 database [34]. Drug-protein
associations are obtained from the combination of three databases: ZINC, ChEMBL, and
DrugBank as explained in Chapter 2 and Chapter 3 [301-303]. Drug-protein associations were
excluded if the drug was not found in the SIDER database. Protein-side effect associations were
obtained from the dataset reported in a publication [283]. The known associations were regarded
as binary relations (i.e. 1 for observed positive associations, and 0 otherwise). The drug-drug
similarity scores were calculated based on chemical 2D structure similarity as described in Chapter
2. We obtained protein-protein interactions from BioGRID database [304] and used as gene-gene
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similarity matrix. We also have tested semantic similarity-based side effect-side effect similarity
scores using UMLS-Similarity software [305]. However, our experiments indicated that the
semantic similarity scores did not improve protein-side effect or drug-side effect prediction
accuracy. To be specific, the best performance using the semantic similarity was within one
standard deviation of the performance without it (data not shown). Therefore, we used an identity
matrix instead, as side effect similarity matrix. The data types and counts are in Table 5.1.

Table 5.1 Data statistics of drug-gene-side effect network
Nodes

Associations

Similarities

Type
Drugs
Genes
Side effects (diseases)
Drug-gene
Drug-side effect
Gene-side effect
Drug-drug
Gene-gene
Side effect-side effect

Count

1549
19116
4251
4727
127595
2209
5303
458135
4251

Description of prediction method, FASCINATE
REMAP is a variation of nonnegative matrix factorization algorithm for inferring novel
binary relations, introduced with details in Chapter 2. FASCINATE is an extension of REMAP on
multi-layered network [287]. The three layers used in this study are drugs, genes (proteins), and
side effects, and the aim is to find low-rank matrices of latent features for each layer that minimizes
the following equation:
\
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Here, g is the number of total layers (3 in this study), and Fi (e.g. F1, F2, or F3) is the lowrank feature matrix for the ith layer, Di,j is the cross-layer association matrix between the ith and jth
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layers (e.g. drug-gene), Ai is the within-layer similarity matrix (e.g. drug-drug or protein-protein),
Ti is the diagonal degree matrix of Ai, Wi,j is the weight matrix, Pi,j is the imputation matrix, ⊙ is
an element-wise product operator (Hadamard product), and ‖M‖3F is the Frobenius norm of matrix
M. For the sake of algorithmic efficiency, we use global scalar weight and imputation values as
done in the REMAP in Chapter 2. Once the low-rank feature matrices for each layer are obtained,
the prediction matrix between the ith and jth layer is the matrix inner product of Fi and Fj. If there
are only two layers, the objective function in Eq. 5.1 is equivalent to that of REMAP in Chapter 2.
We evaluated the effectiveness of REMAP based on multiple metrics. For varying degree
of density in the gene-side effect network, we performed 10-fold cross-validations to evaluate four
different performance metrics that are frequently used to assess recommender systems algorithms.
The four metrics include the standard area under the receiver operating characteristic curve
(AUROC, or AUC), Half-Life Utility (HLU) [306], Mean Average Precision (MAP) [251], and
Mean Percentage Ranking (MPR) [307]. HLU estimates the likelihood that a user accepts the
recommended items with an assumption that the likelihood exponentially decreases with the
ranking of items [308]. MAP is a measure of the average precision over all users in the test dataset
at different recall levels [251]. MPR is a measure of the average of percentile-ranks of positive
associations in the test dataset [307]. For example, an MPR of 0% is obtained if all positive samples
are top-ranked. On the other hand, a 100% MPR indicates that they are ranked to the least. Thus,
the higher AUC, HLU, MAP and the lower MPR, the better performance. During the crossvalidation, we categorized side effects by the number of known associations with drugs and
measured performances from rare side effects to frequently observed ones. For comparison, we
tested feature selection-based multilabel k-nearest neighbor method (MLKNN) [286] under the
same cross-validation and rarity conditions as those for REMAP.
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Since FASCINATE takes several tuning parameters, we found the optimal parameters by
using a grid search and 10-fold cross-validation. For each fold, we randomly selected
approximately 10% of the associations from both drug-protein and drug-side effect layers as test
sets and measured the AUC for each layer separately. Then, we took the sample-count weighted
average to evaluate the performance. In this way, we found the optimal low-rank hyperparameter
and maximum iteration number to be 770 and 100, respectively, while fixing the other
hyperparameters to be the default values. Using the optimal rank parameter and iteration number,
we found the optimal hyperparameters to be α=0.5, β=1.0, and w=0.25.
Random permutation and overrepresentation analysis
Next, we conducted random permutation and overrepresentation analysis on the gene-side
effect layer using the optimal hyperparameters above. We estimated the null distribution of
prediction scores from random permutations, and using the null distribution, we filtered predicted
pairs from FASCINATE without permutation. The filtered pairs were then used to search for
significant pathway-side effect associations by a hypergeometric overrepresentation test. For each
permutation test, we randomly permutated the drug-protein and drug-side effect associations while
keeping the total number of observed associations in each layer intact. Using the permutated layers
and the intact gene-side effect layer as inputs, we ran FASCINATE to obtain the prediction scores
for gene-side effect pairs. We performed 200 iterations of permutation tests and recorded the
prediction scores for each gene-side effect pair. Then, we collected raw prediction scores from
randomly selected 1,000 gene-side effect pairs from unknown associations. With the 200,000 raw
scores (1,000 pairs with 200 scores from each iteration), Epanechnikov kernel was used to fit the
distribution (Figure 5.3). Excluding those for known gene-side effect associations, the raw
prediction scores were converted into p-values by the Epanechnikov kernel probability density
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function obtained above, followed by the False Discovery Rate adjustment. To predict unknown
associations among biological pathways and the side effects, the gene sets for each side effect were
used for KEGG overrepresentation test provided in the Cluster Profiler package [309]. To focus
on rare associations, the enriched pathway-side effect associations were excluded if the pathway
is associated with more than 5 side effects, or the side effect is associated with more than 5
pathways. Also, predicted pairs with q-value (from hypergeometric test) higher than 0.05 were
filtered out.

Figure 5.3 (A) Epanechnikov kernel fitting on FASCINATE prediction scores from random
permutation analysis on gene-side effect associations. (B) Inset of (A) for smaller ranges of both axes.

5.4 Results
Significantly improved performance of REMAP in predicting rare side effects
REMAP showed better performances than MLKNN evaluated by the four metrics in all
tested rarity categories (Table 5.2). The better performance of REMAP over MLKNN is more
noticeable for rarer side effects. The AUC of REMAP drops from 0.95 to 0.84 as the rarity of side
effects increases, while that of MLKNN drops from 0.92 to 0.68. This suggests that REMAP can
be effectively applied for drug-side effect inference tasks from rare to common side effects. It is
noted that while REMAP shows better AUC and MPR for more common side effects, its
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performance is not necessarily improving as the rarity decreases, based on HLU and MAP. The
same trend is observed for MLKNN, suggesting that the use of these four metrics together provides
more objective evaluations. To summarize, our extensive benchmark studies show that REMAP
has a great potential to infer novel associations.

Table 5.2 Performances of REMAP and MLKNN predicting drug-side effect associations
Avg. AUC

Number of
drugs per SE*
< 12
< 25
< 50
< 100
< 200
< 400
< 800
All

Avg. HLU

Avg. MAP

Avg. MPR

REMAP

MLKNN

REMAP

MLKNN

REMAP

MLKNN

REMAP

MLKNN

0.84
0.88
0.90
0.92
0.93
0.94
0.95
0.95

0.68
0.76
0.82
0.85
0.88
0.90
0.91
0.92

5.6
4.9
4.1
3.9
3.5
3.4
3.6
4.0

3.6
2.4
1.6
1.1
0.7
0.4
0.2
0.3

.048
.045
.044
.043
.040
.042
.047
.052

.031
.026
.026
.024
.023
.024
.027
.031

0.26
0.20
0.16
0.13
0.11
0.10
0.08
0.08

0.33
0.24
0.19
0.16
0.13
0.11
0.10
0.09

* Side effects having a certain number of associated drugs per side effect.

Literature supports of top ranked predictions
Furthermore, multiple pieces of clinical evidence support the top ranked predictions from
REMAP as shown in Table 5.3. Newton et al. investigated a total of 984 patients with generalized
anxiety disorder to reported that patient groups receiving diazepam showed decreased libido
compared to other groups including placebo [310]. Although the main cause was unclear, an
ovarian cancer patient treated with paclitaxel and carboplatin was reported to develop acute
myeloid leukemia (AML) in 2006 [311]. In 2016, another group of authors reported a case of a
patient who developed AML after endometrial chemotherapy including paclitaxel, where
paclitaxel was discussed as the likely cause of AML [312]. Patients treated with lenalidomide
showed significant dermatologic side effects although indirectly related to ichthyosis and less
severe [313]. It was reported that one of the most frequent side effect of erlotinib for non-small
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cell lung cancer (NSCLC) is hypocalcemia when treated with emibetuzumab [314]. Furthermore,
erlotinib alone was reported to cause hypocalcemia [315]. Two clinical case reports and human
exposure studies imply that overdosing propranolol may cause cardiac arrest [316, 317]. Although
rare and limited to the elderly population, ranolazine treatment was reported to cause visual
hallucinations, which resolved after discontinuation of treatment [318]. In a study of 5,194 males,
approximately 35% of patients suffered from erectile dysfunction, and it was associated with
cumulative exposure to zalcitabine or enfuvirtide [319]. Ejaculatory failure was reported from
oxcarbazepine treatment [320]. In three cases of long-term corticosteroid treatment, including two
cases with prednisolone, the patients suffered from moderate to severe vision impairment, which
could have resulted in permanent loss of vision [321]. In a study analyzing more than a million
cases from September 1999 to April 2012, use of levofloxacin was found to be a great risk for
patients. Patients who were treated with levofloxacin had higher hazard ratios for serious cardiac
arrhythmia and death compared to amoxicillin and azithromycin [322]. In a case report,
Mahendran and Liew suggested that symptoms of depression need to be carefully monitored when
prescribing alprazolam. They reported a case of a healthy woman in her 20s who developed severe
depression with suicidal thoughts after taking the prescribed doses of alprazolam for three times
[323].
Table 5.3 Predicted top ranked drug-side effect associations with literature support
Drug
Diazepam
Paclitaxel
Lenalidomide
Erlotinib
Propranolol
Ranolazine

Predicted Side
Effect
Libido disorder
Acute myeloid
leukemia
Ichthyosis
Hypocalcemia
Cardiac failure
Visual impairment

Reference

Drug

[310]

Zalcitabine
Oxcarbazepin
e
Prednisone
Levofloxacin
Alprazolam

[311, 312]
[313]
[314, 315]
[316, 317]
[318]
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Predicted Side
Effect
Erectile dysfunction

Reference
[319]

Erectile dysfunction

[320]

Blindness
Cardiac failure
Suicide attempt

[321]
[322]
[323]

Identification of pathway-side effect associations
By FASCINATE and the subsequent random permutation analysis, a total of 7,572 geneside effect pairs for 409 unique genes and 1,150 unique side effects were found with q-values
lower than 0.001. Then, these genes are statistically linked with biological pathways using gene
set overrepresentation analysis. The final inferred pathway-side effect associations with their qvalue are listed in Table 5.4. The list of literatures supporting the inferred top-ranked side effectpathway associations suggests that our method can reliably infer missing one type of binary
relations by jointly learning other types of binary relations from a multilayer network (Table 5.4).
Wirtz and Keller identified mutations and significant up or down regulation in different kinds of
an interleukin family of cytokines in mice with glaucoma, suggesting that disruption of interleukin20 signaling in the eye may be linked to glaucoma [324]. In a more recent study, Gupta et al.
demonstrated that the concentration of tear film cytokines were significantly lower in patients with
primary open-angle glaucoma [325]. Liu and Neufeld found that the epidermal growth factor
receptor (EGFR) is significantly upregulated and tyrosine-phosphorylated in human glaucomatous
optic nerve head in vivo. They showed that it induces nitric oxide synthase to generate excessive
nitric oxide, leading to an increased intraocular pressure and potentially glaucoma [326]. In a
separate study, the authors suggested that EGFR is a common regulatory pathway for neural
injuries in optic nerves, including glaucoma [327]. Kwon and Tomarev showed that several
components in integrin-focal adhesion kinase – serine/threonine kinase signaling pathway are
activated in the eyes of mice expressing high level of myocilin, a protein known to be associated
with glaucoma [328]. Piotrowska et al. found a significant proportion of patients developed druginduced cataracts, including those who had to undergo surgical repair from patients treated with a
selective EGFR tyrosine kinase inhibitor [329]. Though the association between cataract and focal
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adhesion pathway seems subtle, Kokkinos et al. demonstrated that the expression and
phosphorylation pattern of focal adhesion kinase changes as the lens develops in mice [330]. Quite
obviously, sex steroid hormone deficiency is known to be linked to erectile dysfunction [331].
Although we could not find pertinent literature evidence, it may be trivial to validate the predicted
association between steroid hormone synthesis and decreased libido. An indirect association was
shown between erectile dysfunction and gastric acid secretion, which is clinically regulated by
histamine receptor antagonists [332, 333]. In a study involving 55 patients with stage IV NSCLC,
patients having mutations in EGFR showed milder depression compared to those without EGFR
mutations, suggesting a mutation-dependent association between depression and EGFR [334]. In
a review paper, evidence was shown for omega-6 polyunsaturated fatty acid (e.g. linoleic acid)
affecting the function of leukocytes [335]. Several interesting hypotheses rise from the inferred
side effect-pathway associations. First, cataract and glaucoma share two common biological
pathways: EGFR tyrosine kinase inhibitor resistance and focal adhesion pathways. Second, the
results suggest that erectile dysfunction and decreased libido are linked to the steroid hormone
biosynthesis pathway. Further studies with broader computational and biological aspects and
experimental validations are required to refine FASCINATE method for gene-side effectbiological pathway association prediction.
Table 5.4 Predicted pathway-side effect associations by random permutation and
overrepresentation analysis
Side Effect (disease)
Glaucoma
Glaucoma
Glaucoma
Cataract
Cataract
Erectile dysfunction
Libido decreased
Erectile dysfunction
Depression
Leukopenia

KEGG Pathway
Cytokine-cytokine receptor interaction
EGFR tyrosine kinase inhibitor resistance
Focal adhesion
EGFR tyrosine kinase inhibitor resistance
Focal adhesion
Steroid hormone biosynthesis
Steroid hormone biosynthesis
Gastric acid secretion
EGFR tyrosine kinase inhibitor resistance
Linoleic acid metabolism
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Q-value
1.1E-2
9.2E-4
6.9E-3
7.3E-3
2.2E-2
5.6E-3
9.3E-6
8.1E-3
1.2E-2
1.4E-2

Reference

[324, 325]
[326, 327]
[328]
[329]
[330]
[331]
Not found
[332, 333]
[334]
[335]

5.5 Conclusions
In this chapter, we showed that REMAP outperformed state-of-the-art MLKNN on drugside effect prediction evaluated by the four metrics (AUC, HLU, MAP, and MPR), especially for
rare side effects. We apply FASCINATE, a multilayer extension of REMAP, to jointly optimize
and predict the drug-protein-side effect network and to infer missing pathway-side effect
associations by integrating with random permutation analysis and the gene set overrepresentation
analysis. Several of the inferred drug-side effect and pathway-side effect associations are
supported by existing experimental and clinical evidence (Table 5.3 and Table 5.4). These results
suggest that network-regularized weighted imputed one-class collaborative filtering is indeed a
potential tool for inferring missing biological relations on a multi-scale. There are many ways to
further refine the performance of REMAP and FASCINATE. Their performances are dependent
on the similarity measure of drug-drug, gene-gene, and side effect-side effect pairs as well as the
coverage of reconstructed drug-gene-side effect networks. The side effect-side effect semantic
similarity used in this study does not improve the predictive power. Therefore, a new side effectside effect similarity measurement is necessary. In earlier studies, it was shown that the structurebased ligand binding site similarity improves the prediction accuracy for side effects. Furthermore,
the datasets we used in this chapter are not comprehensive. Only 1,549 unique FDA-approved
drugs and 4,727 drug-gene interactions are included in the network. Obviously, it is expected that
more novel relations can be discovered if the reliable chemical-gene network which include
millions of chemical compounds and thousands of targets genes [110] and more complete drugside effect database are used [336].
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CHAPTER SIX

Learning Biochemical Properties from Protein Sequences by ALBERT, a Natural
Language Processing Model
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6.1 Introduction
Data-driven knowledge discovery has been expanding with the unprecedented amount of
available data to train and fine-tune models. Computational biology is one of such research areas,
where the amount of biological and biomedical data is exponentially growing with the
advancement of laboratory techniques and gradually decreasing costs to conduct high-throughput
experiments. As introduced in Chapter 1, many large-scale databases provide the outputs from
such large-scale high-throughput experiments, enabling researchers to perform computational
experiments to mine concealed pieces of knowledge from the multi-omics data sets. A number of
computational methodologies have been developed to learn from biomolecules and infer their
activities that eventually result in drug responses or disease phenotypes.
Despite the advancements and continued research activities, computational learning
methods from protein sequences have been largely limited to the collective statistics of individual
amino acids, termed protein descriptors [73]. The protein descriptors are often based on the
physicochemical properties of individual amino acids with an assumption that the properties of
amino acids are static, where the same behaviors are expected for a type of amino acid regardless
of the position it appears in the protein. For example, an autocorrelation descriptor represents a
protein as an average of certain amino acid properties, such as the net charge or volume of a type
of amino acid, where a particular type of amino acid will always have the same contributions to
the final descriptor. The assumption is unrealistic, however, as the key amino acid residues,
including catalytic and binding site residues, play more important roles than the others. Thus,
computational representations of protein sequences need refinements to account for the positional
differences of amino acids to better model their biological activities, such as enzymatic activities
or protein-ligand binding.
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Developing an efficient and effective representation method for proteins is a challenging
task. Proteins having significant differences in primary sequences may still perform the same
functions via the shared properties in their binding sites. On the contrary, proteins with globally
similar structures do not necessarily share the binding partners. Protein primary sequences may
contain evolutionary information that give rise to the similarities and differences in their biological
activities, which may not be easily detected by conventional sequence comparison methods, such
as BLAST [249]. In a sense, proteins may be considered a natural language, where the primary
sequences are sentences from nature conveying the evolutionary and functional messages through
the combination of words, the amino acids. Deciphering the natural language of proteins is a
critical task in computational biology.
Advanced deep learning architectures have shown promising performances in various
tasks, including computer vision and natural language processing. In recent advancements in
natural language processing projects, models are trained to correctly predict missing words based
on the context [75, 337]. Since the training does not require additional annotations than the text
itself, the scheme is often called self-supervised learning. In a recent study, Rives et al. showed
that a deep learning-based natural language processing method, BERT [75], is capable of learning
biochemical properties from protein sequences via self-supervised learning [76].
The protein representation learned by BERT language model has a few drawbacks. First,
BERT pretraining on the whole 250 million protein sequences is inefficient. As stated in the
manuscript, it takes several days to train the model with 128 of the NVIDIA V100 GPU, the most
advanced GPU as of this writing, implying that it is infeasible to reproduce the work in most
research facilities. Also, it is proposed that BERT architecture itself is suboptimal and can be
refined to significantly reduce the computational burdens without compromising the accuracy [78].
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Second, the size of amino acid vocabulary is suboptimal to be comparable to human languages,
for which BERT was designed. There are only about 30 distinct amino acids even if rare or
unnatural amino acids are included, unlike the size of vocabulary in human language, which is
typically several 10000s. Finally, the pretraining did not consider the evolutionarily conserved
positions in protein families. Evolutionarily related proteins may exert same functions via
conserved residues, which can be pre-sorted by comparing multiple protein sequences.
In this chapter, we attempt to address aforementioned challenges in protein representation
learning using a natural language processing method. We pretrain ALBERT model, a significantly
optimized BERT architecture for predicting hidden words in sentences. We consider protein
sequences as sentences containing words of amino acid triplets. Evolutionarily conserved
positional information is obtained from Pfam database [338]. Our pretrained ALBERT model is
capable of learning biochemical properties of amino acids as well as mutational information from
kinase sequences. Please note that we use the term pretraining interchangeably with training in this
chapter. Typically, pretraining refers to the self-supervised training of the language models, and
training refers to the subsequent fine-tuning tasks, such as protein-ligand interaction predictions
using the pretrained language models. The pretrained ALBERT model is applied to a fine-tuning
task to de-orphanizing GPCRs, which showed promising results and submitted to a peer-reviewed
journal for publication and is under review. We will focus on protein kinases in this chapter.

6.2 Materials and Methods
Protein sequences for kinases and GPCRs are obtained from Pfam database [338]. Pfam is
a database of protein families, where the families are defined by statistical inference of homology
using hidden Markov model [339]. Pfam database provides protein sequences grouped by families
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with multiple sequence alignment within the family. We use the aligned protein sequences as the
sentences and triplets of amino acids as words for pretraining the natural language model,
ALBERT [78]. The overall preprocessing and pretraining steps are illustrated in Figure 6.1.

Figure 6.1 Illustration of preprocessing protein sequences and pretraining ALBERT, a natural language
processing model. From the top, protein sequences are grouped and aligned based on their protein family
memberships as curated in Pfam database, and the triplet amino acids are extracted. Treating triplet amino
acids as words and the aligned sequences as sentences, ALBERT pretraining is performed by randomly
hiding words (red question marks). from sentences and optimize the model to correctly predict the hidden
words. Once pretraining is complete, all possible amino acid triplets are processed by the pretrained
ALBERT model to visualize triplet clusters. Similarly, all trained kinases are processed by the ALBERT
model to cluster and visualize. Asterisks represent the classification token that is prepended to each protein
sequence and used as the barcodes of the proteins.

The raw sentences often contain substantial amounts of gaps, which makes the model
training inefficient. On the other hand, each Pfam family contains the consensus sequence from
the multiple sequence alignment. Thus, we selected evolutionarily conserved positions from the
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multiple sequence alignment provided in the Pfam database. The alignment consensus sequence
contains information about positions that are highly conserved, moderately conserved, and
conservatively substituted. We selected the three different types of conserved positions from the
consensus sequence of a given Pfam family, and the corresponding amino acid residues in each
aligned protein sequence are obtained. The selected amino acids in each protein are then
preprocessed into triplets. The triplets are used to train the ALBERT model with the following
parameters: sentence batch size = 256, maximum sequence length = 256, maximum predictions
per sentence = 40, word masking probability = 0.15, and duplication factor = 10. At 50,000 steps
of pretraining ALBERT, the accuracy of predicting hidden amino acid triplets reached 0.970,
which is more accurate and efficient than that of using BERT, reaching 0.964 accuracy at 100,000
steps. We used a single NVIDIA V100 GPU for training, which were able to run approximately
480 training steps per second.
After pretraining, each triplet of amino acids was used to pull the triplet feature vectors,
and the triplet feature vectors were grouped based on the type of amino acid in their third positions.
The feature vectors were projected onto a 2D space using t-SNE, a popular dimension reduction
technique, to visualize the clusters of triplets. Also, each sentence starts with a classification token,
representing the classification features for the whole sentence. The classification tokens for each
kinase were used to pull the feature vectors for kinases. The kinase feature vectors were visualized
in a similar manner using t-SNE. The kinases are also grouped by the distinct kinase subfamilies
they belong to and whether they contain amino acid mutations or not.
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6.3 Results and Discussions
After pretraining ALBERT model with masked triplets of proteins, we extracted the
pretrained feature vectors for all possible amino acid triplets. We used t-SNE to project the triplet
vectors onto a 2D space. By grouping the triplets based on the type of amino acid on the third
position of the triplets, we visualized the clusters of triplets on the t-SNE projection space (Figure
6.2). Triplets containing an ambiguous or uncommon amino acids, such as amino acid U for
selenocysteine or X for any unresolved amino acids, formed a large distinct cluster that did not
belong to a smaller group (the large black clusters), suggesting that the information regarding such
rare amino acids are scarce and may be insufficient to pretrain the model. When there is no
ambiguity in triplets, they form clearly separated clusters, meaning that the pretraining process
indeed allows the model to extract biochemically meaningful feature vectors from the proteins as
sentences. The same clustering trends were also observed when triplets are grouped by individual
amino acid types, rather than their physicochemical properties of side chains.
Next, we also investigated whether the pretrained ALBERT model can efficiently learn a
higher-level feature from protein sequences. We collected the feature vectors for the classification
tokens for each kinase (asterisks in Figure 6.1) and projected onto a 2D-space using t-SNE. As
shown in Figures 6.3 and 6.4, the classification tokens are initially randomly spread out. As
reaching to more processed ALBERT layers, the kinase classification tokens form distinct clusters,
noticeably for the tyrosine kinases forming several distinct clusters with gentle separation from
other kinase classes (Figure 6.3). The distinct clusters of tyrosine kinases are found to be clusters
of wild-type and mutant kinases, where the wild-type and its mutants are forming distinct clusters.
Note that the classification tokens are the same “[CLS]” characters in the procedures (asterisks in
Figure 6.1). These results demonstrate that ALBERT model can differentiate features for the same
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token or triplets based on the context, and the differentiated features are biologically and
biochemically meaningful.

Figure 6.2 Visualization of pretrained feature vectors for amino acid triplets, projected onto a 2D-space
using t-SNE, a dimensionality reduction technique frequently used to visualize high-dimensional features.
Amino acid triplets are grouped and colored by the properties of the side chain for the third amino acid.
A. The visualization of vectors from initial embedding that are not trained. B-E. The visualization of
vectors from the 1st to 4th layers of ALBERT after pretraining. Legends are enlarged and shown separately
for readability. Standard one-letter or three-letter amino acid codes are used to indicate the type of amino
acids on the legend. The group “Others” includes triplets containing any nonstandard, ambiguous or
unknown amino acids. The group “Gap” includes triplets containing a gap character from the multiple
sequence alignment.
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Figure 6.3 Visualization of pretrained feature vectors for kinases, projected onto a 2D-space using t-SNE,
a dimensionality reduction technique frequently used to visualize high-dimensional features. Kinases are
grouped and colored by the Pfam family they belong to. A. The visualization of vectors from initial
embedding that are not trained. B-E. The visualization of vectors from the 1st to 4th layers of ALBERT
after pretraining. Legends are enlarged and shown separately for readability.

142

Figure 6.4 Visualization of pretrained feature vectors for kinases, projected onto a 2D-space using t-SNE,
a dimensionality reduction technique frequently used to visualize high-dimensional features. Kinases are
grouped and colored by their mutational status. A. The visualization of vectors from initial embedding that
are not trained. B-E. The visualization of vectors from the 1st to 4th layers of ALBERT after pretraining.
Legends are enlarged and shown separately for readability.
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In this chapter, we demonstrated that ALBERT, a natural language processing model
originally developed to learn from human languages is also efficient in learning from protein
sequences. We preprocessed protein sequences to account for the evolutionary conservations in
protein sequences as well as to reduce computational burden for the pretraining. With the highly
optimized ALBERT architecture and reduced amount of sequences and triplets by preprocessing,
we were able to train a highly accurate model within a reasonable computational time. Moreover,
our pretrained language model were able to capture the biophysical properties and evolutionary
relationships from protein sequences. When amino acid triplets were visualized, distinct clusters
of triplets were formed based on the properties of amino acids. When whole kinases were
visualized, on the other hand, they were grouped by the protein families as well as the mutational
information. These results demonstrate that the pretrained ALBERT model is indeed an efficient
strategy to mine biological features from protein sequences.
The ALBERT pretraining strategy can be utilized for several fine-tuning tasks to predict
various biological properties of proteins. After the self-supervised pretraining, models may be finetuned using the binding site or active site residue labels. The model tuned with binding site or
active site can also be further tuned for protein-ligand interaction prediction tasks. For instance,
the feature vectors from the language model can replace protein descriptors in proteochemometric
models introduced in Chapter 1. Also, it is plausible to integrate the language model with other
deep learning architectures, such as Neural Fingerprint [63] for representing ligand molecules and
predict protein-ligand binding activities. We applied the strategy to predict protein-ligand
interactions to de-orphanize GPCRs, which showed promising results and is under review. The
language model can be used for other tasks, such as predictions of protein-protein interactions or
protein stability.
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CHAPTER SEVEN

Future Directions
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7.1 Future Directions
In this dissertation, we covered machine learning applications for predicting drug actions,
including protein-ligand interactions and drug-induced side effects via biological pathways. We
demonstrated that our nonnegative matrix factorization-based methods are highly efficient and
effective in mining undiscovered drug activities from large-scale biochemical and biomedical data
sets. Our subsequent studies have experimentally validated the utility of our methods, which are
discussed in Chapter 2 and Chapter 4. Our results support our hypothesis that the integration of
data-driven molecular screening methods with structure-based bioinformatics tools can present a
powerful computational drug discovery pipeline. Our whole genome-scale drug-off-target
prediction methods showed great scalability and accuracy with promising prediction outcomes,
which are further enriched by methodological extensions in multiple directions. The
experimentally validated predictions support that our contributions to the field of computational
drug discovery are significant.
Despite the successful drug repurposing cases using our methods, a few important points
remain to be refined for optimal outcomes for computational drug discovery. First, the REMAP
algorithm and its variants introduced in this dissertation can be further improved for scalability.
Second, the predictive models need to be extended to include molecular interactions across human
and microbiome to gain better understanding of disease phenotypes. Third, more efficient models
are needed to capture the necessary information from proteins. Finally, a unified systems structural
pharmacology pipeline is needed to accurately predict the drug actions by integrating the largescale interaction networks with sequence- and structure-based predictive modeling, refined by
biophysics-based molecular modeling methods (Figure 7.1).
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Figure 7.1 An overview of the integrated systems structural pharmacology pipeline. The molecular
interactions from human and pathogens are integrated with drugs and potential lead compounds.
Sequence-based and structure-based predictive models prioritize the protein-ligand interactions and
relevant diseases with the aid of homology modeling when structures are unavailable. The prioritized
interactions are then further refined using biophysics-based modeling techniques such as protein-ligand
docking and molecular dynamics simulation with relevant in silico mutational effects in considerations.
The refined predictions can iteratively feedback the structure-based modeling, and the predictions can be
experimentally validated.

The REMAP method and its variants can be further improved for its scalability. As shown
in Chapter 2, current implementation of REMAP is scalable to screen millions of ligands against
whole human genome. However, the most updated PubChem database alone contains over 96
million unique ligands [29], and the size of ligand pool can be even greater if stereochemistry is
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fully considered. The number of potential protein targets can also be larger if all known mutants
are regarded as separate, unique entities. Moreover, it is an active area of research to understand
disease phenotypes as a result of host-microbiome molecular interactions [340, 341], which will
expand the number of unique protein targets to model. With current level of scalability, however,
it is limited to screening millions of ligands against whole human genome. Moreover, WINTF, a
tri-factorization extension of REMAP, is not as scalable as REMAP, implying that it cannot be
applied to projects at similar scales. The sizes of floating-point-valued matrices in such projects
are often beyond the capability of many modern computing machines. The scalability can be
partially addressed by using higher performing machines or by improving the update rules.
Distributed matrix factorization [270] and simultaneous perturbation stochastic approximation
[271, 272] can improve the algorithmic scalability and potentially find global optimum solution.
Network-based predictive methods for drug activities need to integrate the interactions
between human and microbiome, which is known to have multidimensional effects on human
health. Human-microbiome interactions via proteins, small molecules, nucleic acids and
metabolites can intervene the biological pathways to exert beneficial or harmful effects, where the
microbiome can mimic host interactions at sequence, motif, and structural levels [341]. Thus,
computational models that do not consider human-microbiome interactions cannot fully reveal the
potential drug activities in the human biological network. Integration of such interaction network
with protein-ligand-biological pathway-side effect (or disease) associations necessarily form a
large-scale multilayer network, which is not trivial to deal with traditional methods. The proteins
in microbiome may not be well understood in terms of their structures and functions, which
increases the difficulty to accurately model the interaction network. FASCINATE method that is
introduced in Chapter 5 may be utilized to mine from such a multilayer network. Homology
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modeling and molecular dynamics simulation methods may enhance the structural and functional
coverage of the microbiome for better computational modeling.
To develop better predictive models for biomolecular interactions, it is necessary to refine
the representations for protein molecules. As discussed earlier in Chapter 1 and Chapter 6, the
existing molecular descriptors for proteins rely on the static properties of amino acids without
considering positional dependencies. Proteins are three-dimensional complexes consisting of
amino acids, whose detailed physicochemical properties dynamically changes upon the changes
of the environment. An amino acid exposed to the solvent or located near binding pockets may
have significantly different functions compared to the ones that are buried in the complex. A single
amino acid mutation in proteins may alter the properties of the binding or active sites either by
directly modifying the sites or through interactions with neighboring residues that are distant from
the sites but eventually affect the sites in three-dimensional space. These properties cannot be
captured by conventional protein descriptors. A position-dependent feature extraction method,
such as ALBERT-based protein representation introduced in Chapter 6 is necessary to efficiently
model the activities of proteins from sequences. A similar idea to the molecular dynamics
fingerprint can be applied to proteins to provide more informative protein descriptors [62].
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